

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 January 2009 (15.01.2009)

PCT

(10) International Publication Number
WO 2009/007751 A2

(51) International Patent Classification:

C07D 413/14 (2006.01) **A61K 31/5377** (2006.01)
C07D 417/14 (2006.01) **A61P 35/00** (2006.01)
C07D 471/04 (2006.01)

D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(21) International Application Number:

PCT/GB2008/050549

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date: 8 July 2008 (08.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/948,570 9 July 2007 (09.07.2007) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **FINLAY, Maurice, Raymond, Verschoyle** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **PIKE, Kurt, Gordon** [GB/GB]; AstraZeneca R &

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(54) Title: COMPOUND - 946



(I)

(57) Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.

WO 2009/007751 A2

-1-

COMPOUND - 946

The present invention relates to morpholino pyrimidine compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease
5 mediated by an mTOR kinase and/or one or more PI3K enzyme.

It is now well understood that deregulation of oncogenes and tumour-suppressor genes contributes to the formation of malignant tumours, for example by way of increased cell proliferation or increased cell survival. It is also known that signalling pathways mediated by the PI3K/mTOR families have a central role in a number of cell processes including
10 proliferation and survival, and deregulation of these pathways is a causative factor in a wide spectrum of human cancers and other diseases.

The mammalian target of the macrolide antibiotic Rapamycin (sirolimus) is the enzyme mTOR. This enzymes belongs to the phosphatidylinositol (PI) kinase-related kinase (PIKK) family of protein kinases, which also includes ATM, ATR, DNA-PK and hSMG-1.
15 mTOR, like other PIKK family members, does not possess detectable lipid kinase activity, but instead functions as a serine/threonine kinase. Much of the knowledge of mTOR signalling is based upon the use of Rapamycin. Rapamycin first binds to the 12 kDa immunophilin FK506-binding protein (FKBP12) and this complex inhibits mTOR signalling (Tee and Blenis, Seminars in Cell and Developmental Biology, 2005, 16, 29-37). The mTOR protein
20 consists of a catalytic kinase domain, an FKBP12-Rapamycin binding (FRB) domain, a putative repressor domain near the C-terminus and up to 20 tandemly-repeated HEAT motifs at the N-terminus, as well as FRAP-ATM-TRRAP (FAT) and FAT C-terminus domain (Huang and Houghton, Current Opinion in Pharmacology, 2003, 3, 371-377).

mTOR kinase is a key regulator of cell growth and has been shown to regulate a wide
25 range of cellular functions including translation, transcription, mRNA turnover, protein stability, actin cytoskeleton reorganisation and autophagy (Jacinto and Hall, Nature Reviews Molecular and Cell Biology, 2005, 4, 117-126). mTOR kinase integrates signals from growth factors (such as insulin or insulin-like growth factor) and nutrients (such as amino acids and glucose) to regulate cell growth. mTOR kinase is activated by growth factors through the
30 PI3K-Akt pathway. The most well characterised function of mTOR kinase in mammalian cells is regulation of translation through two pathways, namely activation of ribosomal S6K1

-2-

to enhance translation of mRNAs that bear a 5'-terminal oligopyrimidine tract (TOP) and suppression of 4E-BP1 to allow CAP-dependent mRNA translation.

Generally, investigators have explored the physiological and pathological roles of mTOR using inhibition with Rapamycin and related Rapamycin analogues based on their
5 specificity for mTOR as an intracellular target. However, recent data suggests that Rapamycin displays variable inhibitory actions on mTOR signalling functions and suggest that direct inhibition of the mTOR kinase domain may display substantially broader anti-cancer activities than that achieved by Rapamycin (Edinger *et al.*, Cancer Research, 2003, 63, 8451-8460). For this reason, potent and selective inhibitors of mTOR kinase activity would
10 be useful to allow a more complete understanding of mTOR kinase function and to provide useful therapeutic agents.

There is now considerable evidence indicating that the pathways upstream of mTOR, such as the PI3K pathway, are frequently activated in cancer (Vivanco and Sawyers, Nature Reviews Cancer, 2002, 2, 489-501; Bjornsti and Houghton, Nature Reviews Cancer, 2004, 4,
15 335-348; Inoki *et al.*, Nature Genetics, 2005, 37, 19-24). For example, components of the PI3K pathway that are mutated in different human tumours include activating mutations of growth factor receptors and the amplification and/or overexpression of PI3K and Akt.

In addition there is evidence that endothelial cell proliferation may also be dependent upon mTOR signalling. Endothelial cell proliferation is stimulated by vascular endothelial
20 cell growth factor (VEGF) activation of the PI3K-Akt-mTOR signalling pathway (Dancey, Expert Opinion on Investigational Drugs, 2005, 14, 313-328). Moreover, mTOR kinase signalling is believed to partially control VEGF synthesis through effects on the expression of hypoxia-inducible factor-1 α (HIF-1 α) (Hudson *et al.*, Molecular and Cellular Biology, 2002, 22, 7004-7014). Therefore, tumour angiogenesis may depend on mTOR kinase signalling in
25 two ways, through hypoxia-induced synthesis of VEGF by tumour and stromal cells, and through VEGF stimulation of endothelial proliferation and survival through PI3K-Akt-mTOR signalling.

These findings suggest that pharmacological inhibitors of mTOR kinase should be of therapeutic value for treatment of the various forms of cancer comprising solid tumours such
30 as carcinomas and sarcomas and the leukaemias and lymphoid malignancies. In particular, inhibitors of mTOR kinase should be of therapeutic value for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung

cancer and bronchioalveolar cancer) and prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas.

5 In addition to tumourigenesis, there is evidence that mTOR kinase plays a role in an array of hamartoma syndromes. Recent studies have shown that the tumour suppressor proteins such as TSC1, TSC2, PTEN and LKB1 tightly control mTOR kinase signalling. Loss of these tumour suppressor proteins leads to a range of hamartoma conditions as a result of elevated mTOR kinase signalling (Tee and Blenis, *Seminars in Cell and Developmental*
10 *Biology*, 2005, 16, 29-37). Syndromes with an established molecular link to dysregulation of mTOR kinase include Peutz-Jeghers syndrome (PJS), Cowden disease, Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome, Lhermitte-Duclos disease and Tuberous Sclerosis (TSC) (Inoki *et al.*, *Nature Genetics*, 2005, 37, 19-24). Patients with these syndromes characteristically develop benign hamartomatous tumours in multiple organs.

15 Recent studies have revealed a role for mTOR kinase in other diseases (Easton & Houghton, *Expert Opinion on Therapeutic Targets*, 2004, 8, 551-564). Rapamycin has been demonstrated to be a potent immunosuppressant by inhibiting antigen-induced proliferation of T cells, B cells and antibody production (Sehgal, *Transplantation Proceedings*, 2003, 35, 7S-14S) and thus mTOR kinase inhibitors may also be useful immunosuppressives. Inhibition of
20 the kinase activity of mTOR may also be useful in the prevention of restenosis, that is the control of undesired proliferation of normal cells in the vasculature in response to the introduction of stents in the treatment of vasculature disease (Morice *et al.*, *New England Journal of Medicine*, 2002, 346, 1773-1780). Furthermore, the Rapamycin analogue, everolimus, can reduce the severity and incidence of cardiac allograft vasculopathy (Eisen *et al.*, *New England Journal of Medicine*, 2003, 349, 847-858). Elevated mTOR kinase activity has been associated with cardiac hypertrophy, which is of clinical importance as a major risk factor for heart failure and is a consequence of increased cellular size of cardiomyocytes (Tee & Blenis, *Seminars in Cell and Developmental Biology*, 2005, 16, 29-37). Thus mTOR
25 kinase inhibitors are expected to be of value in the prevention and treatment of a wide variety
30 of diseases in addition to cancer.

It is also believed that a number of these morpholino pyrimidine derivatives may have inhibitory activity against the phosphatidylinositol (PI) 3-kinases family of kinases.

Phosphatidylinositol (PI) 3-kinases (PI3Ks) are ubiquitous lipid kinases that function both as signal transducers downstream of cell-surface receptors and in constitutive intracellular membrane and protein trafficking pathways. All PI3Ks are dual-specificity enzymes with a lipid kinase activity that phosphorylates phosphoinositides at the 3-hydroxy position, and a less well characterised protein kinase activity. The lipid products of PI3K-catalysed reactions comprising phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P₃], phosphatidylinositol 3,4-bisphosphate [PI(3,4)P₂] and phosphatidylinositol 3-monophosphate [PI(3)P] constitute second messengers in a variety of signal transduction pathways, including those essential to cell proliferation, adhesion, survival, cytoskeletal rearrangement and vesicle trafficking. PI(3)P is constitutively present in all cells and its levels do not change dramatically following agonist stimulation. Conversely, PI(3,4)P₂ and PI(3,4,5)P₃ are nominally absent in most cells but they rapidly accumulate on agonist stimulation.

The downstream effects of PI3K-produced 3-phosphoinositide second messengers are mediated by target molecules containing 3-phosphoinositide binding domains such as the pleckstrin homology (PH) domain and the recently identified FYVE and phox domains. Well-characterised protein targets for PI3K include PDK1 and protein kinase B (PKB). In addition, tyrosine kinases like Btk and Itk are dependent on PI3K activity.

The PI3K family of lipid kinases can be classified into three groups according to their physiological substrate specificity (Vanhaesebroeck *et al.*, Trends in Biol. Sci., 1997, 22, 267). Class III PI3K enzymes phosphorylate PI alone. In contrast, Class II PI3K enzymes phosphorylate both PI and PI 4-phosphate [PI(4)P]. Class I PI3K enzymes phosphorylate PI, PI(4)P and PI 4,5-bisphosphate [PI(4,5)P₂], although only PI(4,5)P₂ is believed to be the physiological cellular substrate. Phosphorylation of PI(4,5)P₂ produces the lipid second messenger PI(3,4,5)P₃. More distantly related members of the lipid kinase superfamily are Class IV kinases such as mTOR (discussed above) and DNA-dependent kinase that phosphorylate serine/threonine residues within protein substrates. The most studied and understood of the PI3K lipid kinases are the Class I PI3K enzymes.

Class I PI3Ks are heterodimers consisting of a p110 catalytic subunit and a regulatory subunit. The family is further divided into Class Ia and Class Ib enzymes on the basis of regulatory partners and the mechanism of regulation. Class Ia enzymes consist of three distinct catalytic subunits (p110 α , p110 β and p110 δ) that dimerise with five distinct regulatory subunits (p85 α , p55 α , p50 α , p85 β and p55 γ), with all catalytic subunits being able

to interact with all regulatory subunits to form a variety of heterodimers. Class Ia PI3Ks are generally activated in response to growth factor-stimulation of receptor tyrosine kinases *via* interaction of their regulatory subunit SH2 domains with specific phospho-tyrosine residues of activated receptor or adaptor proteins such as IRS-1. Both p110 α and p110 β are

5 constitutively expressed in all cell types, whereas p110 δ expression is more restricted to leukocyte populations and some epithelial cells. In contrast, the single Class Ib enzyme consists of a p110 γ catalytic subunit that interacts with a p101 regulatory subunit. Furthermore, the Class Ib enzyme is activated in response to G-protein coupled receptor systems (GPCRs) and its expression appears to be limited to leukocytes and cardiomyocytes.

10 There is now considerable evidence indicating that Class Ia PI3K enzymes contribute to tumourigenesis in a wide variety of human cancers, either directly or indirectly (Vivanco and Sawyers, Nature Reviews Cancer, 2002, 2, 489-501). For example, the p110 α subunit is amplified in some tumours such as those of the ovary (Shayesteh *et al.*, Nature Genetics, 1999, 21, 99-102) and cervix (Ma *et al.*, Oncogene, 2000, 19, 2739-2744). More recently,

15 activating mutations within the catalytic site of the p110 α catalytic subunit have been associated with various other tumours such as those of the colorectal region and of the breast and lung (Samuels *et al.*, Science, 2004, 304, 554). Tumour-related mutations in the p85 α regulatory subunit have also been identified in cancers such as those of the ovary and colon (Philp *et al.*, Cancer Research, 2001, 61, 7426-7429). In addition to direct effects, it is

20 believed that activation of Class Ia PI3Ks contributes to tumourigenic events that occur upstream in signalling pathways, for example by way of ligand-dependent or ligand-independent activation of receptor tyrosine kinases, GPCR systems or integrins (Vara *et al.*, Cancer Treatment Reviews, 2004, 30, 193-204). Examples of such upstream signalling pathways include over-expression of the receptor tyrosine kinase erbB2 in a variety of

25 tumours leading to activation of PI3K-mediated pathways (Harari *et al.*, Oncogene, 2000, 19, 6102-6114) and over-expression of the ras oncogene (Kauffmann-Zeh *et al.*, Nature, 1997, 385, 544-548). In addition, Class Ia PI3Ks may contribute indirectly to tumourigenesis caused by various downstream signalling events. For example, loss of the effect of the PTEN tumour-suppressor phosphatase that catalyses conversion of PI(3,4,5)P₃ back to PI(4,5)P₂ is

30 associated with a very broad range of tumours *via* deregulation of PI3K-mediated production of PI(3,4,5)P₃ (Simpson and Parsons, Exp. Cell Res., 2001, 264, 29-41). Furthermore,

augmentation of the effects of other PI3K-mediated signalling events is believed to contribute to a variety of cancers, for example by activation of Akt (Nicholson and Anderson, Cellular Signalling, 2002, 14, 381-395).

In addition to a role in mediating proliferative and survival signalling in tumour cells, there is evidence that Class Ia PI3K enzymes contribute to tumourigenesis in tumour-associated stromal cells. For example, PI3K signalling is known to play an important role in mediating angiogenic events in endothelial cells in response to pro-angiogenic factors such as VEGF (Abid *et al.*, Arterioscler. Thromb. Vasc. Biol., 2004, 24, 294-300). As Class I PI3K enzymes are also involved in motility and migration (Sawyer, Expert Opinion Investig. Drugs, 2004, 13, 1-19), PI3K enzyme inhibitors should provide therapeutic benefit *via* inhibition of tumour cell invasion and metastasis. In addition, Class I PI3K enzymes play an important role in the regulation of immune cells contributing to pro-tumourigenic effects of inflammatory cells (Coussens and Werb, Nature, 2002, 420, 860-867).

These findings suggest that pharmacological inhibitors of Class I PI3K enzymes will be of therapeutic value for the treatment of various diseases including different forms of the disease of cancer comprising solid tumours such as carcinomas and sarcomas and the leukaemias and lymphoid malignancies. In particular, inhibitors of Class I PI3K enzymes should be of therapeutic value for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas.

PI3K γ , the Class Ib PI3K, is activated by GPCRs, as was finally demonstrated in mice lacking the enzyme. Thus, neutrophils and macrophages derived from PI3K γ -deficient animals failed to produce PI(3,4,5)P₃ in response to stimulation with various chemotactic substances (such as IL-8, C5a, fMLP and MIP-1a), whereas signalling through protein tyrosine kinase-coupled receptors to Class Ia PI3Ks was intact (Hirsch *et al.*, Science, 2000, 287(5455), 1049-1053; Li *et al.*, Science, 2002, 287(5455), 1046-1049; Sasaki *et al.*, Science 2002, 287(5455), 1040-1046). Furthermore, PI(3,4,5)P₃-mediated phosphorylation of PKB was not initiated by these GPCR ligands in PI3K γ -null cells. Taken together, the results demonstrated that, at least in resting haematopoietic cells, PI3K γ is the sole PI3K isoform that is activated by GPCRs *in vivo*. When murine bone marrow-derived neutrophils and peritoneal

-7-

macrophages from wild-type and PI3K γ ^{-/-} mice were tested *in vitro*, a reduced, but not completely abrogated, performance in chemotaxis and adherence assays was observed. However, this translated into a drastic impairment of IL-8 driven neutrophil infiltration into tissues (Hirsch *et al.*, Science, 2000, 287(5455), 1049-1053.). Recent data suggest that PI3K γ is involved in the path finding process rather than in the generation of mechanical force for motility, as random migration was not impaired in cells that lacked PI3K γ (Hannigan *et al.*, Proc. Nat. Acad. of Sciences of U.S.A., 2002, 99(6), 3603-8). Data linking PI3K γ to respiratory disease pathology came with the demonstration that PI3K γ has a central role in regulating endotoxin-induced lung infiltration and activation of neutrophils leading to acute lung injury (Yum *et al.*, J. Immunology, 2001, 167(11), 6601-8). The fact that although PI3K γ is highly expressed in leucocytes, its loss seems not to interfere with haematopoiesis, and the fact that PI3K γ -null mice are viable and fertile further implicates this PI3K isoform as a potential drug target. Work with knockout mice also established that PI3K γ is an essential amplifier of mast cell activation (Laffargue *et al.*, Immunity, 2002, 16(3), 441-451).

Thus, in addition to tumourigenesis, there is evidence that Class I PI3K enzymes play a role in other diseases (Wymann *et al.*, Trends in Pharmacological Science, 2003, 24, 366-376). Both Class Ia PI3K enzymes and the single Class Ib enzyme have important roles in cells of the immune system (Koyasu, Nature Immunology, 2003, 4, 313-319) and thus they are therapeutic targets for inflammatory and allergic indications. Recent reports demonstrate that mice deficient in PI3K γ and PI3K δ are viable, but have attenuated inflammatory and allergic responses (Ali *et al.*, Nature, 2004, 431(7011), 1007-11). Inhibition of PI3K is also useful to treat cardiovascular disease *via* anti-inflammatory effects or directly by affecting cardiac myocytes (Prasad *et al.*, Trends in Cardiovascular Medicine, 2003, 13, 206-212). Thus, inhibitors of Class I PI3K enzymes are expected to be of value in the prevention and treatment of a wide variety of diseases in addition to cancer.

Several compounds that inhibit PI3Ks and phosphatidylinositol (PI) kinase-related kinase (PI3KKs) have been identified, including wortmannin and the quercetin derivative LY294002. These compounds are reasonably specific inhibitors of PI3Ks and PI3KKs over other kinases but they lack potency and display little selectivity within the PI3K families.

Accordingly, it would be desirable to provide further effective mTOR and/or PI3K inhibitors for use in the treatment of cancer, inflammatory or obstructive airways diseases, immune or cardiovascular diseases.

Morpholino pyrimidine derivatives and PI3K inhibitors are known in the art.

5 International Patent Application WO 2004/048365 discloses compounds that possess PI3K enzyme inhibitory activity and are useful in the treatment of cancer. These compounds are arylamino- and heteroarylamino-substituted pyrimidines which differ from the compounds of the present invention by virtue of their arylamino- and heteroarylamino substituents. WO 2004/048365 does not disclose compounds with the $-XR^1$ substituents of the present
10 invention. Inhibitors of PI3K activity useful in the treatment of cancer are also disclosed in European Patent Application 1 277 738 which mentions 4-morpholino-substituted bicyclic heteroaryl compounds such as quinazoline and pyrido[3,2-*d*]pyrimidine derivatives and 4-morpholino-substituted tricyclic heteroaryl compounds but not monocyclic pyrimidine derivatives.

15 WO2007/080382, WO2008/023180 and WO2008/023159 disclose compounds that possess mTOR and/or PI3K enzyme inhibitory activity and are useful in the treatment of cancer.

A number of compounds such as 4-morpholin-4-yl-6-(phenylsulfonylmethyl)-2-pyridin-4-yl-pyrimidine and 4-{6-[(phenylsulfonyl)methyl]-2-pyridin-2-ylpyrimidin-4-yl}morpholine have been registered in the Chemical Abstracts database but no utility has been
20 indicated and there is no suggestion that these compounds have mTOR and/or PI3K inhibitory activity or useful therapeutic properties.


Surprisingly, we have found that certain morpholino pyrimidine derivatives possess useful therapeutic properties. Without wishing to be bound by theoretical constraints, it is
25 believed that the therapeutic usefulness of the derivatives is derived from their inhibitory activity against mTOR kinase and/or one or more PI3K enzyme (such as the Class Ia enzyme and/or the Class Ib enzyme). Because signalling pathways mediated by the PI3K/mTOR families have a central role in a number of cell processes including proliferation and survival, and because deregulation of these pathways is a causative factor in a wide spectrum of human
30 cancers and other diseases, it is expected that the derivatives will be therapeutically useful. In particular, it is expected that the derivatives will have anti-proliferative and/or apoptotic properties which means that they will be useful in the treatment of proliferative disease such

-9-

as cancer. The compounds of the present invention may also be useful in inhibiting the uncontrolled cellular proliferation which arises from various non-malignant diseases such as inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases.

5 Generally, the compounds of the present invention possess potent inhibitory activity against mTOR kinase but the compound may also possess potent inhibitory activity against one or more PI3K enzyme (such as the Class Ia enzyme and/or the Class Ib enzyme).

In accordance with one aspect of the present invention, there is provided a compound of formula (I)



10

formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from $-\text{CR}^4=\text{CR}^5-$, $-\text{CR}^4=\text{CR}^5\text{CR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{CR}^5=\text{CR}^4-$, $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{C}\equiv\text{C}-$, $-\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{OCR}^6\text{R}^7-$, $-\text{SCR}^6\text{R}^7-$, $-\text{S}(\text{O})\text{CR}^6\text{R}^7-$,
 15 $-\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5\text{CR}^6\text{R}^7-$,
 $-\text{NR}^4\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4-$, $-\text{NR}^4\text{C}(\text{O})-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5-$, $-\text{S}(\text{O})_2\text{NR}^4-$
 and $-\text{NR}^4\text{S}(\text{O})_2-$;

^1Y and Y^2 are independently N or CR^8 provided that one of ^1Y and Y^2 is N and the other is CR^8 ;

20 **R**¹ is a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R⁹, $-\text{OR}^9$, $-\text{SR}^9$, $-\text{SOR}^9$, $-\text{SO}_2\text{R}^9$, $-\text{COR}^9$, $-\text{CO}_2\text{R}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{COR}^{10}$, $-\text{NR}^9\text{CO}_2\text{R}^{10}$, $-\text{NR}^9\text{CONR}^{10}\text{R}^{15}$, $-\text{NR}^9\text{COCONR}^{10}\text{R}^{15}$ and $-\text{NR}^9\text{SO}_2\text{R}^{10}$;

25 **R**² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -

-10-

R^{11} , $-OR^{11}$, $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-COR^{11}$, $-CO_2R^{11}$, $-CONR^{11}R^{12}$, $-NR^{11}R^{12}$, and $-NR^{11}COCONR^{12}R^{16}$;

R^3 is selected from halo, cyano, nitro, $-R^{13}$, $-OR^{13}$, $-SR^{13}$, $-SOR^{13}$, $-SO_2R^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-NR^{13}R^{14}$, $-NR^{13}COR^{14}$, $-NR^{13}CO_2R^{14}$ and $-NR^{13}SO_2R^{14}$;

5 R^4 and R^5 are independently hydrogen or C_{1-6} alkyl;

or R^1 and R^4 together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino, bis(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-6} alkyl, bis(C_{1-6} alkyl)amino C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonylamino, C_{1-6} alkylsulfonyl(C_{1-6} alkyl)amino, sulfamoyl, C_{1-6} alkylsulfamoyl, bis(C_{1-6} alkyl)sulfamoyl, C_{1-6} alkanoylamino, C_{1-6} alkanoyl(C_{1-6} alkyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl and bis(C_{1-6} alkyl)carbamoyl;

15 R^6 and R^7 are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;

R^8 is selected from hydrogen, halo, cyano and C_{1-6} alkyl;

R^9 and R^{10} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl, carbocyclyl C_{1-6} alkyl, heterocyclyl and heterocyclyl C_{1-6} alkyl which group is optionally

20 substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino, bis(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-6} alkyl, bis(C_{1-6} alkyl)amino C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonylamino, C_{1-6} alkylsulfonyl(C_{1-6} alkyl)amino, sulfamoyl, C_{1-6} alkylsulfamoyl, bis(C_{1-6} alkyl)sulfamoyl, C_{1-6} alkanoylamino, C_{1-6} alkanoyl(C_{1-6} alkyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl and bis(C_{1-6} alkyl)carbamoyl;


25 R^{11} and R^{12} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl, carbocyclyl C_{1-6} alkyl, heterocyclyl and heterocyclyl C_{1-6} alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino, bis(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-6} alkyl, bis(C_{1-6} alkyl)amino C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonylamino, C_{1-6} alkylsulfonyl(C_{1-6} alkyl)amino, sulfamoyl, C_{1-6} alkylsulfamoyl, bis(C_{1-6} alkyl)sulfamoyl, C_{1-6} alkanoylamino, C_{1-6} alkanoyl(C_{1-6} alkyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl and bis(C_{1-6} alkyl)carbamoyl;

-11-

₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R¹³, **R¹⁴**, **R¹⁵** and **R¹⁶** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl; for use as a medicament in the treatment of proliferative disease.

In accordance with one aspect of the present invention, there is provided a compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from -CR⁴=CR⁵-, -CR⁴=CR⁵CR⁶R⁷-, -CR⁶R⁷CR⁵=CR⁴-, -C≡C-, -C≡CCR⁶R⁷-, -CR⁶R⁷C≡C-, -NR⁴CR⁶R⁷-, -OCR⁶R⁷-, -SCR⁶R⁷-, -S(O)CR⁶R⁷-, -S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-, -NR⁴C(O)NR⁵CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷-, -C(O)NR⁴-, -NR⁴C(O)-, -NR⁴C(O)NR⁵-, -S(O)₂NR⁴- and -NR⁴S(O)₂-;

¹**Y** and **Y²** are independently N or CR⁸ provided that one of ¹**Y** and **Y²** is N and the other is CR⁸;

R¹ is a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R⁹, -OR⁹, -SR⁹, -SOR⁹, -SO₂R⁹,

-12-

$-\text{COR}^9$, $-\text{CO}_2\text{R}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{COR}^{10}$, $-\text{NR}^9\text{CO}_2\text{R}^{10}$, $-\text{NR}^9\text{CONR}^{10}\text{R}^{15}$,
 $-\text{NR}^9\text{COCONR}^{10}\text{R}^{15}$ and $-\text{NR}^9\text{SO}_2\text{R}^{10}$;

R^2 is a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -
 5 R^{11} , $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SOR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{CONR}^{11}\text{R}^{12}$, $-\text{NR}^{11}\text{R}^{12}$, and -
 $\text{NR}^{11}\text{COCONR}^{12}\text{R}^{16}$;

R^3 is selected from halo, cyano, nitro, $-\text{R}^{13}$, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{SOR}^{13}$, $-\text{SO}_2\text{R}^{13}$, $-\text{COR}^{13}$, $-\text{CO}_2\text{R}^{13}$,
 $-\text{CONR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{COR}^{14}$, $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ and $-\text{NR}^{13}\text{SO}_2\text{R}^{14}$;

R^4 and R^5 are independently hydrogen or C_{1-6} alkyl;

10 or R^1 and R^4 together with the atom or atoms to which they are attached form a 4- to 10-
 membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally
 replaced with N, O or S and which ring is optionally substituted by one or more substituent
 groups selected from halo, cyano, nitro, hydroxy, oxo, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl,
 halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-}
 15 C_{1-6} alkoxy, amino, C_{1-6} alkylamino, bis(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-}
 C_{1-6} alkyl, bis(C_{1-6} alkyl)amino C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-}
 C_{1-6} alkylsulfonylamino, C_{1-6} alkylsulfonyl(C_{1-6} alkyl)amino, sulfamoyl, C_{1-6} alkylsulfamoyl,
 bis(C_{1-6} alkyl)sulfamoyl, C_{1-6} alkanoylamino, C_{1-6} alkanoyl(C_{1-6} alkyl)amino, carbamoyl, C_{1-}
 C_{1-6} alkylcarbamoyl and bis(C_{1-6} alkyl)carbamoyl;

20 R^6 and R^7 are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;

R^8 is selected from hydrogen, halo, cyano and C_{1-6} alkyl;

R^9 and R^{10} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl,
 carbocyclyl C_{1-6} alkyl, heterocyclyl and heterocyclyl C_{1-6} alkyl which group is optionally
 substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-}
 25 C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-}
 C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino, bis(C_{1-6} alkyl)amino,
 amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-6} alkyl, bis(C_{1-6} alkyl)amino C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-}
 C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonylamino, C_{1-6} alkylsulfonyl(C_{1-6} alkyl)amino, sulfamoyl, C_{1-}
 C_{1-6} alkylsulfamoyl, bis(C_{1-6} alkyl)sulfamoyl, C_{1-6} alkanoylamino, C_{1-6} alkanoyl(C_{1-6} alkyl)amino,
 30 carbamoyl, C_{1-6} alkylcarbamoyl and bis(C_{1-6} alkyl)carbamoyl;


R^{11} and R^{12} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl,
 carbocyclyl C_{1-6} alkyl, heterocyclyl and heterocyclyl C_{1-6} alkyl which group is optionally

-13-

substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R¹³, R¹⁴, R¹⁵ and R¹⁶ are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl; for use as a medicament in the treatment of proliferative disease.

In accordance with one aspect of the present invention, there is provided a compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from -CR⁴=CR⁵-, -CR⁴=CR⁵CR⁶R⁷-, -CR⁶R⁷CR⁵=CR⁴-, -C≡C-, -C≡CCR⁶R⁷-, -CR⁶R⁷C≡C-, -NR⁴CR⁶R⁷-, -OCR⁶R⁷-, -SCR⁶R⁷-, -S(O)CR⁶R⁷-, -S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-, -NR⁴C(O)NR⁵CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷-, -C(O)NR⁴-, -NR⁴C(O)-, -NR⁴C(O)NR⁵-, -S(O)₂NR⁴- and -NR⁴S(O)₂-;

¹**Y** and **Y²** are independently N or CR⁸ provided that one of ¹**Y** and **Y²** is N and the other is CR⁸;

-14-

R¹ is a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R⁹, -OR⁹, -COR⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰ and -NR⁹COR¹⁰;

R² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -R¹¹, -OR¹¹, -COR¹¹, -CONR¹¹R¹² and -NR¹¹R¹²;

R³ is selected from halo, cyano, nitro, -R¹³, -OR¹³, -COR¹³, -CONR¹³R¹⁴, -NR¹³R¹⁴ and -NR¹³COR¹⁴;

R⁴ and **R⁵** are independently hydrogen or C₁₋₆alkyl;

R⁶ and **R⁷** are independently selected from hydrogen, halo, cyano, nitro and C₁₋₆alkyl;

R⁸ is selected from hydrogen, halo, cyano and C₁₋₆alkyl;

R⁹ and **R¹⁰** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino;


R¹¹ and **R¹²** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino;

R¹³ and **R¹⁴** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino;

for use as a medicament in the treatment of proliferative disease.

In accordance with another aspect of the present invention, there is provided the use of a compound of formula (I)

-15-



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from $-\text{CR}^4=\text{CR}^5-$, $-\text{CR}^4=\text{CR}^5\text{CR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{CR}^5=\text{CR}^4-$,

5 $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{C}\equiv\text{C}-$, $-\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{OCR}^6\text{R}^7-$, $-\text{SCR}^6\text{R}^7-$, $-\text{S}(\text{O})\text{CR}^6\text{R}^7-$,

$-\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5\text{CR}^6\text{R}^7-$,

$-\text{NR}^4\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4-$, $-\text{NR}^4\text{C}(\text{O})-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5-$, $-\text{S}(\text{O})_2\text{NR}^4-$

and $-\text{NR}^4\text{S}(\text{O})_2-$;

^1Y and Y^2 are independently N or CR^8 provided that one of ^1Y and Y^2 is N and the other is

10 CR^8 ;

R¹ is a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or

more substituent group selected from halo, cyano, nitro, $-\text{R}^9$, $-\text{OR}^9$, $-\text{SR}^9$, $-\text{SOR}^9$, $-\text{SO}_2\text{R}^9$,

$-\text{COR}^9$, $-\text{CO}_2\text{R}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{COR}^{10}$, $-\text{NR}^9\text{CO}_2\text{R}^{10}$, $-\text{NR}^9\text{CONR}^{10}\text{R}^{15}$,

15 $-\text{NR}^9\text{COCONR}^{10}\text{R}^{15}$ and $-\text{NR}^9\text{SO}_2\text{R}^{10}$;

R² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -

R^{11} , $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SOR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{CONR}^{11}\text{R}^{12}$, $-\text{NR}^{11}\text{R}^{12}$ and -

$\text{NR}^{11}\text{COCONR}^{12}\text{R}^{16}$;

20 **R**³ is selected from halo, cyano, nitro, $-\text{R}^{13}$, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{SOR}^{13}$, $-\text{SO}_2\text{R}^{13}$, $-\text{COR}^{13}$, $-\text{CO}_2\text{R}^{13}$,

$-\text{CONR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{COR}^{14}$, $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ and $-\text{NR}^{13}\text{SO}_2\text{R}^{14}$;

R⁴ and **R**⁵ are independently hydrogen or C₁₋₆alkyl;

or **R**¹ and **R**⁴ together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally

25 replaced with N, O or S and which ring is optionally substituted by one or more substituent

groups selected from halo, cyano, nitro, hydroxy, oxo, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋

-16-


- ₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;
- R⁶** and **R⁷** are independently selected from hydrogen, halo, cyano, nitro and C₁₋₆alkyl;
- R⁸** is selected from hydrogen, halo, cyano and C₁₋₆alkyl;
- R⁹** and **R¹⁰** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;
- R¹¹** and **R¹²** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;
- R¹³, R¹⁴, R¹⁵ and R¹⁶** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino,

-17-

sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

in the manufacture of a medicament for use in the treatment of proliferative disease.

In accordance with another aspect of the present invention, there is provided the use of
5 a compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from -CR⁴=CR⁵-, -CR⁴=CR⁵CR⁶R⁷-, -CR⁶R⁷CR⁵=CR⁴-,

10 -C≡C-, -C≡CCR⁶R⁷-, -CR⁶R⁷C≡C-, -NR⁴CR⁶R⁷-, -OCR⁶R⁷-, -SCR⁶R⁷-, -S(O)CR⁶R⁷-,
-S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-, -NR⁴C(O)NR⁵CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷-, -C(O)NR⁴-,
-NR⁴C(O)-, -NR⁴C(O)NR⁵-, -S(O)₂NR⁴- and -NR⁴S(O)₂-;

¹**Y** and **Y**² are independently N or CR⁸ provided that one of ¹**Y** and **Y**² is N and the other is CR⁸;

15 **R**¹ is a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, -R⁹, -OR⁹, -SR⁹, -SOR⁹, -SO₂R⁹, -COR⁹, -CO₂R⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰, -NR⁹COR¹⁰, -NR⁹CO₂R¹⁰, -NR⁹CONR¹⁰R¹⁵, -NR⁹COCONR¹⁰R¹⁵ and -NR⁹SO₂R¹⁰;

20 **R**² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -R¹¹, -OR¹¹, -SR¹¹, -SOR¹¹, -SO₂R¹¹, -COR¹¹, -CO₂R¹¹, -CONR¹¹R¹², -NR¹¹R¹² and -NR¹¹COCONR¹²R¹⁶;

R³ is selected from halo, cyano, nitro, -R¹³, -OR¹³, -SR¹³, -SOR¹³, -SO₂R¹³, -COR¹³, -CO₂R¹³,

25 -CONR¹³R¹⁴, -NR¹³R¹⁴, -NR¹³COR¹⁴, -R¹³CO₂R¹⁴ and -NR¹³SO₂R¹⁴;

R⁴ and **R**⁵ are independently hydrogen or C₁₋₆alkyl;

-18-

or **R**¹ and **R**⁴ together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R⁶ and **R**⁷ are independently selected from hydrogen, halo, cyano, nitro and C₁₋₆alkyl;

R⁸ is selected from hydrogen, halo, cyano and C₁₋₆alkyl;

R⁹ and **R**¹⁰ are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;


R¹¹ and **R**¹² are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R¹³, **R**¹⁴, **R**¹⁵ and **R**¹⁶ are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro,

-19-

hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl; in the manufacture of a medicament for use in the treatment of proliferative disease.

In accordance with another aspect of the present invention, there is provided the use of a compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from -CR⁴=CR⁵-, -CR⁴=CR⁵CR⁶R⁷-, -CR⁶R⁷CR⁵=CR⁴-, -C≡C-, -C≡CCR⁶R⁷-, -CR⁶R⁷C≡C-, -NR⁴CR⁶R⁷-, -OCR⁶R⁷-, -SCR⁶R⁷-, -S(O)CR⁶R⁷-, -S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-, -NR⁴C(O)NR⁵CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷-, -C(O)NR⁴-, -NR⁴C(O)-, -NR⁴C(O)NR⁵-, -S(O)₂NR⁴- and -NR⁴S(O)₂-;

¹**Y** and **Y**² are independently N or CR⁸ provided that one of ¹**Y** and **Y**² is N and the other is CR⁸;

R¹ is a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R⁹, -OR⁹, -COR⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰ and -NR⁹COR¹⁰;

R² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -R¹¹, -OR¹¹, -COR¹¹, -CONR¹¹R¹² and -NR¹¹R¹²;

R³ is selected from halo, cyano, nitro, -R¹³, -OR¹³, -COR¹³, -CONR¹³R¹⁴, -NR¹³R¹⁴ and -NR¹³COR¹⁴;

R⁴ and **R**⁵ are independently hydrogen or C₁₋₆alkyl;

-20-

R^6 and R^7 are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;

R^8 is selected from hydrogen, halo, cyano and C_{1-6} alkyl;


R^9 and R^{10} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected
 5 from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

R^{11} and R^{12} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected
 10 from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

R^{13} and R^{14} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected
 15 from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

in the manufacture of a medicament for use in the treatment of proliferative disease.

In accordance with a further aspect of the present invention, there is also provided a
 20 compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from $-CR^4=CR^5-$, $-CR^4=CR^5CR^6R^7-$, $-CR^6R^7CR^5=CR^4-$, $-C\equiv C-$, $-$
 25 $C\equiv CCR^6R^7-$, $-CR^6R^7C\equiv C-$, $-NR^4CR^6R^7-$, $-OCR^6R^7-$, $-SCR^6R^7-$, $-S(O)CR^6R^7-$,

-21-

-S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-, -NR⁴C(O)CR⁶R⁷-, -NR⁴C(O)NR⁵CR⁶R⁷-,
 -NR⁴S(O)₂CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷-, -C(O)NR⁴-, -NR⁴C(O)-, -NR⁴C(O)NR⁵-, -(O)₂NR⁴-
 and -NR⁴S(O)₂-;

¹Y and Y² are independently N or CR⁸ provided that one of ¹Y and Y² is N and the other is
 5 CR⁸;

R¹ is a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, -R⁹, -OR⁹, -SR⁹, -SOR⁹, -O₂R⁹, -COR⁹, -CO₂R⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰, -NR⁹COR¹⁰, -NR⁹CO₂R¹⁰, -NR⁹CONR¹⁰R¹⁵,
 10 -NR⁹COCONR¹⁰R¹⁵ and NR⁹SO₂R¹⁰;

R² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -R¹¹, -OR¹¹, -SR¹¹, -SOR¹¹, -SO₂R¹¹, -COR¹¹, -CO₂R¹¹, -CONR¹¹R¹², -NR¹¹R¹² and -NR¹¹COCONR¹²R¹⁶;

15 **R³** is selected from halo, cyano, nitro, -R¹³, -OR¹³, -R¹³, -SOR¹³, -SO₂R¹³, -COR¹³, -CO₂R¹³, -CONR¹³R¹⁴, -NR¹³R¹⁴, -NR¹³COR¹⁴, -NR¹³CO₂R¹⁴ and -NR¹³SO₂R¹⁴;

R⁴ and **R⁵** are independently hydrogen or C₁₋₆alkyl;

or **R¹** and **R⁴** together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally
 20 replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R⁶ and **R⁷** are independently selected from hydrogen, halo, cyano, nitro and C₁₋₆alkyl;

R⁸ is selected from hydrogen, halo, cyano and C₁₋₆alkyl;

30 **R⁹** and **R¹⁰** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋


-22-

alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R¹¹ and **R¹²** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R¹³, **R¹⁴**, **R¹⁵** and **R¹⁶** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl.

In accordance with a further aspect of the present invention, there is also provided a compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from $-\text{CR}^4=\text{CR}^5-$, $-\text{CR}^4=\text{CR}^5\text{CR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{CR}^5=\text{CR}^4-$,
 $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{C}\equiv\text{C}-$, $-\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{OCR}^6\text{R}^7-$, $-\text{SCR}^6\text{R}^7-$, $-\text{S}(\text{O})\text{CR}^6\text{R}^7-$,
 $-\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4-$,
 5 $-\text{NR}^4\text{C}(\text{O})-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5-$, $-\text{S}(\text{O})_2\text{NR}^4-$ and $-\text{NR}^4\text{S}(\text{O})_2-$;

¹Y and **Y²** are independently N or CR^8 provided that one of **¹Y** and **Y²** is N and the other is CR^8 ;

R¹ is a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl, carbocyclyl C_{1-6} alkyl, heterocyclyl and heterocyclyl C_{1-6} alkyl, which group is optionally substituted by one or
 10 more substituent group selected from halo, cyano, nitro, $-\text{R}^9$, $-\text{OR}^9$, $-\text{SR}^9$, $-\text{SOR}^9$, $-\text{O}_2\text{R}^9$,
 $-\text{COR}^9$, $-\text{CO}_2\text{R}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{COR}^{10}$, $-\text{NR}^9\text{CO}_2\text{R}^{10}$, $-\text{NR}^9\text{CONR}^{10}\text{R}^{15}$,
 $-\text{NR}^9\text{COCONR}^{10}\text{R}^{15}$ and $\text{NR}^9\text{SO}_2\text{R}^{10}$;

R² is a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -
 15 R^{11} , $-\text{OR}^{11}$, $-\text{SR}^{11}$, $-\text{SOR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{COR}^{11}$, $-\text{CO}_2\text{R}^{11}$, $-\text{CONR}^{11}\text{R}^{12}$, $-\text{NR}^{11}\text{R}^{12}$ and -
 $\text{NR}^{11}\text{COCONR}^{12}\text{R}^{16}$;

R³ is independently selected from halo, cyano, nitro, $-\text{R}^{13}$, $-\text{OR}^{13}$, $-\text{R}^{13}$, $-\text{SOR}^{13}$, $-\text{SO}_2\text{R}^{13}$,
 $-\text{COR}^{13}$, $-\text{CO}_2\text{R}^{13}$, $-\text{CONR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{COR}^{14}$, $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ and $-\text{NR}^{13}\text{SO}_2\text{R}^{14}$;

R⁴ and **R⁵** are independently hydrogen or C_{1-6} alkyl;

20 or **R¹** and **R⁴** together with the atom or atoms to which they are attached form a 4- to 10-
 membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally
 replaced with N, O or S and which ring is optionally substituted by one or more substituent
 groups selected from halo, cyano, nitro, hydroxy, oxo, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl,
 halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-}
 25 C_{6} alkoxy, amino, C_{1-6} alkylamino, bis(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-}
 C_{6} alkyl, bis(C_{1-6} alkyl)amino C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-}
 C_{6} alkylsulfonylamino, C_{1-6} alkylsulfonyl(C_{1-6} alkyl)amino, sulfamoyl, C_{1-6} alkylsulfamoyl,
 bis(C_{1-6} alkyl)sulfamoyl, C_{1-6} alkanoylamino, C_{1-6} alkanoyl(C_{1-6} alkyl)amino, carbamoyl, C_{1-}
 C_{6} alkylcarbamoyl and bis(C_{1-6} alkyl)carbamoyl;

30 **R⁶** and **R⁷** are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;


R⁸ is selected from hydrogen, halo, cyano and C_{1-6} alkyl;

- R⁹** and **R¹⁰** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;
- R¹¹** and **R¹²** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

- R¹³**, **R¹⁴**, **R¹⁵** and **R¹⁶** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl.

In accordance with a further aspect of the present invention, there is also provided a compound of formula (I)

-25-



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from $-\text{CR}^4=\text{CR}^5-$, $-\text{CR}^4=\text{CR}^5\text{CR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{CR}^5=\text{CR}^4-$, $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{C}\equiv\text{C}-$, $-\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{OCR}^6\text{R}^7-$, $-\text{SCR}^6\text{R}^7-$, $-\text{S}(\text{O})\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4-$, $-\text{NR}^4\text{C}(\text{O})-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5-$, $-\text{S}(\text{O})_2\text{NR}^4-$ and $-\text{NR}^4\text{S}(\text{O})_2-$;

^1Y and Y^2 are independently N or CR^8 provided that one of ^1Y and Y^2 is N and the other is CR^8 ;

R¹ is a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R⁹, $-\text{OR}^9$, $-\text{COR}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$ and $-\text{R}^9\text{COR}^{10}$;

R² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, -

R¹¹, $-\text{OR}^{11}$, $-\text{COR}^{11}$, $-\text{CONR}^{11}\text{R}^{12}$ and $-\text{NR}^{11}\text{R}^{12}$;

R³ is selected from halo, cyano, nitro, $-\text{R}^{13}$, $-\text{OR}^{13}$, $-\text{COR}^{13}$, $-\text{CONR}^{13}\text{R}^{14}$, $-\text{NR}^{13}\text{R}^{14}$ and $-\text{NR}^{13}\text{COR}^{14}$;

R⁴ and **R**⁵ are independently hydrogen or C₁₋₆alkyl;

R⁶ and **R**⁷ are independently selected from hydrogen, halo, cyano, nitro and C₁₋₆alkyl;

R⁸ is selected from hydrogen, halo, cyano and C₁₋₆alkyl;

R⁹ and **R**¹⁰ are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino;

R¹¹ and **R**¹² are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected

from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino;

R¹³ and **R¹⁴** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention. Solvates and mixtures thereof also form an aspect of the present invention. For example, a suitable solvate of a compound of formula (I) is, for example, a hydrate such as a hemi-hydrate, a mono-hydrate, a di-hydrate or a tri-hydrate or an alternative quantity thereof.

The present invention relates to the compounds of formula (I) as herein defined as well as to salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (I) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of compounds of formula (I) as herein defined which are sufficiently basic to form such salts. Such acid addition salts include but are not limited to fumarate, methanesulfonate, hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulfuric acid. In addition where compounds of formula (I) are sufficiently acidic, salts are base salts and examples include but are not limited to, an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine, ethanolamine, diethanolamine, triethanolamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, dibenzylamine or amino acids such as lysine.

The compounds of formula (I) may also be provided as *in vivo* hydrolysable esters. An *in vivo* hydrolysable ester of a compound of formula (I) containing carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol. Such esters can be identified by

administering, for example, intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluid.

Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl, 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl, and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention.

10 Suitable pharmaceutically acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups
15 for hydroxy include C₁₋₁₀alkanoyl, for example formyl, acetyl, benzoyl, phenylacetyl, substituted benzoyl and phenylacetyl; C₁₋₁₀alkoxycarbonyl (to give alkyl carbonate esters), for example ethoxycarbonyl; di-C₁₋₄alkylcarbamoyl and *N*-(di-C₁₋₄alkylaminoethyl)-*N*-C₁₋₄alkylcarbamoyl (to give carbamates); di-C₁₋₄alkylaminoacetyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, C₁₋₄alkylaminomethyl and di-(C₁₋₄alkyl)aminomethyl, and morpholino or piperazino linked from
20 a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting *in vivo* hydrolysable esters include, for example, R^AC(O)OC₁₋₆alkyl-CO-, wherein R^A is for example, benzyloxy-C₁₋₄alkyl, or phenyl. Suitable substituents on a phenyl group in such esters include, for example, 4-C₁₋₄piperazino-C₁₋₄alkyl, piperazino-C₁₋₄alkyl
25 and morpholino-C₁₋₄alkyl.

The compounds of the formula (I) may be also be administered in the form of a prodrug which is broken down in the human or animal body to give a compound of the formula (I). Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see:

30 a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);

- b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- 5 d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and
- e) N. Kakeya, et al., Chem Pharm Bull, 32, 692 (1984).

In this specification the generic term "C_{p-q}alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only (i.e. *n*-propyl and isopropyl) and references to
10 individual branched-chain alkyl groups such as "*tert*-butyl" are specific for the branched chain version only.

The prefix C_{p-q} in C_{p-q}alkyl and other terms (where p and q are integers) indicates the range of carbon atoms that are present in the group, for example C₁₋₄alkyl includes C₁alkyl (methyl), C₂alkyl (ethyl), C₃alkyl (propyl as *n*-propyl and isopropyl) and C₄alkyl (*n*-butyl,
15 *sec*-butyl, isobutyl and *tert*-butyl).

The term C_{p-q}alkoxy comprises -O-C_{p-q}alkyl groups.

The term C_{p-q}alkanoyl comprises -C(O)alkyl groups.

The term halo includes fluoro, chloro, bromo and iodo.

"Carbocyclyl" is a saturated, unsaturated or partially saturated monocyclic, bicyclic or
20 tricyclic ring system containing from 3 to 14 ring atoms, wherein a ring CH₂ group may be replaced with a C=O group. "Carbocyclyl" includes "aryl", "C_{p-q}cycloalkyl" and "C_{p-q}cycloalkenyl".

"aryl" is an aromatic monocyclic, bicyclic or tricyclic carbocyclyl ring system.

"C_{p-q}cycloalkenyl" is an unsaturated or partially saturated monocyclic, bicyclic or
25 tricyclic carbocyclyl ring system containing at least 1 C=C bond and wherein a ring CH₂ group may be replaced with a C=O group.

"C_{p-q}cycloalkyl" is a saturated monocyclic, bicyclic or tricyclic carbocyclyl ring system and wherein a ring CH₂ group may be replaced with a C=O group.

"Heterocyclyl" is a saturated, unsaturated or partially saturated monocyclic, bicyclic
30 or tricyclic ring system containing from 3 to 14 ring atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulfur or oxygen, which ring may be carbon or nitrogen linked and wherein a ring nitrogen or sulfur atom may be oxidised and wherein a ring CH₂ group may be

replaced with a C=O group. "Heterocyclyl" includes "heteroaryl", "cycloheteroalkyl" and "cycloheteroalkenyl".

"Heteroaryl" is an aromatic monocyclic, bicyclic or tricyclic heterocyclyl, particularly having 5 to 10 ring atoms, of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulfur or oxygen where a ring nitrogen or sulfur may be oxidised.

"Cycloheteroalkenyl" is an unsaturated or partially saturated monocyclic, bicyclic or tricyclic heterocyclyl ring system, particularly having 5 to 10 ring atoms, of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulfur or oxygen, which ring may be carbon or nitrogen linked and wherein a ring nitrogen or sulfur atom may be oxidised and wherein a ring CH₂ group may be replaced with a C=O group.

"Cycloheteroalkyl" is a saturated monocyclic, bicyclic or tricyclic heterocyclic ring system, particularly having 5 to 10 ring atoms, of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulfur or oxygen, which ring may be carbon or nitrogen linked and wherein a ring nitrogen or sulfur atom may be oxidised and wherein a ring CH₂ group may be replaced with a C=O group.

This specification may make use of composite terms to describe groups comprising more than one functionality. Unless otherwise described herein, such terms are to be interpreted as is understood in the art. For example carbocyclylC_{p-q}alkyl comprises C_{p-q}alkyl substituted by carbocyclyl, heterocyclylC_{p-q}alkyl comprises C_{p-q}alkyl substituted by heterocyclyl, and bis(C_{p-q}alkyl)amino comprises amino substituted by 2 C_{p-q}alkyl groups which may be the same or different.

HaloC_{p-q}alkyl is a C_{p-q}alkyl group that is substituted by 1 or more halo substituents and particularly 1, 2 or 3 halo substituents. Similarly, other generic terms containing halo such as haloC_{p-q}alkoxy may contain 1 or more halo substituents and particularly 1, 2 or 3 halo substituents.

HydroxyC_{p-q}alkyl is a C_{p-q}alkyl group that is substituted by 1 or more hydroxyl substituents and particularly by 1, 2 or 3 hydroxy substituents. Similarly other generic terms containing hydroxy such as hydroxyC_{p-q}alkoxy may contain 1 or more and particularly 1, 2 or 3 hydroxy substituents.

C_{p-q}alkoxyC_{p-q}alkyl is a C_{p-q}alkyl group that is substituted by 1 or more C_{p-q}alkoxy substituents and particularly 1, 2 or 3 C_{p-q}alkoxy substituents. Similarly other generic terms

containing C_{p-q}alkoxy such as C_{p-q}alkoxyC_{p-q}alkoxy may contain 1 or more C_{p-q}alkoxy substituents and particularly 1, 2 or 3 C_{p-q}alkoxy substituents.

Where optional substituents are chosen from “1 or 2”, from “1, 2, or 3” or from “1, 2, 3 or 4” groups or substituents it is to be understood that this definition includes all
 5 substituents being chosen from one of the specified groups i.e. all substituents being the same or the substituents being chosen from two or more of the specified groups i.e. the substituents not being the same.

Compounds of the present invention have been named with the aid of computer software (ACD/Name version 8.0).

10 “Proliferative disease(s)” includes malignant disease(s) such as cancer as well as non-malignant disease(s) such as inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases.

Suitable values for any R group or any part or substituent for such groups include:

for C ₁₋₄ alkyl:	methyl, ethyl, propyl, butyl, 2-methylpropyl and <i>tert</i> -butyl;
15 for C ₁₋₆ alkyl:	C ₁₋₄ alkyl, pentyl, 2,2-dimethylpropyl, 3-methylbutyl and hexyl;
for C ₃₋₆ cycloalkyl:	cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;
for C ₃₋₆ cycloalkylC ₁₋₄ alkyl:	cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl;
20 for aryl:	phenyl and naphthyl;
for arylC ₁₋₄ alkyl:	benzyl, phenethyl, naphthylmethyl and naphthylethyl;
for carbocyl:	aryl, cyclohexenyl and C ₃₋₆ cycloalkyl;
for halo:	fluoro, chloro, bromo and iodo;
for C ₁₋₄ alkoxy:	methoxy, ethoxy, propoxy and isopropoxy;
25 for C ₁₋₆ alkoxy:	C ₁₋₄ alkoxy, pentyloxy, 1-ethylpropoxy and hexyloxy;
for C ₁₋₆ alkanoyl:	acetyl, propanoyl and 2-methylpropanoyl;
for heteroaryl:	pyridyl, imidazolyl, quinolinyl, cinnolyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, triazolyl, oxazolyl, isoxazolyl, furanyl, pyridazinyl, pyrazinyl, indolyl, benzofuranyl, dibenzofuranyl and benzothienyl;
30 for heteroarylC ₁₋₄ alkyl:	pyrrolylmethyl, pyrrolylethyl, imidazolylmethyl, imidazolylethyl, pyrazolylmethyl, pyrazolylethyl,

-31-

furanylmethyl, furanylethyl, thienylmethyl, theinylethyl,
 pyridylmethyl, pyridylethyl, pyrazinylmethyl, pyrazinylethyl,
 pyrimidinylmethyl, pyrimidinylethyl, pyrimidinylpropyl,
 pyrimidinylbutyl, imidazolylpropyl, imidazolylbutyl,
 5 quinolinylpropyl, 1,3,4-triazolylpropyl and oxazolylmethyl;
 for heterocyclyl: heteroaryl, pyrrolidinyl, isoquinolinyl, quinoxalinyl,
 benzothiazolyl, benzoxazolyl, piperidinyl, piperazinyl,
 azetidiny, morpholinyl, tetrahydroisoquinolinyl,
 tetrahydroquinolinyl, indolinyl, dihydro-2H-pyranyl and
 10 tetrahydrofuranyl.

It should be noted that examples given for terms used in the description are not limiting.

Particular values of m, X, ¹Y and Y², XR¹, R¹, X-R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,
 R¹⁰, R¹¹ and R¹² are as follows. Such values may be used idividually or in combination where
 15 appropriate, in connection with any aspect of the invention, or part thereof, and with any of
 the definitions, claims or embodiments defined herein.

X

In one aspect of the invention X is a linker group selected from -NR⁴CR⁶R⁷-,
 -OCR⁶R⁷-, -SCR⁶R⁷-, -S(O)CR⁶R⁷-, -S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-,
 20 -NR⁴C(O)NR⁵CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷-, -NR⁴C(O)-, -C(O)NR⁴-, -S(O)₂NR⁴- and
 -NR⁴S(O)₂-.

In another aspect X is a linker group selected from -NR⁴CR⁶R⁷-, -OCR⁶R⁷-, -SCR⁶R⁷-,
 -S(O)CR⁶R⁷-, -S(O)₂CR⁶R⁷-, -C(O)NR⁴CR⁶R⁷-, -NR⁴C(O)NR⁵CR⁶R⁷-, -S(O)₂NR⁴CR⁶R⁷,
 -C(O)NR⁴- and -NR⁴C(O)-.

25 In a further aspect X is a linker group selected from -NR⁴CR⁶R⁷-, -OCR⁶R⁷-,
 -SCR⁶R⁷-, -S(O)CR⁶R⁷-, -S(O)₂CR⁶R⁷-, -C(O)NR⁴-, and -NR⁴C(O)-.

In a further aspect X is a linker group selected from -NR⁴CR⁶R⁷-, -OCR⁶R⁷-,
 -SCR⁶R⁷-, -S(O)CR⁶R⁷- and -S(O)₂CR⁶R⁷-.

In yet another aspect X is a linker group selected from -SCR⁶R⁷-, -S(O)CR⁶R⁷- and
 30 -S(O)₂CR⁶R⁷-.

In another aspect X is a linker group selected from -NR⁴CH₂-, -OCH₂-, -SCH₂-,
 -S(O)CH₂-, -S(O)₂CH₂-, -C(O)NR⁴-, and -NR⁴C(O)-.

-32-

In another aspect X is a linker group selected from $\text{-NR}^4\text{CH}_2\text{-}$, $\text{-OCH}_2\text{-}$, $\text{-SCH}_2\text{-}$, $\text{-S(O)CH}_2\text{-}$ and $\text{-S(O)}_2\text{CH}_2\text{-}$.

In a further aspect X is a linker group selected from $\text{-NHCH}_2\text{-}$, $\text{-N(CH}_3\text{)CH}_2\text{-}$, $\text{-OCH}_2\text{-}$, $\text{-SCH}_2\text{-}$, $\text{-S(O)CH}_2\text{-}$, $\text{-S(O)}_2\text{CH}_2\text{-}$, -C(O)NH- , $\text{-C(O)N(CH}_3\text{)-}$, -NHC(O)- and $\text{-N(CH}_3\text{)C(O)-}$.

5 In yet a further aspect X is a linker group selected from $\text{-NHCH}_2\text{-}$, $\text{-N(CH}_3\text{)CH}_2\text{-}$, $\text{-OCH}_2\text{-}$, $\text{-SCH}_2\text{-}$ and $\text{-S(O)}_2\text{CH}_2\text{-}$.

In another aspect X is $\text{-SCH}_2\text{-}$ or $\text{-S(O)}_2\text{CH}_2\text{-}$.

In another aspect X is $\text{-S(O)}_2\text{CH}_2\text{-}$.

In a further aspect X is a linker group selected from $\text{-S(O)}_2\text{CR}^6\text{R}^7\text{-}$ and $\text{-C(O)NR}^4\text{-}$.

10 **¹Y and Y²**

In one aspect of the invention ¹Y is N and Y² is CR⁸.

In another aspect ¹Y is N and Y² is CH.

In yet another aspect ¹Y is CR⁸ and Y² is N.

In a further aspect ¹Y is CH or CF and Y² is N.

15 In yet a further aspect ¹Y is CH and Y² is N.

R¹

In one aspect of the invention R¹ is a group selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, aryl, C₃₋₆cycloalkylC₁₋₄alkyl, arylC₁₋₄alkyl, cycloheteroalkyl, heteroaryl, cycloheteroalkylC₁₋₄alkyl, heteroarylC₁₋₄alkyl, which group is optionally substituted by one or more substituent
20 group selected from halo, cyano, nitro, R⁹, -OR⁹, -COR⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰ and -NR⁹COR¹⁰.

In another aspect, R¹ is a group selected from methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, cyclopentyl, cyclohexyl, phenyl, benzyl, phenethyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolidinylmethyl, pyrrolidinylethyl, pyrrolylmethyl, pyrrolylethyl, imidazolylmethyl, imidazolylethyl, pyrazolylmethyl, pyrazolylethyl, furanylmethyl, furanylethyl, thienylmethyl, thienylethyl, pyridinylmethyl, pyridinylethyl, pyrimidinylmethyl, pyrimidinylethyl, pyrazinylmethyl and pyrazinylethyl, which group is optionally substituted by 1, 2 or 3 substituent group selected
25 from halo, cyano, nitro, R⁹, -OR⁹, -COR⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰ and -NR⁹COR¹⁰.

30 In a further aspect, R¹ is a group selected from methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, benzyl, phenethyl, pyridinyl, pyrazolylethyl, furanylmethyl, thienylmethyl, and pyrazinylethyl, which group is optionally substituted by 1 or 2 substituent

-33-

group selected from halo, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, -NHCONHC₆H₅, -NHCOCH₃, -CONH₂ and -CONHCH₃.

In a further aspect, R¹ is a group selected from methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, benzyl, phenethyl, pyridinyl, pyrazolylethyl, furanylmethyl, thienylmethyl, and pyrazinylethyl, which group is optionally substituted by 1 or 2 substituent group selected from halo, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, -CONH₂ and -CONHCH₃.

In yet another aspect R¹ is a group selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclohexyl, -CH₂CN, -CH₂C(O)NH₂, -CH₂CH₂NC(O)CH₃, phenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2-chloro-6-fluorophenyl, 3-chloro-4-fluorophenyl, 4-bromo-2-fluorophenyl, 4-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-(N-methylaminocarbonyl)phenyl, benzyl, 4-fluorobenzyl, 2-chlorobenzyl, 2-chloro-6-fluorobenzyl, 4-methoxybenzyl, phenethyl, 3-trifluorophenethyl, furan-2-ylmethyl, thien-2-ylmethyl, 2-pyrazin-2-ylethyl, pyridin-3-yl, 2-methylpyridin-3-yl, 2-aminocarbonylpyridin-3-yl, 2-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-[(anilincarbonyl)amino]phenyl.

In yet another aspect R¹ is a group selected from methyl, ethyl, isopropyl, sec-butyl, isobutyl, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-[(anilincarbonyl)amino]phenyl.

-X-R¹

In yet another aspect -XR¹ is a group selected from -CH₂SO₂-R¹ and -C(CH₃)₂SO₂-R¹ wherein R¹ is methyl, ethyl, isopropyl, sec-butyl, isobutyl or phenyl.

In yet another aspect -XR¹ is -NHCO-R¹ wherein R¹ is 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl or 4-[(anilincarbonyl)amino]phenyl.

R²

In one aspect of the invention R^2 is selected from aryl and heteroaryl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, $-R^{11}$, $-OR^{11}$, $-COR^{11}$, $-CONR^{11}R^{12}$ and $-NR^{11}R^{12}$.

In another aspect R^2 is selected from phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, $-R^{11}$, $-OR^{11}$, $-COR^{11}$, $-CONR^{11}R^{12}$ and $-NR^{11}R^{12}$.

In another aspect R^2 is selected from morpholinyl, piperidinyl, phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, $-CONH_2$, $-CONHCH_3$ and $-CON(CH_3)_2$.

In another aspect R^2 is selected from phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, $-CONH_2$, $-CONHCH_3$ and $-CON(CH_3)_2$.

In yet another aspect R^2 is 3-(hydroxymethyl)phenyl, 4-(hydroxymethyl)phenyl, 4-(cyanomethyl)phenyl, 3,4-dimethoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-phenoxyphenyl, 3-pyrrolidin-1-ylphenyl, 3-(aminocarbonyl)phenyl, 4-(dimethylaminocarbonyl)phenyl, furan-3-yl, thien-3-yl, 5-(hydroxymethyl)thien-2-yl, pyridin-2-yl, pyridin-4-yl, 2-methoxypyridin-5-yl, 2-methoxypyrimidin-5-yl, 2-methoxynaphth-6-yl, 5,7-diazabicyclo[4.3.0]nona-2,4,8,10-tetraenyl, azaindolyl, indol-5-yl, 1-methylindol-5-yl, quinolin-6-yl, benzimidazolyl, benzofuran-2-yl, dibenzofuran-1-yl and benzothien-3-yl.

In yet a further aspect R^2 is pyridin-2-yl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-hydroxymethylphenyl, 4-hydroxymethylphenyl or indol-5-yl.

In another aspect R^2 is phenyl, pyrazol-3-yl, pyrazol-4-yl, hydroxypiperidinyl, indol-5-yl, azaindolyl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-

-35-

aminocarbonylindol-5-yl morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl, methylmorpholinyl or dimethylmorpholinyl.

In another aspect R^2 is (pyrazol-3yl)amino, hydroxypiperidinyl, indol-4-yl, indol-5-yl, indol-6-yl, azaindolyl, benzimidazol-5-yl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-aminocarbonylindol-5-yl, 2-aminocarbonylindol-6-yl, 3-aminocarbonylindol-6-yl, morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl or methylmorpholinyl.

In yet a further aspect R^2 is azaindolyl, indol-5-yl, benzimidazolyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-hydroxymethylphenyl or 4-hydroxymethylphenyl

In another aspect R^2 is pyridin-2-yl.

10 In a further aspect R^2 is 3-hydroxyphenyl or 4-hydroxyphenyl.

In yet another aspect R^2 is 3-hydroxymethylphenyl or 4-hydroxymethylphenyl.

In yet a further aspect R^2 is indol-5-yl.

In one aspect R^2 is morpholinyl.

In another aspect R^2 is morpholinyl, methylmorpholinyl or dimethylmorpholinyl.

15 R^3

In one aspect of the invention R^3 is methyl.

R^4

In one aspect of the invention R^4 is hydrogen or methyl.

In another aspect R^4 is hydrogen.

20 R^5

In one aspect of the invention R^5 is hydrogen or methyl.

In another aspect R^5 is hydrogen.

R^6

In one aspect of the invention R^6 is hydrogen or methyl.

25 In another aspect R^6 is hydrogen.

R^7

In one aspect of the invention R^7 is hydrogen or methyl.

In another aspect R^7 is hydrogen.

In another aspect of the invention, when R^6 is methyl, R^7 is methyl.

30 R^8

In one aspect of the invention R^8 is hydrogen or halo.

In another aspect R^8 is hydrogen or fluoro.

-36-

In a further aspect R^8 is hydrogen.

R^9

In one aspect of the invention R^9 is hydrogen or C_{1-4} alkyl optionally substituted by 1, 2 or 3 substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-4} alkoxy, amino, C_{1-4} alkylamino and bis(C_{1-4} alkyl)amino.

In another aspect R^9 is hydrogen or C_{1-4} alkyl optionally substituted by 1, 2 or 3 halo substituents.

In a further aspect R^9 is hydrogen, methyl or trifluoromethyl.

R^{10}

In one aspect of the invention R^{10} is hydrogen.

R^{11}

In one aspect of the invention R^{11} is hydrogen or a group selected from C_{1-4} alkyl, aryl and cycloheteroalkyl which group is optionally substituted by 1, 2 or 3 groups selected from halo, hydroxy and cyano.

In another aspect R^{11} is hydrogen, methyl optionally substituted with hydroxy or cyano, phenyl or pyrrolidinyl.

In another aspect R^{11} is hydrogen or methyl.

R^{12}

In one aspect of the invention R^{12} is hydrogen or methyl.

In a particular class of compound of formula (I), or a pharmaceutically acceptable salt thereof;

X is a linker group selected from $-NR^4CR^6R^7-$, $-OCR^6R^7-$, $-SCR^6R^7-$, $-S(O)CR^6R^7-$, $-S(O)_2CR^6R^7-$, $-C(O)NR^4CR^6R^7-$, $-NR^4C(O)NR^5CR^6R^7-$, $-S(O)_2NR^4CR^6R^7-$, $-NR^4C(O)-$, $-C(O)NR^4-$, $-S(O)_2NR^4-$ and $-NR^4S(O)_2-$;

^1Y and Y^2 are independently N or CR^8 provided that one of ^1Y and Y^2 is N and the other is CR^8 ;

R^1 is a group selected from C_{1-6} alkyl, carbocyclyl, carbocyclyl C_{1-6} alkyl, heterocyclyl and heterocyclyl C_{1-6} alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R^9 , $-OR^9$, $-COR^9$, $-CONR^9R^{10}$, $-NR^9R^{10}$ and $-NR^9COR^{10}$;

-37-

R^2 is selected from aryl and heteroaryl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, $-R^{11}$, $-OR^{11}$, $-COR^{11}$, $-CONR^{11}R^{12}$ and $-NR^{11}R^{12}$;

R^3 is methyl;

5 R^4 and R^5 are independently hydrogen or C_{1-6} alkyl;

R^6 and R^7 are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;

R^8 is selected from hydrogen, halo, cyano and C_{1-6} alkyl;

10 R^9 and R^{10} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

15 R^{11} and R^{12} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

20 R^{13} and R^{14} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino.

In another particular class of compound of formula (I), or a pharmaceutically acceptable salt thereof;

25 X is a linker group selected from $-NR^4CR^6R^7-$, $-OCR^6R^7-$, $-SCR^6R^7-$, $-S(O)CR^6R^7-$, $-S(O)_2CR^6R^7-$, $-C(O)NR^4CR^6R^7-$, $-NR^4C(O)NR^5CR^6R^7-$, $-S(O)_2NR^4CR^6R^7-$, $-C(O)NR^4-$ and $-NR^4C(O)-$;

^1Y is CR^8 and Y^2 is N;

30 R^1 is a group selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, C_{3-6} cycloalkyl C_{1-4} alkyl, aryl C_{1-4} alkyl, cycloheteroalkyl, heteroaryl, cycloheteroalkyl C_{1-4} alkyl, heteroaryl C_{1-4} alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R^9 , $-OR^9$, $-COR^9$, $-CONR^9R^{10}$, $-NR^9R^{10}$ and $-NR^9COR^{10}$.

-38-

R^2 is selected from aryl and heteroaryl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, $-R^{11}$, $-OR^{11}$, $-COR^{11}$, $-CONR^{11}R^{12}$ and $-NR^{11}R^{12}$;

R^3 is methyl;

5 R^4 and R^5 are independently hydrogen or C_{1-6} alkyl;

R^6 and R^7 are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;

R^8 is selected from hydrogen, halo, cyano and C_{1-6} alkyl;

10 R^9 and R^{10} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

15 R^{11} and R^{12} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

20 R^{13} and R^{14} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino.

In a further particular class of compound of formula (I), or a pharmaceutically acceptable salt thereof;

25 X is a linker group selected from $-NR^4CR^6R^7-$, $-OCR^6R^7-$, $-SCR^6R^7-$, $-S(O)CR^6R^7-$, $-S(O)_2CR^6R^7-$, $-C(O)NR^4-$, and $-NR^4C(O)-$;

^1Y is CH or CF and Y^2 is N;

30 R^1 is a group selected from methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, benzyl, phenethyl, pyridinyl, pyrazolylethyl, furanylmethyl, thienylmethyl, and pyrazinylethyl, which group is optionally substituted by 1 or 2 substituent group selected from halo, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, $-NHCONHC_6H_5$, $-NHCOCH_3$, $-CONH_2$ and $-CONHCH_3$;

-39-

R^2 is selected from morpholinyl, piperidinyl, phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothieryl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, $-CONH_2$, $-CONHCH_3$ and $-CON(CH_3)_2$;

R^3 is methyl;

R^4 is hydrogen or methyl;

R^6 is hydrogen or methyl;

10 R^7 is hydrogen or methyl.

In another particular class of compound of formula (I), or a pharmaceutically acceptable salt thereof;

X is a linker group selected from $-NR^4CR^6R^7-$, $-OCR^6R^7-$, $-SCR^6R^7-$, $-S(O)CR^6R^7-$, $-S(O)_2CR^6R^7-$, $-C(O)NR^4CR^6R^7-$, $-NR^4C(O)NR^5CR^6R^7-$, $-S(O)_2NR^4CR^6R^7-$, $-C(O)NR^4-$ and -
15 $NR^4C(O)-$;

^1Y is CR^8 and Y^2 is N;

R^1 is a group selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, C_{3-6} cycloalkyl C_{1-4} alkyl, aryl C_{1-4} alkyl, cycloheteroalkyl, heteroaryl, cycloheteroalkyl C_{1-4} alkyl, heteroaryl C_{1-4} alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R^9 , $-OR^9$, $-COR^9$, $-CONR^9R^{10}$, $-NR^9R^{10}$ and $-NR^9COR^{10}$.

R^2 is selected from aryl and heteroaryl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, $-R^{11}$, $-OR^{11}$, $-COR^{11}$, $-CONR^{11}R^{12}$ and $-NR^{11}R^{12}$;

R^3 is methyl;

25 R^4 and R^5 are independently hydrogen or C_{1-6} alkyl;

R^6 and R^7 are independently selected from hydrogen, halo, cyano, nitro and C_{1-6} alkyl;

R^8 is selected from hydrogen, halo, cyano and C_{1-6} alkyl;

R^9 and R^{10} are independently hydrogen or a group selected from C_{1-6} alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected
30 from halo, cyano, nitro, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkoxy, amino, C_{1-6} alkylamino and bis(C_{1-6} alkyl)amino;

-40-

R¹¹ and **R¹²** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino;

R¹³ and **R¹⁴** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino and bis(C₁₋₆alkyl)amino.

In a further particular class of compound of formula (I), or a pharmaceutically acceptable salt thereof;

X is a linker group selected from -S(O)₂CR⁶R⁷-, -C(O)NR⁴- and -NR⁴C(O)-;

¹**Y** is CH or CF and **Y²** is N;

R¹ is a group selected from methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, cyclohexyl, phenyl, benzyl, phenethyl, pyridinyl, pyrazolylethyl, furanylmethyl, thienylmethyl, and pyrazinylethyl, which group is optionally substituted by 1 or 2 substituent group selected from halo, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, -NHCONHC₆H₅, -NHCOCH₃, -CONH₂ and -CONHCH₃;

R² is selected from morpholinyl, piperidinyl, phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, -CONH₂, -CONHCH₃ and -CON(CH₃)₂;

R³ is methyl;

R⁴ is hydrogen or methyl;

R⁶ is hydrogen or methyl;

R⁷ is hydrogen or methyl.

In a further particular class of compound of formula (I), or a pharmaceutically acceptable salt thereof;

X is a linker group selected from -S(O)₂CR⁶R⁷- and -C(O)NR⁴-;

-41-

¹Y is CH and Y² is N;

R¹ is a group selected from methyl, ethyl, isopropyl, sec-butyl, isobutyl, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-[(anilincarbonyl)amino]phenyl;
 5 R² is is (pyrazol-3yl)amino, hydroxypiperidinyl, indol-4-yl, indol-5-yl, indol-6-yl, azaindolyl, benzimidazol-5-yl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-aminocarbonylindol-5-yl, 2-aminocarbonylindol-6-yl, 3-aminocarbonylindol-6-yl, morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl or methylmorpholinyl;

10 R³ is methyl;

R⁴ is hydrogen or methyl;

R⁶ is hydrogen or methyl;

R⁷ is hydrogen or methyl.

In a further particular class of compound of formula (I), or a pharmaceutically
 15 acceptable salt thereof;

¹Y is CH and Y² is N;

R¹ is a group selected from methyl, ethyl, isopropyl, sec-butyl, isobutyl, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-[(anilincarbonyl)amino]phenyl;
 20 R² is is (pyrazol-3yl)amino, hydroxypiperidinyl, indol-4-yl, indol-5-yl, indol-6-yl, azaindolyl, benzimidazol-5-yl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-aminocarbonylindol-5-yl, 2-aminocarbonylindol-6-yl, 3-aminocarbonylindol-6-yl, morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl or methylmorpholinyl;

25 R³ is methyl;

R⁴ is hydrogen or methyl;

R⁶ is hydrogen or methyl;

R⁷ is hydrogen or methyl; and

-XR¹ is a group selected from -CH₂SO₂-R¹ and -C(CH₃)₂SO₂-R¹ wherein R¹ is methyl, ethyl,
 30 isopropyl, sec-butyl, isobutyl or phenyl; or

-XR¹ is -NHCO-R¹ wherein R¹ is 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-

methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl or 4-[(anilincarbonyl)amino]phenyl.

Another aspect of the invention provides a compound, or a combination of compounds, selected from any of the Examples or a pharmaceutically acceptable salt thereof.

- 5 Another aspect of the invention provides a compound, or a combination of compounds, selected from any of
- N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-methoxy-benzamide,
N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-methoxy-3-(trifluoromethyl)benzamide,
- 10 N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-3-methoxy-benzamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-methoxy-3-(trifluoromethyl)benzamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-3-methoxy-benzamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-6-methoxy-pyridine-3-
- 15 carboxamide,
N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-2-methoxy-pyridine-4-carboxamide,
6-Acetamido-N-[2,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]pyridine-3-carboxamide,
- 20 N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-2-methoxy-benzamide,
2-Acetamido-N-[2,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]pyridine-4-carboxamide,
N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-3-fluoro-4-methoxy-benzamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-2-methoxy-pyridine-4-
- 25 carboxamide,
6-Acetamido-N-[4,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridine-3-carboxamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-2-methoxy-benzamide,
2-Acetamido-N-[4,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridine-4-
- 30 carboxamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-3-fluoro-4-methoxy-benzamide,

- N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-(phenylcarbamoylamino)benzamide,
 N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-(phenylcarbamoylamino)benzamide,
- 5 N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-methoxy-benzamide,
 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine,
 1-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]piperidin-3-ol,
 4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-morpholin-4-yl-pyrimidine,
- 10 3-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-5,7-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene,
 5-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
 5-[4-[(3R)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
 5-[4-(Butan-2-ylsulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
- 15 5-[4-(butan-2-ylsulfinylmethyl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
 5-[4-[(3R)-3-methylmorpholin-4-yl]-6-(propan-2-ylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
 5-[4-(ethylsulfonylmethyl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-N-(1H-pyrazol-3-yl)pyrimidin-2-
- 20 amine,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[4-(1H-pyrazol-4-yl)phenyl]pyrimidine,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[3-(1H-pyrazol-4-yl)phenyl]pyrimidine,
- 25 5-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-3-carboxamide,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[2-(1H-pyrazol-4-yl)-1,3-thiazol-5-yl]pyrimidine,
 6-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
- 30 6-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-3-carboxamide,


- 5- $[4-[(3S)-3\text{-Methylmorpholin-4-yl}]-6\text{-(methylsulfonylmethyl)pyrimidin-2-yl}]-1H\text{-indole-2-carboxamide}$,
- 6- $[4-[(3S)-3\text{-Methylmorpholin-4-yl}]-6\text{-(methylsulfonylmethyl)pyrimidin-2-yl}]-1H\text{-indole-2-carboxamide}$,
- 5 5- $[4-[(3S)-3\text{-Methylmorpholin-4-yl}]-6\text{-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl}]-1H\text{-benzoimidazole}$,
- 3- $[4-[(3S)-3\text{-Methylmorpholin-4-yl}]-6\text{-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl}]-5,7\text{-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene}$,
- 5- $[4-[(3S)-3\text{-methylmorpholin-4-yl}]-6\text{-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl}]-1H\text{-indole}$,
- 10 4- $[4-[(3S)-3\text{-methylmorpholin-4-yl}]-6\text{-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl}]-1H\text{-indole}$,
- 6- $[4-[(3S)-3\text{-methylmorpholin-4-yl}]-6\text{-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl}]-1H\text{-indole}$,
- 15 4- $[4\text{-(Benzenesulfonylmethyl)}]-6\text{-(}(3S)\text{-3-methylmorpholin-4-yl)pyrimidin-2-yl}]-1H\text{-indole}$,
- 5- $[4\text{-(benzenesulfonylmethyl)}]-6\text{-(}(3S)\text{-3-methylmorpholin-4-yl)pyrimidin-2-yl}]-1H\text{-indole}$,
- 3- $[4\text{-(benzenesulfonylmethyl)}]-6\text{-(}(3S)\text{-3-methylmorpholin-4-yl)pyrimidin-2-yl}]-5,7\text{-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene}$,
- 6- $[4\text{-(benzenesulfonylmethyl)}]-6\text{-(}(3S)\text{-3-methylmorpholin-4-yl)pyrimidin-2-yl}]-1H\text{-indole}$,
- 20 and
- 5- $[4\text{-(benzenesulfonylmethyl)}]-6\text{-(}(3S)\text{-3-methylmorpholin-4-yl)pyrimidin-2-yl}]-1H\text{-benzoimidazole}$,
- or a pharmaceutically acceptable salt thereof.

In certain aspects of the invention such as a compound of formula (I) for use as a
 25 medicament for the treatment of proliferative disease; or the use of a compound of formula (I) in the manufacture of a medicament for use in the treatment of proliferative disease.


The invention also provides processes for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

A compound of formula (I), wherein $X = -S(O)_2CR^6R^7-$, may be prepared by oxidising
 30 a compound of the formula (I), wherein $X = SCR^6R^7-$, for example by using Oxone® at room temperature in a mixed solvent system of water and ethanol


-45-



A compound of formula (I), wherein R¹X = R¹OCR⁶R⁷-, may be prepared by the reaction of a compound of formula (I), wherein R¹X = HO-CR⁶R⁷-, with a compound of formula (II), wherein L¹ is a leaving group (such as halo, tosyl, mesyl etc.) optionally in the presence of a suitable base such as triethylamine and a solvent such as tetrahydrofuran or *N,N*-dimethylformamide.




A compound of formula (I), wherein R¹X = R¹R⁴N-CR⁶R⁷-, may be prepared by the reaction of a compound of formula (I), wherein R¹X = HR⁴N-CR⁶R⁷-, with a compound of formula (II), wherein L¹ is a leaving group (such as halo, tosyl, mesyl etc.) optionally in the presence of a suitable base such as triethylamine and a solvent such as tetrahydrofuran or *N,N*-dimethylformamide; or by the reaction of a compound of formula (I), wherein R¹X = HR⁴N-CR⁶R⁷-, with a compound of formula (III) in the presence of a suitable reducing agent such as NaCNBH₃.




A compound of formula (I), wherein X¹ = -S(O)₂CR⁶R⁷-, -SCR⁶R⁷-, -OCR⁶R⁷-, -R⁴N-CR⁶R⁷-, -S(O)CR⁶R⁷-, may be prepared by the reaction of a compound of formula (IV), wherein L¹ is a leaving group (such as halo, tosyl, mesyl etc.), with a compound of formula (V) optionally in the presence of a suitable base such as triethylamine and a solvent such as tetrahydrofuran or *N,N*-dimethylformamide.


-46-



A compound of formula (I), wherein $\text{X} = \text{--SCR}^6\text{R}^7\text{--}$, may be prepared by the reaction of a compound of formula (IV), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), with thiourea in a suitable solvent such as ethanol to generate a compound of formula (VI) which is then subsequently reacted with a compound of formula (II) in the presence of a suitable base such as sodium hydroxide and a solvent such as *N,N*-dimethylformamide.




A compound of formula (I), wherein $\text{X} = \text{--R}^4\text{NC(O)--}$, may be prepared by the reaction of a compound of formula (VII) with an amine of formula $\text{R}^1\text{R}^4\text{NH}$ following the suitable activation of the carboxylic acid by methods known in the literature such as the use of a coupling agent such as HATU or the conversion to an acyl chloride.




A compound of formula (I), wherein $\text{X} = \text{--S(O)}_2\text{CR}^6\text{R}^7\text{--}$, may be prepared by the sequential reaction of a compound of formula (I), wherein $\text{X} = \text{--S(O)}_2\text{CH}_2\text{--}$, with a compound of formula (VIII) followed by reaction with a compound of formula (IX), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), in the presence of a suitable base such as sodium hydride or potassium *tert*-butoxide in a suitable solvent such as tetrahydrofuran or *N,N*-dimethylformamide.


-47-



A compound of formula (I), wherein $R^1X = HO-CR^6R^7-$, may be prepared by the reaction of a compound of formula (X), with suitable organometallic reagents of formula (XI) and formula (XII) such as the grignard reagent in a suitable solvent. Where R^6 and R^7 are different then it may be possible to use techniques known in the literature such the conversion of a compound of formula (X) to the Weinreb amide and reaction with an organometallic reagent of formula (XI) and then reaction with an organometallic reagent of formula (XII) in a subsequent step.




A compound of formula (I) may be prepared from a compound of formula (XIII), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, $-SMe$, $-S(O)_2Me$ etc.), with a suitable organometallic reagent (such as the boronic acid $R^2B(OH)_2$ or the boronic ester $R^2B(OR)_2$ etc.) in the presence of a suitable metal catalyst (such as palladium or copper) in a suitable solvent such as 1,4-dioxane. Alternatively where R^2 connects to the pyrimidine ring through a nitrogen, oxygen or sulphur atom a compound of formula (I) may be prepared from a compound of formula (XIII), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, $-SMe$, $-S(O)_2Me$ etc.), by reaction with the required amine, alcohol or thiol in the presence of a suitable base such as potassium carbonate in a suitable solvent such as *N,N*-dimethylformamide.




-48-

It will be appreciated that a compound of formula (XIII) may be transformed into another compound of formula (XIII) by techniques such as oxidation, alkylation, reductive amination etc., either listed above or otherwise known in the literature.


A compound of formula (XIII), wherein $X^1 = -S(O)_2CR^6R^7-$, $-SCR^6R^7-$, $-OCR^6R^7-$, $-R^4NCR^6R^7-$, $-S(O)CR^6R^7-$, may be prepared by the reaction of a compound of formula (XIV),
 5 wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), with a compound of formula (V) optionally in the presence of a suitable base such as triethylamine and a solvent such as tetrahydrofuran or *N,N*-dimethylformamide.



A compound of formula (XIII), wherein $X = -SCR^6R^7-$, may be prepared by the reaction of a compound of formula (XIV), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), with thiourea in a suitable solvent such as ethanol to generate a compound of formula (XV) which is then subsequently reacted with a compound of formula (II) in the presence of a suitable base such as sodium hydroxide and a solvent such as *N,N*-
 15 dimethylformamide.




A compound of formula (XIII), wherein $X = -R^4NC(O)-$, may be prepared by the reaction of a compound of formula (XVI) with an amine of formula R^1R^4NH following the suitable activation of the carboxylic acid by methods known in the literature such as the use of
 20 a coupling agent such as HATU or the conversion to an acyl chloride.




-49-

A compound of formula (XIII), wherein $X = -S(O)_2CR^6R^7-$, may be prepared by the sequential reaction of a compound of formula (XIII), wherein $X = -S(O)_2CH_2-$, with a compound of formula (VIII) followed by reaction with a compound of formula (IX), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), in the presence of a suitable base such as sodium hydride or potassium *tert*-butoxide in a suitable solvent such as tetrahydrofuran or *N,N*-dimethylformamide.




A compound of formula (XIII), wherein $R^1X = HO-CR^6R^7-$, may be prepared by the reaction of a compound of formula (XVII), with suitable organometallic reagents of formula (XI) and formula (XII) such as the grignard reagent in a suitable solvent. Where R^6 and R^7 are different then it may be possible to use techniques known in the literature such the conversion of a compound of formula (XVII) to the Weinreb amide and reaction with an organometallic reagent of formula (XI) and then reaction with an organometallic reagent of formula (XII) in a subsequent step.




A compound of formula (IV) may be prepared from a compound of formula (XIV), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, $-SMe$, $-S(O)_2Me$ etc.) and L^1 is a leaving group (such as halo, tosyl, mesyl etc.), with a suitable organometallic reagent (such as the boronic acid $R^2B(OH)_2$ or the boronic ester $R^2B(OR)_2$ etc.) in the presence of a suitable metal catalyst (such as palladium or copper) in a suitable solvent such as 1,4-dioxane. Alternatively where R^2 connects to the pyrimidine ring through a nitrogen, oxygen or sulphur atom a compound of formula (IV) may be prepared from a compound of formula (XIV), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, $-SMe$, $-S(O)_2Me$ etc.), by reaction with the required amine, alcohol or thiol in the presence of a suitable base such as potassium carbonate in a suitable solvent such as *N,N*-dimethylformamide.

-50-




A compound of formula (X) may be prepared from a compound of formula (XVII), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.) and R is a hydrogen or C₁₋₄ alkyl group, with a suitable organometallic reagent (such as the boronic acid $R^2B(OH)_2$ or the boronic ester $R^2B(OR)_2$ etc.) in the presence of a suitable metal catalyst (such as palladium or copper) in a suitable solvent such as 1,4-dioxane. Alternatively where R^2 connects to the pyrimidine ring through a nitrogen, oxygen or sulphur atom a compound of formula (X) may be prepared from a compound of formula (XVII), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), by reaction with the required amine, alcohol or thiol in the presence of a suitable base such as potassium carbonate in a suitable solvent such as *N,N*-dimethylformamide.




A compound of formula (XVIII) may be prepared from a compound of formula (XIX), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), with a suitable organometallic reagent (such as the boronic acid $R^2B(OH)_2$ or the boronic ester $R^2B(OR)_2$ etc.) in the presence of a suitable metal catalyst (such as palladium or copper) in a suitable solvent such as 1,4-dioxane. Alternatively where R^2 connects to the pyrimidine ring through a nitrogen, oxygen or sulphur atom a compound of formula (XVIII) may be prepared from a compound of formula (XIX), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), by reaction with the required amine, alcohol or thiol in the presence of a suitable base such as potassium carbonate in a suitable solvent such as *N,N*-dimethylformamide.


-51-



A compound of formula (XX) may be prepared from a compound of formula (XXI), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), with a suitable organometallic reagent (such as the boronic acid $R^2B(OH)_2$ or the boronic ester $R^2B(OR)_2$ etc.) in the presence of a suitable metal catalyst (such as palladium or copper) in a suitable solvent such as 1,4-dioxane. Alternatively where R^2 connects to the pyrimidine ring through a nitrogen, oxygen or sulphur atom a compound of formula (XX) may be prepared from a compound of formula (XXI), wherein L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), by reaction with the required amine, alcohol or thiol in the presence of a suitable base such as potassium carbonate in a suitable solvent such as *N,N*-dimethylformamide.



A compound of formula (I), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), may be prepared by the reaction of a compound of formula (XXII) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




It will be appreciated that a compound of formula (XXII) may be transformed into another compound of formula (XXII) by techniques such as oxidation, alkylation, reductive amination etc., either listed above or otherwise known in the literature.


A compound of formula (IV), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), may be prepared by the reaction of a compound of formula (XXIV) with a compound of

-52-


formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




A compound of formula (X), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and R is a hydrogen or a C_{1-4} alkyl group, may be prepared by the reaction of a compound of formula (XXV) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.



A compound of formula (XVIII), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.), may be prepared by the reaction of a compound of formula (XXVI) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




A compound of formula (XX), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), may be prepared by the reaction of a compound of formula (XXVII) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




-53-

A compound of formula (XIII), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), may be prepared by the reaction of a compound of formula (XXVIII) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent
 5 such as *N,N*-dimethylformamide.




It will be appreciated that a compound of formula (XIII) may be transformed into another compound of formula (XIII) by techniques such as oxidation, alkylation, reductive amination etc., either listed above or otherwise known in the literature.

10 A compound of formula (XIV), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), may be prepared by the reaction of a compound of formula (XXIX) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




A compound of formula (XVII), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.) and R is a hydrogen or a C₁₋₄ alkyl group, may be prepared by the reaction of a compound of formula (XXX) with a compound of formula (XXIII) optionally in the presence of a suitable
 20 base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




-54-


A compound of formula (XIX), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), may be prepared by the reaction of a compound of formula (XXXI) with a compound of formula (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent
 5 such as *N,N*-dimethylformamide.



A compound of formula (XXI), wherein L^1 is a leaving group (such as halo, tosyl, mesyl etc.) and L^2 is a leaving group (such as halo, tosyl, mesyl, -SMe, -S(O)₂Me etc.), may be prepared by the reaction of a compound of formula (XXXII) with a compound of formula
 10 (XXIII) optionally in the presence of a suitable base such as triethylamine in a suitable solvent such as *N,N*-dimethylformamide.




A compound of formula (I), wherein $R^1X = H_2NCH_2-$, may be prepared from a compound of formula (XVIII) by a reduction such as hydrogenation with hydrogen gas and a
 15 suitable catalyst such as Palladium on carbon in a suitable solvent such as ethanol.




A compound of formula (I), wherein $R^1X = H_2NC(O)-$, may be prepared from a compound of formula (XVIII) by hydrolysis with, for example, sodium hydroxide in a suitable solvent such as a water ethanol mix.


-55-




A compound of formula (I), wherein $R^1X = H_2NCR^6R^7-$, may be prepared from a compound of formula (XVIII) by reaction with organometallic reagents (XI) and (XII).




- 5 A compound of formula (XIII), wherein $R^1X = H_2NCH_2-$, may be prepared from a compound of formula (XIX) by a reduction such as hydrogenation with hydrogen gas and a suitable catalyst such as Palladium on carbon in a suitable solvent such as ethanol.



- 10 A compound of formula (XIII), wherein $R^1X = H_2NC(O)-$, may be prepared from a compound of formula (XIX) by hydrolysis with, for example, sodium hydroxide in a suitable solvent such as a water ethanol mix.



A compound of formula (XIII), wherein $R^1X = H_2NCR^6R^7-$, may be prepared from a compound of formula (XIX) by reaction with organometallic reagents (XI) and (XII).



It will be appreciated that the R^2 group may be introduced and subsequently converted to another group of the formula R^2 at a subsequent stage in the synthesis using methods known in the literature.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. For example compounds of formula (I) may be converted into further compounds of formula (I) by standard aromatic substitution reactions or by conventional functional group modifications. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulfinyl or alkylsulfonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *tert*-butoxycarbonyl group, an arylmethoxycarbonyl

group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *tert*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *tert*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

Many of the intermediates defined herein are novel and these are provided as a further feature of the invention.

Biological Assays

The following assays can be used to measure the effects of the compounds of the present invention as mTOR kinase inhibitors, as PI3 kinase inhibitors, as inhibitors *in vitro* of the activation of PI3 kinase signalling pathways and as inhibitors *in vitro* of the proliferation
5 of MDA-MB-468 human breast adenocarcinoma cells.

(a)(i) In Vitro mTOR Kinase Assay

The assay used AlphaScreen technology (Gray *et al.*, Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.

10 A C-terminal truncation of mTOR encompassing amino acid residues 1362 to 2549 of mTOR (EMBL Accession No. L34075) was stably expressed as a FLAG-tagged fusion in HEK293 cells as described by Vilella-Bach *et al.*, Journal of Biochemistry, 1999, 274, 4266-4272. The HEK293 FLAG-tagged mTOR (1362-2549) stable cell line was routinely maintained at 37°C with 5% CO₂ up to a confluency of 70-90% in Dulbecco's modified
15 Eagle's growth medium (DMEM; Invitrogen Limited, Paisley, UK Catalogue No. 41966-029) containing 10% heat-inactivated foetal calf serum (FCS; Sigma, Poole, Dorset, UK, Catalogue No. F0392), 1% L-glutamine (Gibco, Catalogue No. 25030-024) and 2 mg/ml Geneticin (G418 sulfate; Invitrogen Limited, UK Catalogue No. 10131-027). Following expression in the mammalian HEK293 cell line, expressed protein was purified using the FLAG epitope tag
20 using standard purification techniques.

Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 µl) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 30 µl mixture of recombinant purified mTOR
25 enzyme, 1 µM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH₂; Bachem UK Ltd), ATP (20 µM) and a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/mL), DTT (1.25 mM) and manganese chloride (10 mM)] was agitated at room temperature for 90 minutes.

30 Control wells that produced a maximum signal corresponding to maximum enzyme activity were created by using 5% DMSO instead of test compound. Control wells that produced a minimum signal corresponding to fully inhibited enzyme were created by adding

EDTA (83 mM) instead of test compound. These assay solutions were incubated for 2 hours at room temperature.

Each reaction was stopped by the addition of 10 µl of a mixture of EDTA (50 mM), bovine serum albumin (BSA; 0.5 mg/mL) and Tris-HCl pH7.4 buffer (50 mM) containing
5 p70 S6 Kinase (T389) 1A5 Monoclonal Antibody (Cell Signalling Technology, Catalogue No. 9206B) and AlphaScreen Streptavidin donor and Protein A acceptor beads (200 ng; Perkin Elmer, Catalogue No. 6760002B and 6760137R respectively) were added and the assay plates were left for about 20 hours at room temperature in the dark. The resultant signals arising from laser light excitation at 680 nm were read using a Packard Envision
10 instrument.

Phosphorylated biotinylated peptide is formed *in situ* as a result of mTOR mediated phosphorylation. The phosphorylated biotinylated peptide that is associated with AlphaScreen Streptavidin donor beads forms a complex with the p70 S6 Kinase (T389) 1A5 Monoclonal Antibody that is associated with Alphascreen Protein A acceptor beads. Upon
15 laser light excitation at 680 nm, the donor bead : acceptor bead complex produces a signal that can be measured. Accordingly, the presence of mTOR kinase activity results in an assay signal. In the presence of an mTOR kinase inhibitor, signal strength is reduced.

mTOR enzyme inhibition for a given test compound was expressed as an IC₅₀ value.

(a)(ii) In Vitro mTOR Kinase Assay (Echo)

20 The assay used AlphaScreen technology (Gray *et al.*, Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.

A C-terminal truncation of mTOR encompassing amino acid residues 1362 to 2549 of mTOR (EMBL Accession No. L34075) was stably expressed as a FLAG-tagged fusion in
25 HEK293 cells as described by Vilella-Bach *et al.*, Journal of Biochemistry, 1999, 274, 4266-4272. The HEK293 FLAG-tagged mTOR (1362-2549) stable cell line was routinely maintained at 37°C with 5% CO₂ up to a confluency of 70-90% in Dulbecco's modified Eagle's growth medium (DMEM; Invitrogen Limited, Paisley, UK Catalogue No. 41966-029) containing 10% heat-inactivated foetal calf serum (FCS; Sigma, Poole, Dorset, UK, Catalogue
30 No. F0392), 1% L-glutamine (Gibco, Catalogue No. 25030-024) and 2 mg/ml Geneticin (G418 sulfate; Invitrogen Limited, UK Catalogue No. 10131-027). Following expression in

-60-

the mammalian HEK293 cell line, expressed protein was purified using the FLAG epitope tag using standard purification techniques.

Test compounds were prepared as 10 mM stock solutions in DMSO and diluted in into waterDMSO as required to give a range of final assay concentrations. Aliquots (120nl2 µl) of each compound dilution were acoustically dispensedplaced using a Labcyte Echo 550 into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 1230 µl mixture of recombinant purified mTOR enzyme, 1 µM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH₂; Bachem UK Ltd), ATP (20 µM) and a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/mL), DTT (1.25 mM) and manganese chloride (10 mM)] was incubated at room temperature for 12090 minutes.

Control wells that produced a maximum signal corresponding to maximum enzyme activity were created by using 1005% DMSO instead of test compound. Control wells that produced a minimum signal corresponding to fully inhibited enzyme were created by adding LY294002EDTA (100uM83 mM) compound. These assay solutions were incubated for 2 hours at room temperature.

Each reaction was stopped by the addition of 510 µl of a mixture of EDTA (50 mM), bovine serum albumin (BSA; 0.5 mg/mL) and Tris-HCl pH7.4 buffer (50 mM) containing p70 S6 Kinase (T389) 1A5 Monoclonal Antibody (Cell Signalling Technology, Catalogue No. 9206B) and AlphaScreen Streptavidin donor and Protein A acceptor beads (200 ng; Perkin Elmer, Catalogue No. 6760002B and 6760137R respectively) were added and the assay plates were left overnight at room temperature in the dark. The resultant signals arising from laser light excitation at 680 nm were read using a Packard Envision instrument.

Phosphorylated biotinylated peptide is formed *in situ* as a result of mTOR mediated phosphorylation. The phosphorylated biotinylated peptide that is associated with AlphaScreen Streptavidin donor beads forms a complex with the p70 S6 Kinase (T389) 1A5 Monoclonal Antibody that is associated with Alphascree Protein A acceptor beads. Upon laser light excitation at 680 nm, the donor bead : acceptor bead complex produces a signal that can be measured. Accordingly, the presence of mTOR kinase activity results in an assay signal. In the presence of an mTOR kinase inhibitor, signal strength is reduced. mTOR enzyme inhibition for a given test compound was expressed as an IC₅₀ value.

-61-

(b)(i) In Vitro PI3K Enzyme Assay

The assay used AlphaScreen technology (Gray *et al.*, Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant Type I PI3K enzymes of the lipid PI(4,5)P₂.

5 DNA fragments encoding human PI3K catalytic and regulatory subunits were isolated from cDNA libraries using standard molecular biology and PCR cloning techniques. The selected DNA fragments were used to generate baculovirus expression vectors. In particular, full length DNA of each of the p110 α , p110 β and p110 δ Type Ia human PI3K p110 isoforms (EMBL Accession Nos. HSU79143, S67334, Y10055 for p110 α , p110 β and p110 δ 10 respectively) were sub-cloned into a pDEST10 vector (Invitrogen Limited, Fountain Drive, Paisley, UK). The vector is a Gateway-adapted version of Fastbac1 containing a 6-His epitope tag. A truncated form of Type Ib human PI3K p110 γ isoform corresponding to amino acid residues 144-1102 (EMBL Accession No. X8336A) and the full length human p85 α regulatory subunit (EMBL Accession No. HSP13KIN) were also sub-cloned into pFastBac1 15 vector containing a 6-His epitope tag. The Type Ia p110 constructs were co-expressed with the p85 α regulatory subunit. Following expression in the baculovirus system using standard baculovirus expression techniques, expressed proteins were purified using the His epitope tag using standard purification techniques.

DNA corresponding to amino acids 263 to 380 of human general receptor for 20 phosphoinositides (Grp1) PH domain was isolated from a cDNA library using standard molecular biology and PCR cloning techniques. The resultant DNA fragment was sub-cloned into a pGEX 4T1 *E. coli* expression vector containing a GST epitope tag (Amersham Pharmacia Biotech, Rainham, Essex, UK) as described by Gray *et al.*, Analytical Biochemistry, 2003, 313: 234-245). The GST-tagged Grp1 PH domain was expressed and 25 purified using standard techniques.

Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 μ l) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one, Brunel Way, Stonehouse, Gloucestershire, UK Catalogue 30 No. 784075). A mixture of each selected recombinant purified PI3K enzyme (15 ng), DiC8-PI(4,5)P₂ substrate (40 μ M; Cell Signals Inc., Kinnear Road, Columbus, USA, Catalogue No.

901), adenosine triphosphate (ATP; 4 μ M) and a buffer solution [comprising Tris-HCl pH7.6 buffer (40 mM, 10 μ l), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; 0.04%), dithiothreitol (DTT; 2 mM) and magnesium chloride (10 mM)] was agitated at room temperature for 20 minutes.

5 Control wells that produced a minimum signal corresponding to maximum enzyme activity were created by using 5% DMSO instead of test compound. Control wells that produced a maximum signal corresponding to fully inhibited enzyme were created by adding wortmannin (6 μ M; Calbiochem / Merck Bioscience, Padge Road, Beeston, Nottingham, UK, Catalogue No. 681675) instead of test compound. These assay solutions were also agitated
10 for 20 minutes at room temperature.

Each reaction was stopped by the addition of 10 μ l of a mixture of EDTA (100 mM), bovine serum albumin (BSA, 0.045 %) and Tris-HCl pH7.6 buffer (40 mM).

Biotinylated-DiC8-PI(3,4,5)P3 (50 nM; Cell Signals Inc., Catalogue No. 107), recombinant purified GST-Grp1 PH protein (2.5 nM) and AlphaScreen Anti-GST donor and
15 acceptor beads (100 ng; Packard Bioscience Limited, Station Road, Pangbourne, Berkshire, UK, Catalogue No. 6760603M) were added and the assay plates were left for about 5 to 20 hours at room temperature in the dark. The resultant signals arising from laser light excitation at 680 nm were read using a Packard AlphaQuest instrument.

PI(3,4,5)P3 is formed *in situ* as a result of PI3K mediated phosphorylation of
20 PI(4,5)P2. The GST-Grp1 PH domain protein that is associated with AlphaScreen Anti-GST donor beads forms a complex with the biotinylated PI(3,4,5)P3 that is associated with Alphascreen Streptavidin acceptor beads. The enzymatically-produced PI(3,4,5)P3 competes with biotinylated PI(3,4,5)P3 for binding to the PH domain protein. Upon laser light excitation at 680 nm, the donor bead : acceptor bead complex produces a signal that can be
25 measured. Accordingly, PI3K enzyme activity to form PI(3,4,5)P3 and subsequent competition with biotinylated PI(3,4,5)P3 results in a reduced signal. In the presence of a PI3K enzyme inhibitor, signal strength is recovered.

PI3K enzyme inhibition for a given test compound was expressed as an IC₅₀ value.

(b)(ii) In Vitro PI3K Enzyme Assay (Echo)

30 The assay used AlphaScreen technology (Gray *et al.*, Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant Type I PI3K enzymes of the lipid PI(4,5)P2.

DNA fragments encoding human PI3K catalytic and regulatory subunits were isolated from cDNA libraries using standard molecular biology and PCR cloning techniques. The selected DNA fragments were used to generate baculovirus expression vectors. In particular, full length DNA of each of the p110 α , p110 β and p110 δ Type Ia human PI3K p110 isoforms
5 (EMBL Accession Nos. HSU79143, S67334, Y10055 for p110 α , p110 β and p110 δ respectively) were sub-cloned into a pDEST10 vector (Invitrogen Limited, Fountain Drive, Paisley, UK). The vector is a Gateway-adapted version of Fastbac1 containing a 6-His epitope tag. A truncated form of Type Ib human PI3K p110 γ isoform corresponding to amino acid residues 144-1102 (EMBL Accession No. X8336A) and the full length human p85 α
10 regulatory subunit (EMBL Accession No. HSP13KIN) were also sub-cloned into pFastBac1 vector containing a 6-His epitope tag. The Type Ia p110 constructs were co-expressed with the p85 α regulatory subunit. Following expression in the baculovirus system using standard baculovirus expression techniques, expressed proteins were purified using the His epitope tag using standard purification techniques.

15 DNA corresponding to amino acids 263 to 380 of human general receptor for phosphoinositides (Grp1) PH domain was isolated from a cDNA library using standard molecular biology and PCR cloning techniques. The resultant DNA fragment was sub-cloned into a pGEX 4T1 *E. coli* expression vector containing a GST epitope tag (Amersham Pharmacia Biotech, Rainham, Essex, UK) as described by Gray *et al.*, Analytical
20 Biochemistry, 2003, 313: 234-245). The GST-tagged Grp1 PH domain was expressed and purified using standard techniques.

Test compounds were prepared as 10 mM stock solutions in DMSO and diluted in DMSO to water as required to give a range of final assay concentrations. Aliquots (120 nl) of each compound dilution were acoustically dispensed using a Labcyte Echo 550 placed into
25 a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one, Brunel Way, Stonehouse, Gloucestershire, UK Catalogue No. 784075). A mixture of each selected recombinant purified PI3K enzyme (15 ng), DiC8-PI(4,5)P2 substrate (40 μ M; Cell Signals Inc., Kinnear Road, Columbus, USA, Catalogue No. 901), adenosine triphosphate (ATP; 4 μ M) and a buffer solution [comprising Tris-HCl pH7.6 buffer (40 mM, 10 μ l), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS; 0.04%), dithiothreitol
30

-64-

(DTT; 2 mM) and magnesium chloride (10 mM)] was agitated/incubated at room temperature for 20 minutes.

Control wells that produced a minimum signal corresponding to maximum enzyme activity were created by using 100% DMSO instead of test compound. Control wells that produced a maximum signal corresponding to fully inhibited enzyme were created by adding Wwortmannin (6 μ M; Calbiochem / Merck Bioscience, Padge Road, Beeston, Nottingham, UK, Catalogue No. 681675) instead of test compound. These assay solutions were also incubated/agitated for 20 minutes at room temperature.

Each reaction was stopped by the addition of 10 μ l of a mixture of EDTA (100 mM), bovine serum albumin (BSA, 0.045 %) and Tris-HCl pH7.6 buffer (40 mM).

Biotinylated-DiC8-PI(3,4,5)P3 (50 nM; Cell Signals Inc., Catalogue No. 107), recombinant purified GST-Grp1 PH protein (2.5 nM) and AlphaScreen Anti-GST donor and acceptor beads (100 ng; Packard Bioscience Limited, Station Road, Pangbourne, Berkshire, UK, Catalogue No. 6760603M) were added and the assay plates were left for about 5 to 20 hours at room temperature in the dark. The resultant signals arising from laser light excitation at 680 nm were read using a Packard AlphaQuest instrument.

PI(3,4,5)P3 is formed *in situ* as a result of PI3K mediated phosphorylation of PI(4,5)P2. The GST-Grp1 PH domain protein that is associated with AlphaScreen Anti-GST donor beads forms a complex with the biotinylated PI(3,4,5)P3 that is associated with Alphascreen Streptavidin acceptor beads. The enzymatically-produced PI(3,4,5)P3 competes with biotinylated PI(3,4,5)P3 for binding to the PH domain protein. Upon laser light excitation at 680 nm, the donor bead : acceptor bead complex produces a signal that can be measured. Accordingly, PI3K enzyme activity to form PI(3,4,5)P3 and subsequent competition with biotinylated PI(3,4,5)P3 results in a reduced signal. In the presence of a PI3K enzyme inhibitor, signal strength is recovered.

PI3K enzyme inhibition for a given test compound was expressed as an IC₅₀ value.

(c) In Vitro phospho-Ser473 Akt assay

This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.

A MDA-MB-468 human breast adenocarcinoma cell line (LGC Promochem, Teddington, Middlesex, UK, Catalogue No. HTB-132) was routinely maintained at 37°C with 5% CO₂ up to a confluency of 70–90% in DMEM containing 10% heat-inactivated FCS and 1% L-glutamine.

5 For the assay, the cells were detached from the culture flask using ‘Accutase’ (Innovative Cell Technologies Inc., San Diego, CA, USA; Catalogue No. AT104) using standard tissue culture methods and resuspended in media to give 1.7×10^5 cells per mL. Aliquots (90 µl) were seeded into each of the inner 60 wells of a black Packard 96 well plate (PerkinElmer, Boston, MA, USA; Catalogue No. 6005182) to give a density of ~15000 cells
10 per well. Aliquots (90 µl) of culture media were placed in the outer wells to prevent edge effects. The cells were incubated overnight at 37°C with 5% CO₂ to allow them to adhere.

On day 2, the cells were treated with test compounds and incubated for 2 hours at 37°C with 5% CO₂. Test compounds were prepared as 10 mM stock solutions in DMSO and serially diluted as required with growth media to give a range of concentrations that were 10-
15 fold the required final test concentrations. Aliquots (10 µl) of each compound dilution were placed in a well (in triplicate) to give the final required concentrations. As a minimum reponse control, each plate contained wells having a final concentration of 100 µM LY294002 (Calbiochem, Beeston, UK, Catalogue No. 440202). As a maximum response control, wells contained 1% DMSO instead of test compound. Following incubation, the contents of the
20 plates were fixed by treatment with a 1.6% aqueous formaldehyde solution (Sigma, Poole, Dorset, UK, Catalogue No. F1635) at room temperature for 1 hour.

All subsequent aspiration and wash steps were carried out using a Tecan 96 well plate washer (aspiration speed 10 mm/sec). The fixing solution was removed and the contents of the plates were washed with phosphate-buffered saline (PBS; 50 µl; Gibco, Catalogue No.
25 10010015). The contents of the plates were treated for 10 minutes at room temperature with an aliquot (50 µl) of a cell permeabilisation buffer consisting of a mixture of PBS and 0.5% Tween-20. The ‘permeabilisation’ buffer was removed and non-specific binding sites were blocked by treatment for 1 hour at room temperature of an aliquot (50 µl) of a blocking buffer consisting of 5% dried skimmed milk [‘Marvel’ (registered trade mark); Premier Beverages,
30 Stafford, GB] in a mixture of PBS and 0.05% Tween-20. The ‘blocking’ buffer was removed and the cells were incubated for 1 hour at room temperature with rabbit anti phospho-Akt

-66-

(Ser473) antibody solution (50 µl per well; Cell Signalling, Hitchin, Herts, U.K., Catalogue No 9277) that had been diluted 1:500 in 'blocking' buffer. Cells were washed three times in a mixture of PBS and 0.05% Tween-20. Subsequently, cells were incubated for 1 hour at room temperature with Alexafluor488 labelled goat anti-rabbit IgG (50 µl per well; Molecular
5 Probes, Invitrogen Limited, Paisley, UK, Catalogue No. A11008) that had been diluted 1:500 in 'blocking' buffer. Cells were washed 3 times with a mixture of PBS and 0.05% Tween-20. An aliquot of PBS (50 µl) was added to each well and the plates were sealed with black plate sealers and the fluorescence signal was detected and analysed.

Fluorescence dose response data obtained with each compound were analysed and the
10 degree of inhibition of Serine 473 in Akt was expressed as an IC₅₀ value.

(d) *In Vitro* MDA-MB-468 human breast adenocarcinoma Proliferation Assay

This assay determines the ability of test compounds to inhibit cell proliferation as assessed using Cellomics Arrayscan technology. A MDA-MB-468 human breast adenocarcinoma cell line (LGC Promochem, Catalogue No. HTB-132) was routinely
15 maintained as described in Biological Assay (b) herein.

For the proliferation assay, the cells were detached from the culture flask using Accutase and seeded into the inner 60 wells of a black Packard 96 well plate at a density of 8000 cells per well in 100 µl of complete growth media. The outer wells contained 100 µl of sterile PBS. The cells were incubated overnight at 37°C with 5% CO₂ to allow them to
20 adhere.

On day 2, the cells were treated with test compounds and incubated for 48 hours at 37°C with 5% CO₂. Test compounds were prepared as 10 mM stock solutions in DMSO and serially diluted as required with growth media to give a range of test concentrations. Aliquots (50 µl) of each compound dilution were placed in a well and the cells were incubated for 2
25 days at 37°C with 5% CO₂. Each plate contained control wells without test compound.

On day 4, BrdU labelling reagent (Sigma, Catalogue No. B9285) at a final dilution of 1:1000 was added and the cells were incubated for 2 hours at 37°C. The medium was removed and the cells in each well were fixed by treatment with 100 µl of a mixture of ethanol and glacial acetic acid (90% ethanol, 5% glacial acetic acid and 5% water) for 30
30 minutes at room temperature. The cells in each well were washed twice with PBS (100 µl). Aqueous hydrochloric acid (2M, 100 µl) was added to each well. After 20 minutes at room

-67-

temperature, the cells were washed twice with PBS. Hydrogen peroxide (3%, 50 μ l; Sigma, Catalogue No. H1009) was added to each well. After 10 minutes at room temperature, the wells were washed again with PBS.

BrdU incorporation was detected by incubation for 1 hour at room temperature with
5 mouse anti-BrdU antibody (50 μ l; Caltag, Burlingame, CA, US; Catalogue No. MD5200) that was diluted 1:40 in PBS containing 1% BSA and 0.05% Tween-20. Unbound antibody was removed with two washes of PBS. For visualisation of incorporated BrdU, the cells were treated for 1 hour at room temperature with PBS (50 μ l) and 0.05% Tween-20 buffer containing a 1:1000 dilution of Alexa fluor 488-labelled goat anti-mouse IgG. For
10 visualisation of the cell nucleus, a 1:1000 dilution of Hoechst stain (Molecular Probes, Catalogue No. H3570) was added. Each plate was washed in turn with PBS. Subsequently, PBS (100 μ l) was added to each well and the plates were analysed using a Cellomics array scan to assess total cell number and number of BrdU positive cells.

Fluorescence dose response data obtained with each compound were analysed and the
15 degree of inhibition of MDA-MB-468 cell growth was expressed as an IC₅₀ value.

Although the pharmacological properties of the compounds of formula (I) vary with structural change as expected, in general, it is believed that activity possessed by compounds of formula (I) may be demonstrated at the following concentrations or doses in one or more of the above tests (a) to (d) :-

- 20 Test (a)(i):- IC₅₀ versus mTOR kinase at less than 10 μ M, in particular 0.001 - 0.5 μ M for many compounds; for example 35 the IC₅₀ was measured on two occasions, the values were 0.566 and 0.404 μ M.
- Test (b)(i):- IC₅₀ versus p110 γ Type Ib human PI3K at less than 10 μ M, in particular 0.001 - 0.5 μ M for many compounds; and IC₅₀ versus p110 α
25 Type Ia human PI3K at less than 10 μ M, in particular 0.001 - 0.5 μ M for many compounds;
for example 35 the IC₅₀ was measured on two occasions, the values were 37 and >127 μ M.
- Test (c):- IC₅₀ versus Serine 473 in Akt at less than 10 μ M, in particular 0.1 - 20
30 μ M for many compounds); for example 35 the IC₅₀ was measured on one occasions, the value was 3.357 μ M.
- Test (d):- IC₅₀ at less than 20 μ M.

The following examples were tested in enzyme assay Test (a)(i):

Ex No.	Test (a)(i) IC ₅₀ (μM)	Ex No.	Test (a)(i) IC ₅₀ (μM)	Ex No.	Test (a)(i) IC ₅₀ (μM)
1	4.65	17	9.39	33	0.154
2	0.236	18	1.12	34	0.573
3	0.234	19	0.181	35	0.478
4	0.442	20	1.65	36	1.64
5	0.364	21	2.3	37	0.336
6	2.68	22	1.7	38	5.35
7	2.84	23	0.0377	39	0.192
8	1.78	24	0.303	40	0.588
9	0.894	25	0.385	41	0.117
10	26.4	26	1.38	42	0.335
11	3.58	27	1.17	43	0.88
12	4	28	0.626	44	0.366
13	1.58	29	0.351	45	0.119
14	0.886	30	0.897	46	0.932
15	9.55	31	0.99	47	0.512
16	2.47	32	0.437	48	0.108

In some cases, these values may represent the average of two or more measurements.

By way of comparison, the corresponding unsubstituted morpholine compound (R3 is hydrogen) has the following data: Test (a) 2.007 and 0.650 μM; Test (b) 131.992, 11.134,
5 79.939, 31.705, and 32.644 μM; Test (c) 16.170 μM.

The compounds of the present invention are advantageous in that they possess pharmacological activity. In particular, the compounds of the present invention modulate (in particular, inhibit) mTOR kinase and/or phosphatidylinositol-3-kinase (PI3K) enzymes, such as the Class Ia PI3K enzymes (*e.g.* PI3Kalpha, PI3Kbeta and PI3Kdelta) and the Class Ib
10 PI3K enzyme (PI3Kgamma). More particularly compounds of the present invention modulate (in particular, inhibit) mTOR kinase. More particularly compounds of the present invention modulate (in particular, inhibit) one or more PI3K enzyme. The inhibitory properties of compounds of formula (I) may be demonstrated using the test procedures set out herein and in

the experimental section. Accordingly, the compounds of formula (I) may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are mediated by mTOR kinase and/or one or more PI3K enzyme(s), and in particular by mTOR kinase.

5 The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in association with a pharmaceutically acceptable diluent or carrier.

 The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible
10 powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intraperitoneal or intramuscular
15 dosing or as a suppository for rectal dosing).

 The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

20 The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 1 mg to 1 g of active agent (more suitably from 1 to 250 mg, for example from 1 to 100 mg) compounded with an
25 appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

 The size of the dose for therapeutic or prophylactic purposes of a compound of formula I will naturally vary according to the nature and severity of the disease state, the age and sex of the animal or patient and the route of administration, according to well known
30 principles of medicine.

 In using a compound of formula (I) for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 1 mg/kg to 100

-70-

mg/kg body weight is received, given if required in divided doses. In general, lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 1 mg/kg to 25 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 1 mg/kg to 25 mg/kg body weight will be used. Typically, unit dosage forms will contain about 10 mg to 0.5 g of a compound of this invention.

As stated herein, it is known that mTOR kinase and the PI3K enzymes have roles in tumourigenesis as well as numerous other diseases. We have found that the compounds of formula (I) possess potent anti-tumour activity which it is believed is obtained by way of inhibition of mTOR kinase and/or one or more of the PI3K enzymes.

Accordingly, the compounds of the present invention are of value as anti-tumour agents. Particularly, the compounds of the present invention are of value as anti-proliferative, apoptotic and/or anti-invasive agents in the containment and/or treatment of solid and/or liquid tumour disease. Particularly, the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours which are sensitive to inhibition of mTOR and/or one or more of the PI3K enzymes such as the Class Ia PI3K enzymes and the Class Ib PI3K enzyme. Further, the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours which are mediated alone or in part by mTOR and/or one or more of the PI3K enzymes such as the Class Ia PI3K enzymes and the Class Ib PI3K enzyme. The compounds may thus be used to produce an mTOR enzyme inhibitory effect in a warm-blooded animal in need of such treatment. Certain compounds may be used to produce an PI3K enzyme inhibitory effect in a warm-blooded animal in need of such treatment.

As stated herein, inhibitors of mTOR kinase and/or one or more PI3K enzymes should be of therapeutic value for the treatment of proliferative disease such as cancer and in particular solid tumours such as carcinoma and sarcomas and the leukaemias and lymphoid malignancies and in particular for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias [including acute lymphocytic leukaemia (ALL) and chronic myelogenous leukaemia (CML)], multiple myeloma and lymphomas.

According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use as a medicament in a warm-blooded animal such as man.

According to a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use in the
5 production of an anti-proliferative effect in a warm-blooded animal such as man.

According to a further aspect of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use in the production of an apoptotic effect in a warm-blooded animal such as man.

10 According to a further feature of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use in a warm-blooded animal such as man as an anti-invasive agent in the containment and/or treatment of proliferative disease such as cancer.

According to a further aspect of the invention, there is provided the use of a compound
15 of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for the production of an anti-proliferative effect in a warm-blooded animal such as man.

According to a further feature of this aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the production of an anti-proliferative effect in
20 a warm-blooded animal such as man.

According to a further aspect of the invention, there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for the production of an apoptotic effect in a warm-blooded animal such as man.

According to a further feature of this aspect of the invention there is provided the use
25 of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the production of an apoptotic effect in a warm-blooded animal such as man.

According to a further feature of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the
30 manufacture of a medicament for use in a warm-blooded animal such as man as an anti-invasive agent in the containment and/or treatment of proliferative disease such as cancer.

According to a further feature of this aspect of the invention there is provided a method for producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

5 According to a further feature of this aspect of the invention there is provided a method for producing an anti-invasive effect by the containment and/or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

10 According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the prevention or treatment of proliferative disease such as cancer in a warm-blooded animal such as man.

15 According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of proliferative disease such as cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

20 According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use in the prevention or treatment of those tumours which are sensitive to inhibition of mTOR kinase and/or one or more PI3K enzymes (such as the Class Ia enzymes and/or the Class Ib PI3K enzyme) that are involved in the signal transduction steps which lead to the proliferation, survival, invasiveness and migratory ability of tumour cells.

25 According to a further feature of this aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the prevention or treatment of those tumours which are sensitive to inhibition of mTOR kinase and/or one or more PI3K enzymes (such as the Class Ia enzymes and/or the Class Ib PI3K enzyme) that are involved in the signal
30 transduction steps which lead to the proliferation, survival, invasiveness and migratory ability of tumour cells.

According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of those tumours which are sensitive to inhibition of mTOR kinase and/or one or more PI3K enzymes (such as the Class Ia enzymes and/or the Class Ib PI3K enzyme) that are involved in the signal transduction steps which lead to the proliferation, survival, invasiveness and migratory ability of tumour cells which comprises
5 administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use in
10 providing a mTOR kinase inhibitory effect and/or a PI3K enzyme inhibitory effect (such as a Class Ia PI3K enzyme or Class Ib PI3K enzyme inhibitory effect).

According to a further feature of this aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in providing a mTOR kinase inhibitory effect
15 and/or a PI3K enzyme inhibitory effect (such as a Class Ia PI3K enzyme or Class Ib PI3K enzyme inhibitory effect).

According to a further aspect of the invention there is also provided a method for providing a mTOR kinase inhibitory effect and/or a PI3K enzyme inhibitory effect (such as a Class Ia PI3K enzyme or Class Ib PI3K enzyme inhibitory effect) which comprises
20 administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein.

According to a further feature of the invention there is provided a compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein for use in the treatment of cancer, inflammatory diseases, obstructive airways diseases, immune diseases or
25 cardiovascular diseases.

According to a further feature of the invention there is provided a compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein for use in the treatment of solid tumours such as carcinoma and sarcomas and the leukaemias and lymphoid malignancies.

30 According to a further feature of the invention there is provided a compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein for use in the

treatment of cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate.

According to a further feature of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein for use in the
5 treatment of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas.

According to a further feature of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the
10 manufacture of a medicament for use in the treatment of cancer, inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases.

According to a further feature of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the treatment of of solid tumours such as carcinoma
15 and sarcomas and the leukaemias and lymphoid malignancies.

According to a further feature of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the treatment of cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar
20 cancer) and prostate.

According to a further feature of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the treatment of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas,
25 skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas.

According to a further feature of the invention there is provided a method for treating cancer, inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases in a warm blooded animal such as man that is in need of such
30 treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

According to a further feature of the invention there is provided a method for treating solid tumours such as carcinoma and sarcomas and the leukaemias and lymphoid malignancies in a warm blooded animal such as man that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a
5 pharmaceutically acceptable salt thereof, as defined herein.

According to a further feature of the invention there is provided a method for treating cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate in a warm blooded animal such as man that is in need of such treatment which comprises administering an effective amount of a
10 compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

According to a further feature of the invention there is provided a method for treating cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas in a warm blooded animal
15 such as man that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined herein.

As stated herein, the *in vivo* effects of a compound of formula (I) may be exerted in part by one or more metabolites that are formed within the human or animal body after
20 administration of a compound of formula (I).

The invention further relates to combination therapies wherein a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of formula (I) is administered concurrently or sequentially or as a combined preparation with another treatment of use in the control of
25 oncology disease.

In particular, the treatment defined herein may be applied as a sole therapy or may involve, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy. Accordingly, the compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer.

30 Suitable agents to be used in combination include :-

(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide,

- nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like paclitaxel and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecins);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;
- (iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application WO 01/94341) and *N*-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; *J. Med. Chem.*, 2004, 47, 6658-6661), and metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM] and the anti-erbB1 antibody cetuximab [C225]); such inhibitors also include, for example, tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as *N*-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839), *N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-*N*-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033) and erbB2 tyrosine kinase inhibitors such as lapatinib), inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-

-77-

derived growth factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006)) and inhibitors of cell signalling through MEK and/or Akt kinases;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WO 98/35985) and SU11248 (sunitinib; WO 01/60814), and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin)];

(vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;

(vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense agent;

(viii) gene therapy approaches, including approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(ix) immunotherapeutic approaches, including *ex-vivo* and *in-vivo* approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

The invention will now be further explained by reference to the following illustrative examples.

Unless stated otherwise, starting materials were commercially available. All solvents and commercial reagents were of laboratory grade and were used as received.

-78-

In the examples ^1H NMR spectra were recorded on a Bruker DPX 300 (300 MHz), Bruker DRX 400 (400 MHz) instrument or a Bruker DRX 500 (500 MHz) instrument. The central peaks of chloroform- d (δ_{H} 7.27 ppm), dimethylsulfoxide- d_6 (δ_{H} 2.50 ppm) or acetone- d_6 (δ_{H} 2.05 ppm) were used as internal references. The following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.

Column chromatography was carried out using silica gel (0.04-0.063 mm, Merck). In general, a Kromasil KR-100-5-C18 reversed-phase column (250 x 20 mm, Akzo Nobel) was used for preparative HPLC with mixtures of acetonitrile and water [containing 0.1% trifluoroacetic acid (TFA)] used as the eluent at a flow rate of 10 mL/min.

The following methods were used for liquid chromatography (LC) / mass spectral (MS) analysis :-

HPLC: Agilent 1100 or Waters Alliance HT (2790 & 2795)

Mass Spectrometer: Waters ZQ ESCi

HPLC Column

The standard HPLC column used is the Phenomenex Gemini C18 5 μm , 50 x 2 mm.

Acidic HPLC Methods

The mobile phases used are: Mobile phase A: Water

Mobile Phase B: Acetonitrile

Mobile Phase C: 1% Formic Acid in 50:50 Water:MeCN (v/v)

Each method is followed by a rapid equilibration using a 5 mL flow rate for 0.45 min.

Four generic HPLC methods are available:

5 Minute Monitor Acidic method

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase C:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
4	0	95	5	6	1.1
4.5	0	95	5	6	1.1

Early Acidic method for early eluting compounds

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase C:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
4	57.5	37.5	5	6	1.1
4.5	57.5	37.5	5	6	1.1

Mid Acidic method for middle eluting compounds

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase C:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
0.01	67.5	27.5	5	6	1.1
4.5	27.5	67.5	5	6	1.1

5 **Late Acidic method for late eluting compounds**

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase C:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
0.01	27.5	67.5	5	6	1.1
4.5	5	95	5	6	1.1

Basic HPLC methods

In some instances the standard acidic methods may be unsuitable for either the compound
 10 ionisation or the chromatography separation required. In such cases four comparable Basic
 HPLC methods are available.

The mobile phases used are: Mobile phase A: Water
 Mobile Phase B: Acetonitrile

-80-

Mobile Phase D: 0.1% 880 Ammonia in acetonitrile

Each method is followed by a rapid equilibration using a 5 mL flow rate for 0.45 min.

Minute Monitor Basic method

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase D:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
4	0	95	5	6	1.1
4.5	0	95	5	6	1.1

5

Early Basic method for early eluting compounds

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase D:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
4	57.5	37.5	5	6	1.1
4.5	57.5	37.5	5	6	1.1

Mid Basic method for middle eluting compounds

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase D:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
0.01	67.5	27.5	5	6	1.1
4.5	27.5	67.5	5	6	1.1

10

Late Basic method for late eluting compounds

Time /min	Mobile Phase A:	Mobile Phase B:	Mobile Phase C:	Curve	Flow Rate /mL/min
0.00	95	0	5	1	1.1
0.01	27.5	67.5	5	6	1.1
4.5	5	95	5	6	1.1

The following method was used for liquid chromatography (LC) / mass spectral (MS) analysis :- Instrument: Agilent 1100; Column: Waters 'Symmetry' 2.1 x 30 mm; Mass Spectral analysis using chemical ionisation (APCI); Flow rate: 0.7 mL/min; Absorption Wavelength: 254 nm; Solvent A: water + 0.1% TFA; Solvent B: acetonitrile + 0.1% TFA ; Solvent Gradient: 15-95% Solvent B for 2.7 minutes followed by 95% Solvent B for 0.3 minutes.

The following methods were used for LC analysis :-

Method A :- Instrument: Agilent 1100; Column: Kromasil C18 reversed-phase silica, 100 x 3 mm, 5µm particle size; Solvent A: 0.1% TFA/water, Solvent B: 0.08% TFA/acetonitrile; Flow Rate: 1 mL/min; Solvent Gradient: 10-100% Solvent B for 20 minutes followed by 100% Solvent B for 1 minute; Absorption Wavelengths: 220, 254 and 280 nm. In general, the retention time of the product was noted.

Method B :- Instrument: Agilent 1100; Column: Waters 'Xterra' C8 reversed-phase silica, 100 x 3 mm, 5µm particle size; Solvent A: 0.015M ammonia in water, Solvent B: acetonitrile; Flow Rate: 1 ml/min, Solvent Gradient: 10-100% Solvent B for 20 minutes followed by 100% Solvent B for 1 minute; Absorption Wavelength: 220, 254 and 280 nm. In general, the retention time of the product was noted.

The following abbreviations are used herein or within the following illustrative examples :-

HPLC High Performance Liquid Chromatography

HBTU *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate;

HATU *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate;

HOBT 1-hydroxybenzotriazole;


-82-

HOAT	1-hydroxy-7-azabenzotriazole;
NMP	<i>N</i> -methylpyrrolidin-2-one;
DMSO	dimethylsulfoxide;
DMF	<i>N,N</i> -dimethylformamide;
5 DMA	<i>N,N</i> -dimethylacetamide;
THF	tetrahydrofuran;
DME	1,2-dimethoxyethane;
DCCI	dicyclohexylcarbodiimide;
MeOH	methanol;
10 MeCN	acetonitrile;
DCM	dichloromethane;
DIPEA	<i>N,N</i> -diisopropylethylamine
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene;
RT	room temperature (approximately 17 to 25°C);
15 tR	retention time;
m/z	mass/charge ratio.

The chemical names were generated by software which used the Lexichem Toolkit (v. 1.40) from OpenEye Scientific Software (www.eyesopen.com) to generate IUPAC conforming names.

20

Example 1: *N*-[4,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-methoxybenzamide



4,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine (150 mg) was dissolved in pyridine
 25 (5 mL) and 4-methoxybenzoyl chloride (96 mg) added. The reaction was heated to 90°C for 1 hour. Further 4-methoxybenzoyl chloride (96 mg) was added and the reaction heated at 90°C for a further 3 hours. The reaction was allowed to cool, evaporated to dryness then dissolved in methanol. The material was passed down a SCX-2 column and eluted with 7N ammonia in

-83-


methanol. The fractions were concentrated *in vacuo* and chromatographed on silica, eluting with 2.5% methanol in DCM, to give the desired compound (107 mg) as a pale blue solid.

NMR Spectrum: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.11 - 1.15 (6H, m), 3.01 - 3.08 (2H, m), 3.40 (2H, q), 3.54 - 3.57 (2H, m), 3.68 (2H, d), 3.84 (3H, s), 3.87 - 3.91 (2H, m), 3.93 (1H, s), 3.96 (1H, s), 4.35 (2H, t), 5.57 (1H, s), 6.98 - 7.02 (2H, m), 7.86 - 7.88 (2H, m), 9.79 (1H, s)

Mass Spectrum; $\text{M}+\text{H}^+$ 428.

The preparation of 4,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine is described below.

4,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine




2-Amino-4,6-dichloropyrimidine (3.28 g) and (3*S*)-3-methylmorpholine (4.44 g) were dissolved in NMP (15 mL) under nitrogen. Calcium carbonate powder (4.4 g) was added and the stirred mixture heated to 200°C for 2.5 hours. The mixture was allowed to cool and partitioned between ethyl acetate and a saturated aqueous solution of sodium hydrogen carbonate. Solid residue was removed by filtration and the phases separated. The aqueous phase was washed with ethyl acetate and then the organics combined, washed with 10% aqueous brine (1 x 50 mL), 50% brine (1 x 50 mL) and brine (2 x 50 mL), dried (MgSO_4) and concentrated *in vacuo*. The residue was chromatographed on silica, eluting with 0 – 2% isopropanol in DCM (with a few drops of triethylamine added), to give the desired compound as a colourless oil (2.76 g).

NMR Spectrum: ^1H NMR (400.13 MHz, CDCl_3) δ 1.22 – 1.28 (6H, d), 3.12 – 3.19 (2H, m), 3.51 – 3.57 (2H, m), 3.67 – 3.75 (4H, m), 3.81 – 3.85 (2H, m), 3.92 – 3.96 (2H, m), 4.26 (2H, q), 4.46 (2H, br.s), 5.03 (1H, s)

Mass Spectrum; $\text{M}+\text{H}^+$ 295

Example 2: N-[2,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-methoxy-3-(trifluoromethyl)benzamide



2,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine (120 mg) was dissolved in pyridine
 5 (5 mL) and 4-methoxy-3-(trifluoromethyl)benzoyl chloride (196 mg) added. The reaction was
 heated at 90°C for 2 hours then the reaction allowed to cool and concentrated *in vacuo*. The
 residue was dissolved in methanol, passed down a SCX-2 column and the desired material
 eluted with 7N ammonia in methanol. The fractions were concentrated *in vacuo* and the
 residue purified by prep-HPLC (basic) to give the desired compound (97 mg) as a white solid.
 10 **NMR Spectrum:** ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.18 - 1.20 (6H, m), 3.07 - 3.10 (1H,
 m), 3.11 - 3.14 (1H, m), 3.40 (1H, d), 3.43 (1H, d), 3.55 - 3.61 (1H, m), 3.58 - 3.62 (1H, m),
 3.68 - 3.74 (2H, m), 3.87 - 3.95 (2H, m), 3.94 (1H, d), 3.99 (3H, s), 4.21 - 4.22 (1H, m), 4.25 -
 4.28 (1H, m), 4.62 - 4.64 (1H, m), 6.93 (1H, s), 7.39 (1H, d), 8.24 (2H, d), 10.28 (1H, s)


Mass Spectrum; M+H⁺ 496.

15

The following compounds were made in an analogous fashion from 4,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine or 2,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine and the appropriate acid chloride.

Example	Structure	NAME	LCMS MH+
3		N-[2,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-3-methoxybenzamide	428
4		N-[4,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-methoxy-3-(trifluoromethyl)benzamide	496

-85-

Example	Structure	NAME	LCMS MH+
5		N-[4,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-3-methoxybenzamide	428


Example 3: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.19 (6H, t), 3.06 - 3.15 (2H, m), 3.36 - 3.40 (1H, m), 3.42 - 3.47 (1H, m), 3.53 - 3.62 (2H, m), 3.67 - 3.74 (2H, m), 3.85 (3H, s), 3.90 - 3.96 (2H, m), 4.23 (1H, d), 4.28 (1H, d), 4.61 - 4.63 (1H, m), 6.93 (1H, s), 7.15 - 7.18 (1H, m), 7.42 (1H, t), 7.50 (1H, t), 7.54 - 7.57 (1H, m), 10.06 (1H, s)

Example 4: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.13 - 1.14 (6H, m), 3.04 (1H, d), 3.07 (1H, s), 3.37 (1H, s), 3.40 (1H, d), 3.53 - 3.57 (2H, m), 3.67 (2H, d), 3.86 - 3.90 (2H, m), 3.92 - 3.95 (1H, m), 3.98 (4H, s), 4.34 (2H, t), 5.58 (1H, s), 7.35 (1H, d), 8.11 (1H, d), 8.14 - 8.17 (1H, m), 10.15 (1H, s)

Example 5: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.13 - 1.14 (6H, m), 3.01 - 3.07 (2H, m), 3.37 - 3.42 (2H, m), 3.53 - 3.57 (2H, m), 3.68 (2H, d), 3.82 (3H, s), 3.87 - 3.90 (2H, m), 3.92 (1H, s), 4.34 (2H, t), 5.58 (1H, s), 7.09 - 7.12 (1H, m), 7.37 (1H, d), 7.40 - 7.43 (1H, m), 7.39 - 7.45 (1H, m), 9.95 (1H, s)

The preparation of 4,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine was described earlier, the preparation of 2,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine is described below.

2,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-4-amine



A mixture of 4-amino-2,6-dichloropyrimidine (4.33 g), (3*S*)-3-methylmorpholine (6.00 g) and calcium carbonate (5.81 g) in NMP (15 mL) was heated at 170-180°C for 3.5 hours under nitrogen with a water-cooled condenser fitted to the flask. The mixture was allowed to cool and partitioned between ethyl acetate and a saturated aqueous solution of sodium hydrogen


-86-

carbonate. Solid residue was removed by filtration and the phases separated. The aqueous phase was washed with ethyl acetate and then the organics combined, washed with 20% aqueous brine (1 x 50 mL), 50% brine (1 x 50 mL) and brine (2 x 50 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was chromatographed on silica, eluting with 0 – 2.4% isopropanol in DCM (with a few drops of triethylamine added), to give the desired compound as a light brown gum (4.5 g).

NMR Spectrum: ¹H NMR (400.13 MHz, CDCl₃) δ 1.23 - 1.25 (6H, m), 3.13 - 3.21 (2H, m), 3.48 - 3.58 (2H, m), 3.65 - 3.75 (4H, m), 3.86 - 3.96 (3H, m), 4.14 - 4.17 (1H, m), 4.23 - 4.30 (3H, m), 4.59 - 4.64 (1H, m), 5.03 (1H, s)

10 Mass Spectrum; M+H⁺ 295

Example 6: N-[4,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-6-methoxy-pyridine-3-carboxamide










15 2-Methoxy-5-pyridinecarboxylic acid (180 mg) was dissolved in DMA (2 mL) and DIPEA (0.216 mL) and HATU (350 mg) were added to the solution. The reaction was allowed to stir at room temperature for 10 minutes then 4,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine (120 mg) added and the reaction stirred for 18 hours at 40°C. The reaction was passed down a SCX-2 column, washed with methanol and the desired material eluted with 7N ammonia in methanol. The fractions were concentrated *in vacuo* and the residue purified by prep-HPLC (basic) to give the desired compound (28 mg) as a pale red solid.

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.10 - 1.14 (6H, m), 3.00 - 3.08 (2H, m), 3.53 - 3.57 (2H, m), 3.67 (2H, d), 3.86 - 3.87 (1H, m), 3.88 (1H, d), 3.90 (1H, s), 3.93 - 3.95 (5H, m), 4.16 (1H, d), 4.33 (2H, d), 5.57 (1H, s), 7.18 (1H, d), 8.09 - 8.12 (1H, m), 8.65 - 8.66 (1H, m), 10.05 (1H, s)






25 Mass Spectrum; M+H⁺ 429.

-87-

The following compounds were made in an analogous fashion from 4,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine or 2,6-bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine and the appropriate carboxylic acid.

Example	Structure	NAME	LCMS MH+
7		<i>N</i> -[2,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-2-methoxy-pyridine-4-carboxamide	429
8		6-Acetamido- <i>N</i> -[2,6-bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]pyridine-3-carboxamide	456
9		<i>N</i> -[2,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-2-methoxy-benzamide	428
10		2-Acetamido- <i>N</i> -[2,6-bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]pyridine-4-carboxamide	456
11		<i>N</i> -[2,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-3-fluoro-4-methoxy-benzamide	446
12		<i>N</i> -[4,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-2-methoxy-pyridine-4-carboxamide	429
13		6-Acetamido- <i>N</i> -[4,6-bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridine-3-carboxamide	456

-88-

Example	Structure	NAME	LCMS MH+
14		<i>N</i> -[4,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-2-methoxybenzamide	428
15		2-Acetamido- <i>N</i> -[4,6-bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridine-4-carboxamide	456
16		<i>N</i> -[4,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-3-fluoro-4-methoxybenzamide	446
17		<i>N</i> -[2,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-(phenylcarbamoylamino)benzamide	532
18		<i>N</i> -[4,6-Bis[(3 <i>S</i>)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-(phenylcarbamoylamino)benzamide	532

Example 7: ^1H NMR (400.13 MHz, DMSO- d_6) δ 0.94 (3H, d), 1.24 (3H, d), 2.67 - 2.69 (1H, m), 2.96 (1H, d), 3.10 (1H, s), 3.13 - 3.21 (1H, m), 3.35 - 3.38 (1H, m), 3.39 - 3.45 (1H, m), 3.50 (1H, d), 3.57 - 3.60 (1H, m), 3.71 (1H, d), 3.90 (5H, s), 3.88 - 3.96 (1H, m), 4.33 (1H, d), 4.66 (1H, d), 6.80 (1H, d), 7.02 - 7.03 (1H, m), 7.50 (1H, s), 8.25 - 8.26 (1H, m)

Example 8: ^1H NMR (400.13 MHz, DMSO- d_6) δ 0.97 (3H, d), 1.24 (3H, d), 2.14 (3H, s), 2.33 - 2.35 (1H, m), 2.61 (1H, s), 2.67 - 2.69 (1H, m), 2.96 (1H, d), 3.14 - 3.19 (2H, m), 3.39 - 3.46 (1H, m), 3.50 (1H, d), 3.57 - 3.60 (1H, m), 3.71 (1H, d), 3.87 (1H, s), 3.88 - 3.92 (1H, m), 4.32 (1H, d), 4.64 (1H, d), 7.88 - 7.91 (1H, m), 7.50 (1H, s), 8.14 (1H, d), 8.40 (1H, d), 10.74 (1H, s)

Example 9: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.17 - 1.21 (6H, m), 3.05 - 3.15 (2H, m), 3.36 - 3.48 (2H, m), 3.54 - 3.62 (2H, m), 3.67 - 3.74 (2H, m), 3.86 - 3.95 (3H, m), 4.00 (3H,

s), 4.17 - 4.21 (1H, m), 4.24 (1H, d), 4.54 (1H, d), 6.95 (1H, s), 7.11 - 7.15 (1H, m), 7.25 (1H, d), 7.56 - 7.61 (1H, m), 7.88 - 7.90 (1H, m), 10.08 (1H, s)

Example 10: ^1H NMR (400.13 MHz, DMSO- d_6) δ 0.94 (3H, d), 1.24 (3H, d), 2.10 (3H, s), 2.64 (1H, d), 2.68 (1H, q), 2.94 - 3.01 (1H, m), 2.98 (1H, d), 3.09 (1H, d), 3.14 - 3.21 (3H, m), 3.58 - 3.61 (1H, m), 3.71 (1H, d), 3.89 - 3.93 (2H, m), 4.33 (1H, d), 4.66 (1H, d), 7.14 - 7.16 (1H, m), 7.50 (1H, s), 8.17 (1H, s), 8.39 - 8.40 (1H, m), 10.59 (1H, s)

Example 11: ^1H NMR (400.13 MHz, DMSO- d_6) δ 0.98 (3H, d), 1.23 (3H, d), 2.34 (1H, t), 2.53 - 2.57 (1H, m), 2.69 (1H, q), 2.71 (1H, s), 2.94 (1H, s), 3.13 - 3.18 (1H, m), 3.15 - 3.18 (1H, m), 3.34 (1H, d), 3.42 (1H, d), 3.50 (1H, d), 3.57 - 3.60 (1H, m), 3.71 (1H, d), 3.91 (3H, s), 4.29 (1H, d), 4.63 - 4.65 (1H, m), 7.23 (1H, t), 7.31 (1H, s), 7.33 (2H, d)

Example 12: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.10 (6H, d), 2.97 - 3.04 (2H, m), 3.33 - 3.40 (2H, m), 3.50 - 3.53 (2H, m), 3.65 (2H, d), 3.84 - 3.85 (2H, m), 3.87 - 3.90 (5H, m), 4.24 (2H, t), 5.55 (1H, s), 7.08 (1H, s), 7.22 - 7.24 (1H, m), 8.24 - 8.26 (1H, m), 10.24 (1H, s)


Example 13: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.10 - 1.14 (6H, m), 2.14 (3H, d), 3.00 - 3.08 (2H, m), 3.36 - 3.43 (2H, m), 3.53 - 3.56 (2H, m), 3.66 (2H, q), 3.84 - 3.94 (5H, m), 4.33 (2H, d), 5.57 (1H, s), 8.12 (1H, d), 8.17 - 8.20 (1H, m), 10.10 (1H, s), 10.75 (1H, s)

Example 14: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.08 (6H, d), 2.95 - 2.99 (2H, m), 3.34 - 3.38 (1H, m), 3.48 - 3.51 (2H, m), 3.63 (2H, d), 3.76 (1H, s), 3.79 - 3.82 (6H, m), 3.84 (1H, d), 3.86 (1H, s), 4.15 - 4.17 (2H, m), 5.49 (1H, s), 7.01 - 7.05 (1H, m), 7.09 - 7.11 (1H, m), 7.43 (1H, d), 9.87 (1H, s)

Example 15: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.08 - 1.13 (6H, m), 2.11 - 2.12 (3H, m), 2.99 - 3.03 (2H, m), 3.33 - 3.39 (2H, m), 3.48 - 3.52 (2H, m), 3.63 (2H, d), 3.80 - 3.87 (4H, m), 4.21 (2H, d), 5.53 (1H, s), 7.28 - 7.29 (1H, m), 8.27 (1H, s), 8.36 - 8.37 (1H, m), 10.26 (1H, s), 10.60 (1H, s)

Example 16: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.14 - 1.15 (6H, m), 3.01 - 3.09 (2H, m), 3.37 - 3.44 (2H, m), 3.54 - 3.58 (2H, m), 3.68 (2H, d), 3.87 - 3.94 (3H, m), 3.92 (4H, s), 4.36 (2H, t), 5.58 (1H, s), 7.25 (1H, t), 7.74 - 7.75 (1H, m), 7.77 (1H, s), 9.92 (1H, s)


-90-

Example 19: N-[2,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-methoxybenzamide

2,6-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-amine) (150 mg) was dissolved in
 5 pyridine (5 mL) and 4-methoxybenzoyl chloride (96 mg) was added to the reaction and heated
 to 90°C for 1 hour. Additional 4-methoxybenzoyl chloride (96 mg) was added and heating
 was continued for a further 1 hour. The reaction was left to cool and then evaporated to
 dryness and the compound dissolved in methanol and loaded onto a SCX-2 column (20g). The
 compound was removed with 7N ammonia in methanol, concentrated in vacuo and the
 10 residue chromatographed on silica, eluting with 2.5% methanol in DCM, to give the desired
 material (136 mg) as a pale blue solid.

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.18 - 1.20 (6H, m), 3.08 - 3.14 (2H,
 m), 3.37 - 3.43 (2H, m), 3.57 - 3.61 (3H, m), 3.69 (2H, d), 3.85 (3H, s), 3.87 - 3.94 (2H, m),
 4.25 (2H, d), 4.61 - 4.64 (1H, m), 6.93 (1H, s), 7.03 - 7.05 (2H, m), 7.97 - 7.99 (2H, m), 9.87
 15 (1H, s)

Mass Spectrum; M+H⁺ 428.

Example 20: 2-[(2*R*,6*S*)-2,6-Dimethylmorpholin-4-yl]-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine

20

A mixture of 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine
 (150 mg), cis-2,6-dimethylmorpholine (0.263 mL) and sodium carbonate (104 mg) in DMA
 (3 mL) was heated at 180°C for 0.5 hours in a microwave reactor. The reaction mixture was
 loaded onto a SCX-2 column, the column washed with methanol then the desired material



-91-

eluted with 7N ammonia in methanol. The fractions were concentrated *in vacuo* and the residue purified by prep-HPLC (basic) to give the desired compound (151 mg) as a solid.

NMR Spectrum: (DMSO- d_6) 1.14 - 1.16 (6H, m), 1.18 - 1.19 (3H, m), 2.44 (2H, d), 3.12 (4H, s), 3.43 (1H, d), 3.52 - 3.58 (2H, m), 3.55 - 3.61 (1H, m), 3.72 - 3.75 (1H, m), 3.96 (2H, s),
 5 4.26 (3H, s), 4.42 - 4.45 (2H, m), 6.20 (1H, s)

Mass Spectrum; $M+H^+$ 385.

The following compounds were made in an analogous fashion using the appropriate amine.


Example	Structure	NAME	LCMS MH+
21		1-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]piperidin-3-ol	371
22		4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-morpholin-4-yl-pyrimidine	

10 **Example 21:** ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.16 - 1.18 (3H, m), 1.35 (2H, d), 1.68 (1H, s), 1.89 (1H, s), 2.73 - 2.79 (1H, m), 2.91 - 2.95 (1H, m), 3.09 (1H, s), 3.12 (3H, s), 3.40 - 3.45 (2H, m), 3.56 - 3.59 (1H, m), 3.72 (1H, d), 3.90 - 3.94 (2H, m), 4.06 (1H, q), 4.22 (2H, s), 4.27 (1H, d), 4.39 - 4.43 (1H, m), 4.78 (1H, d), 6.12 (1H, s)

Example 22: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.16 - 1.18 (3H, m), 3.12 (4H, s), 3.18
 15 (2H, d), 3.63 (8H, s), 3.71 (1H, d), 3.90 - 3.94 (2H, m), 4.25 (3H, s), 6.21 (1H, s)

The preparation of 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine is described below.

-92-


2-Chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine

2,4-Dichloro-6-(methylsulfonylmethyl)pyrimidine (30 g, 0.13 mol) was dissolved in dichloromethane and stirred (under nitrogen) at -5°C. Triethylamine (17.4 mL, 0.13 mol) was added to give a clear brown solution. (3*S*)-3-Methylmorpholine was dissolved in dichloromethane and added dropwise keeping the reaction below -5°C. The cooling bath was then removed and the mixture stirred for 1 hour. The reaction mixture was heated at reflux for 2 hours, then the reaction mixture was washed with water, dried then evaporated. The crude material was purified by preparative HPLC to give the desired material as a solid (19.3 g).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.21 - 1.23 (m, 3H), 3.11 (s, 3H), 3.19 - 3.26 (m, 1H), 3.42 - 3.49 (m, 1H), 3.58 - 3.62 (1H, m), 3.73 (d, 1H), 3.92 - 3.96 (m, 2H), 4.27 - 4.31 (m, 1H), 4.45 (s, 2H), 6.92 (s, 1H)

LCMS Spectrum: MH⁺ 306, retention time 1.42 min, Method 5 Min Acid

15 2,4-Dichloro-6-(methylsulfonylmethyl)pyrimidine




6-(Methylsulfonylmethyl)-1*H*-pyrimidine-2,4-dione (132 g, 0.65 mol) was added to phosphorus oxychloride (1.2 L) and the mixture heated to reflux for 16 hours, then cooled to room temperature. The excess phosphorus oxychloride was removed *in vacuo*, the residue azeotroped with toluene (2 x 500 mL) and dissolved in dichloromethane. This mixture was then poured slowly onto ice (4 L) and stirred for 20 minutes, then extracted with dichloromethane (3 x 1 L) (the insoluble black material was filtered off and discarded) and ethyl acetate (2 x 1 L). The extracts were combined, dried, then evaporated to leave the desired material as a dark brown solid (51 g). The material was used without further purification.

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 3.13 (s, 3H), 4.79 (s, 2H), 7.87 (s, 1H)


LCMS Spectrum: MH⁺ 239, retention time 1.21 min, Method 5 Min Acid

-93-

6-(Methylsulfonylmethyl)-1H-pyrimidine-2,4-dione

6-(Chloromethyl)-1H-pyrimidine-2,4-dione (175 g, 1.09 mol) was dissolved in DMF (2L) and methanesulphonic acid sodium salt (133.5 g, 1.31 mol) was added. The reaction was heated to 125°C for 2 hours then allowed to cool and the suspension filtered and concentrated *in vacuo* to give a yellow solid. The crude material was washed with water, filtered, then triturated with toluene. The solid was filtered then triturated with isohexane to leave the desired compound as a yellow solid (250 g). The material was used without further purification.

10 **Example 23: 3-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-5,7-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene**



A mixture of 5-bromo-1H-pyrrolo[2,3-b]pyridine (250 mg), potassium acetate (374 mg) and bis(pinacolato)diboron (387 mg) in 1,4 dioxane (12 mL) was degassed for 5 minutes then 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct added (63 mg). The reaction was heated to 80°C for 4 hours. 2-Chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (388 mg), ethanol (0.75 mL), 2M sodium carbonate solution (3.2 mL) and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct (63 mg) were added and the heating continued for 16 hour. The reaction mixture was allowed to cool and neutralised with 2M hydrochloric acid. The reaction mixture was passed through a SCX-2 column, the column washed with methanol then the desired material eluted with 7N ammonia in methanol. The fractions were concentrated *in vacuo* then chromatographed on silica, eluting with 2.5% methanol in DCM, to give the desired compound (176 mg) as a white solid.


-94-

NMR Spectrum: (DMSO- d_6) 1.27 (3H, d), 3.23 (3H, s), 3.51 (1H, d), 3.67 (1H, d), 3.80 (1H, d), 4.01 (1H, d), 4.25 (1H, s), 4.52 (3H, s), 5.75 (1H, s), 6.59 (1H, s), 6.83 (1H, s), 7.52 (1H, s), 8.85 (1H, s), 9.22 - 9.23 (1H, m), 11.83 (1H, s)

Mass Spectrum: $M+H^+$ 388.

5

Example 24: 5-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole



To a solution of 5-[4-chloro-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole (97 mg, 0.30 mmol) and DIPEA (174.5 mg, 1.35 mmol) in THF (4 mL) was added, dropwise, 3S-3-Methylmorpholine (106 mg, 1.05 mmol) and the reaction warmed to 70°C overnight. The reaction mixture was evaporated to dryness and applied direct to a basic prep HPLC system for purification using a water/MeCN gradient. The title compound was obtained as a cream solid (38 mg).

NMR Spectrum: ^1H NMR (300.132 MHz, DMSO) δ 1.27 (3H, d), 3.24 (1H, s), 3.28 (3H, s), 3.52 (1H, td), 3.67 (1H, dd), 3.80 (1H, d), 4.01 (1H, dd), 4.21 (1H, d), 4.51 (3H, s), 6.55 (1H, d), 6.77 (1H, s), 7.39 (1H, m), 7.45 (1H, d), 8.16 (1H, dd), 8.61 (1H, s), 11.24 (1H, s)

LCMS Spectrum: MH^+ 387.5 Retention time 1.29 Method: Monitor Mid Basic

The following compound was prepared in an analogous fashion from 5-[4-chloro-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole and the appropriate amine.


Example	Structure	NAME	LCMS MH+	Retention Time
25		5-[4-[(3R)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole	387.6	1.27

-95-

Example 25: ^1H NMR (300.132 MHz, DMSO) δ 1.26 (3H, d), 3.24 (3H, s), 3.43 - 3.55 (1H, m), 3.67 (1H, dd), 3.80 (1H, d), 3.98 - 4.08 (2H, m), 4.21 (1H, d), 4.50 (3H, s), 6.55 (1H, d), 6.77 (1H, s), 7.39 (1H, d), 7.45 (1H, d), 8.16 (1H, dd), 8.61 (1H, s), 11.24 (1H, s)

- 5 The preparation of 5-[4-chloro-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole is described below.

5-[4-chloro-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole




- 10 2-(1H-indol-5-yl)-6-(methylsulfonylmethyl)-3H-pyrimidin-4-one (626 mg, 2.06 mmol) was refluxed in phosphorous oxychloride (15 mL) for 1 hour, the mixture allowed to cool and the phosphorous oxychloride removed under reduced pressure. The mixture was azeotroped with toluene, water added and the mixture made basic (pH=10) with 6N sodium hydroxide solution. The mixture was extracted with ethyl acetate, washed with brine, dried (MgSO_4) and
 15 evaporated under reduced pressure to afford the desired material as yellow gum which solidified on standing (547 mg)

NMR Spectrum: ^1H NMR (300.132 MHz, DMSO) δ 3.23 (3H, s), 4.80 (2H, s), 6.61 - 6.62 (1H, m), 7.45 (1H, t), 7.53 (1H, d), 7.59 (1H, s), 8.16 (1H, dd), 8.66 (1H, s), 11.40 (1H, s)

LCMS Spectrum: MH+ 322.43 Retention time 1.36 Method: Monitor Mid Acid

20

2-(1H-indol-5-yl)-6-(methylsulfonylmethyl)-3H-pyrimidin-4-one



- 2-Methylsulfonyl-6-(methylsulfonylmethyl)pyrimidin-4-ol (657 mg, 2.80 mmol), 5-Indolyl boronic acid (992 mg, 6.16 mmol), Copper (I) thiophene-2-carboxylate (1.39 g, 7.28 mmol)
 25 and Palladium tetrakis triphenylphosphine (259 mg, 0.08 mmol) in 1,4 dioxane (17 mL) were placed in a microwave tube, degassed with nitrogen, sealed and irradiated at 130°C for


-96-

45minutes. The reaction mixture was solubilised with NMP (8 mL) and applied to a pre-equilibrated SCX-2 column. The material was eluted using a gradient of 0-6% ammonium hydroxide in methanol. The residue was triturated with a small volume of ethyl acetate, filtered and the solid washed with diethyl ether to give the desired material as a pale brown solid (626 mg).

NMR Spectrum: ^1H NMR (300.132 MHz, DMSO- d_6) δ 3.20 (3H, s), 4.47 (2H, s), 6.38 (1H, s), 6.58 (1H, d), 7.47 (1H, t), 7.51 (1H, d), 7.91 (1H, d), 8.43 (1H, s), 11.43 (1H, s), 12.43 (1H, s)

LCMS Spectrum: MH+ 304.5 Retention time 2.03 Method: Monitor Early Acid

2-Methylsulfanyl-6-(methylsulfonylmethyl)pyrimidin-4-ol




6-(Chloromethyl)-2-methylsulfanyl-pyrimidin-4-ol (19.07 g, 100 mmol) was suspended in acetonitrile (400 ml). To this stirring suspension was added methanesulphonic acid sodium salt (12.26 g, 120 mmol) and DMF (100 mL). The reaction was then heated to 100°C to give a dark suspension and monitored by LCMS. Once complete, the solvents were removed and the resultant product added to 1:1 methanol:DCM (200 mL) and acidified with acetic acid (10 mL). The resultant precipitate was collected, washed with water (200 mL) and methanol (100 mL) and dried overnight *in vacuo* to afford the title compound as a white solid (16.45 g).

NMR Spectrum: ^1H NMR (300.132 MHz, DMSO- d_6) δ 2.50 (s, 3H), 3.12 (s, 3H), 4.39 (s, 2H), 6.25 (s, 1H), 13.09 (s, 1H)

LCMS Spectrum: MH+ 235.2, Retention Time 0.5 minutes, Method: 5min Early Base

6-(Chloromethyl)-2-methylsulfanyl-pyrimidin-4-ol



S-Methyl-2-thiopseudourea sulphate (20 g, 71.85 mmol), ethyl 4-chloroacetoacetate (10.76 ml, 79.04 mmol) and sodium carbonate (13.93 g, 107.78 mmol) were dissolved in water (100 mL) and stirred at RT overnight. The reaction was monitored by TLC, and once complete, the


-97-

reaction precipitate was collected and the supernatant was neutralised with 6N hydrochloric acid to yield more reaction precipitate which was also collected. The accumulated precipitate was then washed with water and an off-white solid was obtained. This was dried *in vacuo* at 60°C for 48 hours to yield the desired compound as a pale yellow/white solid (43.2 g).

5 NMR Spectrum: ^1H NMR (300.132 MHz, CDCl_3) δ 2.59 (s, 3H), 4.35 (s, 2H), 6.41 (s, 1H), 12.70 (s, 1H)

Mass Spectrum: M^+ 190

10 **Example 26: 5-[4-(Butan-2-ylsulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole**






sec-Butyl thiol (25 mg, 0.28 mmol) was dissolved in DMF (1 mL) and sodium hydride (60% suspension in mineral oil) (12 mg, 0.3 mmol) was added. The reaction was stirred for 10 minutes then 5-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonyloxymethyl)pyrimidin-2-yl]-1H-indole (101 mg, 0.25 mmol) was added. The reaction was stirred at RT for a further 16 hours, to afford a solution of the sulphide intermediate. Water (1 mL) was added to the reaction followed by *m*-chloroperbenzoic acid (0.5 mmol) and the reaction stirred at RT for 1 hour. The reaction mixture was diluted to 5 mL volume with acetonitrile and purified by basic prep HPLC to afford the desired product as a pale yellow solid (17 mg).

20 LCMS Spectrum: MH^+ 429.52, Retention Time 1.77 Method: Monitor Base

The following compounds were prepared in an analogous fashion


-98-

Example	Structure	NAME	LCMS MH+	Retention Time (min)
27*		5-[4-(butan-2-ylsulfonylmethyl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole	413.5	1.36
28		5-[4-[(3R)-3-methylmorpholin-4-yl]-6-(propan-2-ylsulfonylmethyl)pyrimidin-2-yl]-1H-indole	415.5	1.70
29		5-[4-(ethylsulfonylmethyl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole	401.5	1.69

* This material was isolated from the same preparation which gave 5-[4-(butan-2-ylsulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole.

The preparation of 5-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonyloxymethyl)pyrimidin-2-yl]-1H-indole is described below.

5-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonyloxymethyl)pyrimidin-2-yl]-1H-indole




[2-(1H-Indol-5-yl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]methanol (340 mg, 1.05 mmol) was suspended in DCM (8 mL) and treated with methane sulfonylchloride (0.125 mL,

-99-

1.57 mmol) and triethylamine (0.219 mL, 1.57 mmol). After 15 minutes the suspension was evaporated to give the desired product as a gummy solid (180 mg).

LCMS Spectrum: MH⁺ 403.61, Retention Time 2.26 Method: Monitor Base

5 2-(1*H*-Indol-5-yl)-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-4-yl]methanol




To 2-(1*H*-indol-5-yl)-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylic acid (1 g, 2.96 mmol) suspended in dry THF (40 mL) was added borane-THF complex, (1M in THF, 18 mL, 18 mmol). The reaction mixture was heated slowly to 50°C for 20 minutes then partitioned
 10 between ethyl acetate and aqueous sodium hydrogen carbonate solution. The organics were dried (MgSO₄), filtered and concentrated to give a dark oil. The oil was chromatographed on silica, eluting with 20-100% ethyl acetate in isohexane, to give the desired material as a pale white solid (350 mg).

NMR Spectrum: ¹H NMR (300.132 MHz, DMSO-*d*₆) δ 1.25 (3H, d), 3.21 (1H, td), 3.51 (1H, td), 3.66 (1H, dd), 3.79 (1H, d), 4.00 (1H, dd), 4.20 (1H, d), 4.48 (2H, d), 4.51 - 4.57 (1H, m),
 15 5.39 (1H, t), 6.54 (1H, dd), 6.66 (1H, s), 7.37 (1H, t), 7.42 (1H, d), 8.16 (1H, dd), 8.60 (1H, s), 11.18 (1H, s)

LCMS Spectrum: MH⁺ 325.49, Retention Time 1.72 Method: Monitor Base

20 2-(1*H*-Indol-5-yl)-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylic acid



Methyl 2-chloro-6-[(3*S*)-3-methylmorpholin-4-yl] pyrimidine-4-carboxylate (1 g, 3.68 mmol), indole-5-boronic acid (711 mg, 4.42 mmol) and dichlorobis(triphenylphosphine)palladium (130 mg, 0.18 mmol) were dissolved in 18% DMF


-100-

in 7:3:2 DME:Water:EtOH (15 mL) and aqueous sodium carbonate (2M, 5 mL) was added. The reaction was sealed and heated to 125°C for 30 minutes in the microwave reactor. The reaction was then evaporated and the mixture dissolved in 7:2:1 DMSO:Acetonitrile:Water and acidified to pH=2 with hydrochloric acid. The resulting precipitate was collected by
5 filtration and dried to afford the title compound as a pale yellow solid (1.1 g).

NMR Spectrum: ¹H NMR (300.132 MHz, DMSO-d₆) δ 1.28 (3H, d), 3.14 - 4.85 (7H, m), 6.57 (1H, s), 7.13 (1H, s), 7.30 - 7.86 (3H, m), 8.23 (1H, d), 8.70 (1H, s), 11.30 (1H, s)

LCMS Spectrum: MH⁺ 339.40, Retention Time 1.31 Method: Monitor Base

10 Methyl 2-chloro-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylate




Methyl 2,6-dichloropyrimidine-4-carboxylate (4.4 g, 21.25 mmol) in DCM (20 mL) was cooled in ice and treated dropwise with 3*S*-3-methylmorpholine (2.37g, 23.4 mmol) and DIPEA (8.15 mL, 46.8 mmol). After 3 hours polymer supported isocyanate scavenger resin
15 (1g) was added and the mixture was stirred for 30 minutes then filtered. The solution was evaporated and purified by flash silica chromatography, eluting with 5 – 20% methanol in DCM, to give the desired material as a white solid (5.0 g).

NMR Spectrum: ¹H NMR (300.132 MHz, DMSO-d₆) δ 1.23 (3H, d), 3.16 - 3.36 (2H, m), 3.45 (1H, td), 3.59 (1H, dd), 3.71 (1H, d), 3.87 (3H, s), 3.93 (1H, dd), 4.33 - 4.56 (1H, m),
20 7.28 (1H, s)

LCMS Spectrum: MH⁺ 272.38, Retention Time 1.52 Method: Monitor Base


-101-

Example 30: 4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-*N*-(1*H*-pyrazol-3-yl)pyrimidin-2-amine

2-Chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (1.00 g), 1*H*-
 5 pyrazol-3-amine (300 mg) and potassium carbonate (498 mg) were dissolved in butyronitrile (20 mL). The mixture was heated at reflux (117°C) for 24 hours. The reaction was diluted with ethyl acetate (20 mL) and washed with water (20 mL). The water was extracted with ethyl acetate (20 mL) and the combined organic extracts dried over magnesium sulfate and evaporated. The crude product was purified by chromatography on silica, eluting with 0-5%
 10 methanol in DCM. The minor isomer was collected and gave the desired material as a yellow gum (45 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, CDCl₃) δ 1.32 - 1.37 (3H, m), 1.68 (1H, s), 3.02 (3H, s), 3.07 (1H, m), 3.34 - 3.41 (1H, m), 3.55 - 3.62 (1H, m), 3.71 - 3.75 (1H, m), 3.81 (1H, d), 4.02 - 4.06 (1H, m), 4.28 (2H, s), 4.31 (1H, m), 5.30 (1H, s), 5.51 (1H, d), 5.75 (2H, s),
 15 6.48 (1H, s), 7.48 (1H, d)

LCMS Spectrum: MH⁺ 353, Retention Time 1.01min, Method Monitor Acid

Example 31: 4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[4-(1*H*-pyrazol-4-yl)phenyl]pyrimidine

20

Nitrogen was bubbled through a mixture of 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (210 mg, 0.69 mmol), *tert*-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole-1-carboxylate (270 mg, 0.73 mmol), potassium phosphate tribasic (511 mg, 2.4 mmol) in dioxane for 10 minutes. Bis(*tri-tert*-
 25 butylphosphine)palladium(0) (18 mg) was added and the reaction was degassed several times

-102-

then heated at 80°C for 16 hours. After cooling the mixture was extracted with ethyl acetate, washed with water, dried (MgSO₄), filtered and evaporated. The crude material was chromatographed on silica, eluting with 60-75% ethyl acetate in hexane, to give the desired material (71 mg) as a white solid.

- 5 NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.26 (3H, d), 3.22 (2H, s), 3.25-3.30 (2H, m), 3.55 (1H, dd), 3.68 (1H, d), 3.78 - 3.81 (1H, d), 4.03 (1H, dd), 4.15 (1H, s), 4.50 (3H, s), 6.84 (1H, s), 7.71 - 7.73 (2H, d), 8.00 (1H, s), 8.27 (1H, s), 8.30 - 8.33 (2H, d)


LCMS Spectrum: MH+414, retention time 1.81 mins, method monitor base.

- 10 The preparation of 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine was described earlier.

The preparation of *tert*-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole-1-carboxylate is described below.

15

tert-Butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole-1-carboxylate




- A mixture of *tert*-butyl 4-(4-bromophenyl)pyrazole-1-carboxylate (1.1 g, 3.4 mmol), bispinacolato diborane (1.04 g, 4.1 mmol), potassium acetate (1 g, 10.2 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct (167 mg) in dioxane (15 mL), were heated at 90°C for 5 hours. The mixture was diluted with water and extracted into ethyl acetate. The organics were dried (MgSO₄), filtered and evaporated and the residue chromatographed on silica, eluting with 30% ethyl acetate in hexane, to give the desired material (835 mg).

- 25 NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.31 (12H, s), 1.61 (9H, s), 7.68 (2H, d), 7.75 (2H, d), 8.30 (1H, s), 8.78 (1H, s).

LCMS Spectrum: no MH⁺ ion observed, retention time 2.82mins, method monitor base


-103-

tert-Butyl 4-(4-bromophenyl)pyrazole-1-carboxylate

A mixture of 4-(4-bromophenyl)-1*H*-pyrazole (800 mg, 3.6 mmol), (2-methylpropan-2-yl)oxycarbonyl *tert*-butyl carbonate (1.18 g, 5.38 mmol) and DMAP (100 mg), in THF (20 mL) were heated at 80°C for 3 hours. The mixture was evaporated, dissolved in DCM and chromatographed on silica, eluting with 40% ethyl acetate in hexane, to give the desired material (960 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.61 (9H, s), 7.58 (2H, d), 7.70 (2H, s), 8.30 (1H, s), 8.80 (1H, s).

10 LCMS Spectrum no MH⁺, retention time 2.81mins, method monitor base.

Example 32: 4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[3-(1*H*-pyrazol-4-yl)phenyl]pyrimidine

15 A mixture of *tert*-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole-1-carboxylate (270 mg, 0.73 mmol), 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (210 mg, 0.69 mmol), potassium phosphate tribasic (511 mg, 2.4 mmol), bis(tri-*tert*-butylphosphine)palladium(0) (18 mg) in toluene (2 mL), ethanol (4 mL) and water (2 mL) was stirred at 80°C for 16 hours. After cooling the mixture was
20 extracted with ethyl acetate, washed with water, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 70-100 % ethyl acetate in hexane, to give the desired material (116 mg).

NMR Spectrum ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.26 - 1.28 (3H, d), 3.24 (2H, s), 3.52 (2H, d), 3.55 (1H, dd), 3.66 - 3.69 (1H, dd), 3.80 (1H, d), 3.99 - 4.03 (1H, dd), 4.20 (1H, s),
25 4.54 (3H, s), 6.88 (1H, s), 7.48 (1H, dd), 7.72 - 7.75 (1H, d), 7.95 (1H, s), 8.16 (1H, d), 8.22 (2H, s), 8.50 (1H, s), 12.99 (1H, s)


-104-

LCMS Spectrum MH⁺ 414, retention time 1.86 mins, method monitor base.

The preparation of *tert*-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole-1-carboxylate is described below.

5

tert-Butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole-1-carboxylate




A mixture of *tert*-butyl 4-(3-bromophenyl)pyrazole-1-carboxylate (1.1 g, 3.4 mmol), bispinacolatodiborane (1.038 g, 4 mmol), potassium acetate (1 g, 10.2 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct (167 mg) in dioxane (15 mL) was heated at 90°C for 5 hours. The mixture was diluted with water and extracted into ethyl acetate. The organics were dried (MgSO₄), filtered and evaporated and the residue chromatographed on silica, eluting with 30% ethyl acetate in hexane, to give the desired material (1.1 g).

15 NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.33 (12H, s), 1.62 (9H, s), 7.40 (1H, dd), 7.60 (1H, d), 7.88 (1H, d), 7.92 (1H, d), 8.29 (1H, s), 8.70 (1H, s).

LCMS Spectrum: no MH⁺ ion observed, retention time 2.89mins, method monitor base.

tert-Butyl 4-(3-bromophenyl)pyrazole-1-carboxylate



20

A mixture of 4-(3-bromophenyl)-1*H*-pyrazole (800 mg, 3.6 mmol), (2-methylpropan-2-yl)oxycarbonyl *tert*-butyl carbonate (1.18 g, 5.38 mmol) and DMAP (100 mg), in THF (20 mL) were heated at 80°C for 3 hours. The mixture was evaporated, dissolved in DCM and chromatographed on silica, eluting with 40% ethyl acetate in hexane, to give the desired material (1.1 g).


25

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.62 (9H, s) 7.35 (1Hdd), 7.50 (1H, dd), 7.78 (1H, dd), 8.05 (1, d), 8.35 (1H, s), 8.84 (1H, s).

-105-

LCMS Spectrum; no MH⁺ ion observed, retention time 2.67mins, method monitor base.

Example 33: 5-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxamide



5

Triethylamine (0.064 mL, 0.52 mmol) and HATU (95 mg, 0.25 mmol) were added to a stirred suspension of 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxylic acid (90 mg, 0.2 mmol), in DCM (8 mL) at RT. After 10 minutes an aqueous solution of ammonia (1 mL) was added and the reaction stirred for 45 minutes. The mixture was washed with a saturated aqueous solution of sodium hydrogen carbonate, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 0-10% methanol in ethyl acetate, and the solid obtained triturated with a mixture of diethyl ether and hexane to give the desired material (11 mg).

NMR Spectrum: ¹H NMR (500.13 MHz, DMSO-*d*₆) δ 1.27 (3H, d), 3.27 - 3.28 (4H, m), 3.6 (1H, t), 3.69 (1H, d), 3.78 (1H, d), 4.0 (1H, d), 4.20 (1H, s), 4.49 (1H, s), 4.51 (3H, s), 6.75 (2H, s), 7.48 (1H, s), 8.09 (1H, s), 8.18 (1H, d), 9.20 (1H, s), 11.62 (1H, s).


15

LCMS Spectrum; MH⁺ 430, retention time 1.45mins, method monitor base.

The preparation of 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxylic acid is described below.

20

5-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxylic acid




-106-

A mixture of methyl 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxylate (177 mg, 0.4 mmol) in 2M sodium hydroxide solution (3 mL), methanol (7 mL) and THF (5 mL) was heated at 90°C for 4 hours then left to stir at RT for 16 hours. The organics were removed *in vacuo* and the mixture washed with ethyl acetate. The aqueous layer was acidified (pH = 4-6) and the product extracted with ethyl acetate. The organics were washed with water, dried (MgSO₄) and evaporated to give the desired material (90 mg) which was used without further purification.

LCMS Spectrum MH⁺ 431, retention time 0.73mins, method monitor base.

10 Methyl 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxylate




A mixture of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indole-3-carboxylate (250 mg, 0.83 mmol), 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (230 mg, 0.75 mmol), potassium phosphate tribasic (560 mg), bis(tri-*tert*-butylphosphine)palladium(0) (24 mg) in toluene (2 mL), ethanol (4 mL) and water (2 mL) was stirred at 80°C for 16 hours. After cooling the mixture was extracted with ethyl acetate, washed with water, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 65 % ethyl acetate in hexane, to give the desired material (190 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.28 (3H, d), 3.25 (4H, d), 3.53 (1H, d), 3.66 (1H, d), 3.84 (4H, s), 4.03 (1H, d), 4.20 (1H, d), 4.55 (3H, s), 6.82 (1H, s), 7.55 (1H, d), 8.13 (1H, d), 8.25 (1H, d), 9.09 (1H, d), 12.05 (1H, s)

LCMS Spectrum: MH⁺ 445, retention time 1.93mins, method monitor base.


-107-

Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxylate

A mixture of methyl *tert*-butyl 5-bromoindole-1,3-dicarboxylate (600 mg, 1.7 mmol), bispinacolatodiborane (516 mg, 2.3 mmol), potassium acetate (498 mg, 5.1 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct (83 mg) in dioxane (10 mL) was degassed several times and heated at 90°C for 14 hours. The reaction was diluted with water and extracted with ethyl acetate, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 50% ethyl acetate in hexane to give the desired material.

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.32 (12H, s), 3.82 (3H, s), 7.46 (1H, d), 7.50 (1H, d), 8.10 (1H, s), 8.43 (1H, s), 12.00 (1H, s)

LCMS Spectrum: MH⁺ 302, retention time 2.23mins, monitor base.

Methyl *tert*-butyl 5-bromoindole-1,3-dicarboxylate


A mixture of 5-bromo-1-[(2-methylpropan-2-yl)oxycarbonyl]indole-3-carboxylic acid (1 g, 2.9 mmol), potassium carbonate (609 mg, 4.4 mmol) and iodomethane (626 mg, 4.4 mmol) in DMF (15 mL) was heated at 70°C for 1.5 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The organics were washed with water, dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 15-20% ethyl acetate in hexane, to give the desired material as a white solid (600 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.65 (9H, s), 3.89 (3H, s), 7.58 (1H, dd), 8.07 (1H, d), 8.19 (1H, d), 8.26 (1H, s)

LCMS Spectrum: no MH⁺ ion observed, retention time 3.32mins, method monitor base

-108-

Example 34: 4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[2-(1*H*-pyrazol-4-yl)-1,3-thiazol-5-yl]pyrimidine




A mixture of 2-(2-bromo-1,3-thiazol-5-yl)-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (150 mg, 0.346 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (100 mg, 0.515 mmol), 2*M* aqueous solution of sodium hydrogen carbonate (1 mL), dichlorobis(triphenylphosphine)palladium(II) (20 mg) in DMF (2 mL), DME (4 mL), water (1.5 mL) and ethanol (2 mL) was degassed several times then heated at 95°C under a nitrogen atmosphere. The reaction was allowed to cool, diluted with
 10 water and extracted with ethyl acetate. The organics were washed with water, dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with ethyl acetate, and the solid obtained was triturated with a mixture of ethyl acetate and hexane to give the desired material (50 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.25 (3H, d), 3.20 (1H, d), 3.28 (3H, s),
 15 3.50 (1H, dd), 3.62 (1H, dd), 3.78 (1H, d), 4.00 (1H, dd), 4.15 (1H, s), 4.40 (1H, s), 4.50 (2H, s), 6.81 (1H, s), 8.05 (1H, s), 8.42 (1H, s), 8.46 (1H, s), 13.35 (1H, s).

LCMS Spectrum: MH⁺ 421, retention time 1.59mins, method monitor base.

The preparation of 2-(2-bromo-1,3-thiazol-5-yl)-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine is described below.

2-(2-Bromo-1,3-thiazol-5-yl)-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine




-109-

tert-Butyl nitrite (0.921 mL) was added to a mixture of copper (I) bromide (282 mg, 2 mmol), in acetonitrile (8 mL). After stirring for 45 minutes, 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1,3-thiazol-2-amine (600 mg, 1.38 mmol) was added. The reaction was stirred for 45 minute then heated at 60°C for 2 hours. The reaction was
 5 allowed to cool, partitioned between ethyl acetate and water, the organics dried (MgSO₄), filtered, and evaporated. The residue was chromatographed on silica, eluting with 50-60% ethyl acetate in hexane, and the solid obtained triturated with a mixture of diethyl ether and hexane to give the desired material as a pale yellow solid (255 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.24 (3H, d), 3.17 (3H, s), 3.23 (1H, d),
 10 3.46 - 3.51 (1H, dd), 3.65 (1H, d), 3.77 (1H, d), 3.96 - 3.99 (1H, d), 4.12 (1H, s), 4.40 (1H, s), 4.49 (2H, s), 6.88 (1H, s), 8.30 (1H).

LCMS Spectrum: MH⁺ 435, retention time 2.11mins, method monitor base.

5-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1,3-thiazol-2-
 15 amine




A solution of *tert*-butyl *N*-[5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1,3-thiazol-2-yl]-*N*[(2-methylpropan-2-yl)oxycarbonyl]carbamate (1.7 g, 2.9 mmol) and TFA (8 mL) in DCM (15 mL) was stirred at
 20 RT for 16 hours. The solvent was removed under reduced pressure and the residue made basic with aqueous ammonia solution. The product was extracted with ethyl acetate, the organics dried over sodium sulphate, filtered and evaporated to give the desired material as a white solid (1 g).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.16 - 1.22 (3H, m), 3.13 - 3.18 (1H, m), 3.19 (3H, s), 3.43 - 3.50 (1H, m), 3.60 - 3.63 (1H, m), 3.75 (1H, d), 3.94 - 3.97 (1H, dd),
 25 4.04 (1H, d), 4.37 (1H, s), 4.40 (2H, s), 5.75 (1H, s), 6.64 (1H, s), 7.40 (2H, s), 7.73 (1H, s)

LCMS Spectrum: MH⁺ 370, retention time 1.38 mins, method monitor base.

-110-


tert-Butyl *N*-[5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1,3-thiazol-2-yl]-*N*-[(2-methylpropan-2-yl)oxycarbonyl]carbamate



A mixture of *tert*-butyl *N*-[(2-methylpropan-2-yl)oxycarbonyl]-*N*-(5-tributylstannyl-1,3-thiazol-2-yl)carbamate (3 g, 5.1 mmol), 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (1 g, 3.2 mmol) and palladium tetrakis (triphenylphosphine) (50 mg), in toluene (10 mL) was heated at 105°C for 2 hours under nitrogen. The mixture was chromatographed on silica to give the desired material (1.7 g).
NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.20 (3H, d), 1.53 (9H, s), 3.18 (3H, s), 3.55 (1H, t), 3.62 (1H, d), 3.75 (1H, d), 3.98 (1H, d), 4.10 (1H, s), 3.90 (1H, s), 3.98 (2H, s), 6.80 (1H, s), 8.18 (1H, s)

LCMS Spectrum: MH⁺ 570, retention time 2.89mins, method monitor base.

tert-Butyl *N*-[(2-methylpropan-2-yl)oxycarbonyl]-*N*-(5-tributylstannyl-1,3-thiazol-2-yl)carbamate



n-Butyl lithium (1.6M in hexanes, 30 mL, 0.48 mol), was added to diisopropylamine (6.7 mL, 0.48mol) in THF (480 mL) at 0°C. The mixture was stirred at 0°C for 30 mins then cooled to -78°C. *tert*-Butyl *N*-[(2-methylpropan-2-yl)oxycarbonyl]-*N*-(1,3-thiazol-2-yl)carbamate (12 g, 0.05 mol) was added and solution stirred for 30 minutes. Tributyltin chloride (16.3 mL) was added and solution stirred for 30minutes before allowing to warm to RT. The reaction was quenched with a saturated aqueous solution of ammonium chloride (20 mL) and the product extracted with ethyl acetate. The organics were dried over sodium sulphate, concentrated *in*


-111-

vacuo and chromatographed on silica, eluting with 5-15% ethyl acetate in hexane, to give the desired material as a clear oil (9 g).

NMR Spectrum: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.49 (18H, s), 7.50 (1H, d), 7.55 (1H, d)

5

tert-Butyl N-[(2-methylpropan-2-yl)oxycarbonyl]-N-(1,3-thiazol-2-yl)carbamate




A solution of 2-aminothiazole (5 g, 0.05 mol), (2-methylpropan-2-yl)oxycarbonyl tert-butyl carbonate (27.8 g, 0.15 mol) and DMAP (100 mg) in THF (100 mL) was stirred at reflux
10 overnight. The mixture was allowed to cool and concentrated *in vacuo*. The residue was chromatographed on silica, eluting with 8% ethyl acetate in hexane, to give the desired material as a white solid (12 g).

NMR Spectrum: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.49 (18H, s), 7.50 (1H, d), 7.55 (1H, d)

15 LCMS Spectrum MH- 299, retention time 2.6 mins, method monitor base

Example 35: 6-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole



20

A mixture of 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (350 mg, 1.15 mmol), 1H-indol-6-ylboronic acid (277 mg, 1.72 mmol), 2M aqueous solution of sodium hydrogen carbonate (1.5 mL), dichlorobis(triphenylphosphine)palladium(II) (45 mg) in DMF (2 mL), DME (4 mL), water (2 mL) and ethanol (2 mL), was degassed several

-112-


times then heated at 95°C under a nitrogen atmosphere. The reaction was allowed to cool, diluted with water and extracted with ethyl acetate. The organics were washed with water, dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with ethyl acetate, and the solid obtained was triturated with a mixture of ethyl acetate and
5 hexane to give the desired material as a beige solid (390 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.35 (3H, d), 3.18-3.28 (4H, m), 3.51 (1H, dd), 3.68 (1H, dd), 3.79 (1H, d), 4.00 (1H, dd), 4.20 (1H, d), 4.52 (3H, s), 6.48 (1H, s), 6.79 (1H, s), 7.45 (1H, s), 7.58 (1H, d), 8.07 (1H, d), 8.45 (1H, s), 11.30 (1H, s).

LCMS Spectrum: MH⁺ 387, retention time (2.12mins , method monitor base.

10

Example 36: 6-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carboxamide



A suspension of 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carbonitrile (43 mg, 0.10 mmol), in a 30% solution of hydrogen peroxide (2
15 mL), aqueous ammonia (1.5 mL) and ethanol (2 mL) was stirred at RT for 7 hours. The reaction was diluted with water and extracted with ethyl acetate. The organics were dried (MgSO₄), filtered, evaporated and the residue triturated with a mixture of diethyl ether and hexane to give the desired material as a yellow solid (27 mg).

20 NMR Spectrum: ¹H NMR (500.13 MHz, DMSO-d₆) δ 1.33 (3H, d), 3.19 (3H, s), 3.30 (1H, dd), 3.40 (1H, t), 3.55 (1H, dd), 3.70 (1H, d), 3.75 (1H, d), 3.99 (1H, d), 4.18 (1H, d), 4.45 (2H, s), 4.53 (1H, s), 6.68 (1H, s), 6.72 (1H, s), 8.05 (1H, s), 8.12 (2H, s), 8.43 (1H, s), 9.80 (1H, s), 11.40 (1H, s).


LCMS Spectrum: MH⁺ 430, retention time 1.46mins, method monitor base.

25

The preparation of 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carbonitrile is described below.

-113-

6-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-3-carbonitrile




- 5 A suspension of 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole (200 mg, 0.52 mmol), in dry acetonitrile (15 mL), was warmed until all material dissolved. The reaction was cooled to 0°C and chlorosulphonyl isocyanate (0.045 mL) added, followed by dry DMF (3 mL). After 3.5 hours the mixture was extracted into ethyl acetate and the organics washed with water, dried (MgSO₄), filtered and evaporated.
- 10 The residue was chromatographed on silica, eluting with 70% ethyl acetate in hexane, to give the desired material as a cream solid (45 mg).

LCMS Spectrum: ¹H NMR (500.13 MHz, DMSO-*d*₆) δ 1.30 (3H, t), 3.15 (3H, s), 3.30 (1H, dd), 3.58 (1H, dd), 3.70 (1H, d), 3.80 (1H, d), 4.0 (1H, dd), 4.18 (1H, d), 4.47 (2H, s), 4.53 (1H, s), 6.79 (1H, s), 7.68 (1H, d), 8.20 (1H, s), 8.25 (1H, d), 8.55 (1H, s), 12.0 (1H, s).

- 15 LCMS Spectrum: MH⁺ 412, retention time 2.01mins, method monitor base.

The preparation of 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole was described earlier.

- 20 **Example 37: 5-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxamide**



Triethylamine (0.1 mL, 0.73 mmol) and HATU (222 mg, 0.58 mmol) were added to a stirred suspension of 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-

-114-


1*H*-indole-2-carboxylic acid (210 mg, 0.48 mmol), in DCM (10 mL) at RT. After 10 minutes an aqueous solution of ammonia (2 mL) was added and the reaction stirred for 45 minutes. The mixture was washed with a saturated aqueous solution of sodium hydrogen carbonate, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica,
5 eluting with 0-5% methanol in ethyl acetate, and the solid obtained triturated with a mixture of diethyl ether and hexane to give the desired material (85 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.27 (3H, d), 3.24 - 3.26 (3H, m), 3.55 (1H, dd), 3.68 (1H, dd), 3.80 (1H, d), 4.0 (1H, dd), 4.20 (1H, d), 4.5 (3H, s), 6.80 (1H, s), 7.21 (1H, s), 7.35 (1H, s), 7.48 (1H, d), 7.95 (1H, s), 8.24 (1H, d), 8.65 (1H, s), 11.70 (1H, s).

10 LCMS Spectrum: MH⁺ 430, retention time 1.59mins, method monitor base.

The preparation of 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylic acid is described below.

15 5-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylic acid




A mixture of ethyl 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylate (390 mg, 0.85 mmol) in 2M aqueous sodium hydroxide
20 solution (3 mL) and methanol (10 mL), was refluxed for 4 hours. The organics were removed *in vacuo* and the mixture adjusted to pH = 5 with 2M hydrochloric acid. The mixture was extracted with DCM and the organics dried (MgSO₄), filtered and evaporated. The residue was triturated with a mixture of diethyl ether and hexane to give the desired material as a cream solid (210 mg).

25 NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.22 (3H, d), 3.22 (3H, s), 3.38 (1H, t), 3.50 (1H, dd), 3.68 (1H, dd), 3.80 (1H, d), 4.0 (1H, dd), 4.21' (1H, d), 4.51 (3H, s), 6.78 (1H, s), 7.03 (1H, s), 7.45 (1H, d), 8.24 (1H, d), 8.65 (1H, s), 11.

LCMS Spectrum: MH⁺ 431, retention time 0.79mins, method monitor base.

-115-

Ethyl 5-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-2-carboxylate




- 5 A soln of ethyl *tert*-butyl 5-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]indole-1,2-dicarboxylate (600 mg, 1.07 mmol) in TFA (6 mL) and DCM (20 mL) was stirred at RT for 2 hours. The mixture was concentrated in vacuo and the residue made basic with aqueous ammonia. The mixture was extracted with ethyl acetate and the organics dried (MgSO₄), filtered and evaporated. The residue was
- 10 triturated with diethyl ether and filtered to give the desired material as a pale yellow solid (450 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.28 (3H, d), 1.36 31H, t), 3.23 (3H, s), 3.55 (1H, dd), 3.68 (1H, dd), 3.78 (1H, d), 3.89 (1H, s), 4.0 (1H, dd), 4.21 (1H, s), 4.38 (2H, q), 4.52 (3H, s), 6.81 (1H, s), 7.29 (1H, s), 7.52 (1H, d), 8.31 (1H, d), 8.71 (1H, s).

- 15 LCMS Spectrum: MH⁺ 459, retention time 2.26mins, method monitor base.

Ethyl *tert*-butyl 5-[4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]indole-1,2-dicarboxylate




- 20 A mixture of ethyl *tert*-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1,2-dicarboxylate (1.2 g, 2.9 mmol), 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (450 mg, 1.45 mmol), potassium phosphate tribasic (1 g, 4.7 mmol) and bis(*tri-tert*-butylphosphine)palladium(0) (50 mg) in toluene (5 mL), ethanol

-116-

(10 mL) and water (5 mL) was stirred at 80°C for 16 hours. After cooling the mixture was extracted with ethyl acetate, washed with water, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 50-70 % ethyl acetate in hexane, to give the desired material contaminated with ethyl 5-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylate (600 mg). The crude mixture was used without further purification.

LCMS Spectrum MH+559, retention time 2.91 mins, method monitor base.

Ethyl *tert*-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1,2-dicarboxylate



10


A mixture of ethyl *tert*-butyl 5-chloroindole-1,2-dicarboxylate (1.45 g, 4.5 mmol), bispinacolatodiborane (1.4 g, 5.5 mmol) tricyclohexylphosphine (93 mg, 0.33 mol), bis(dibenzylideneacetone)palladium (80 mg) and potassium acetate (684 mg, 6.97 mmol) in dioxane (30 mL), was degassed several times, then heated at 90°C for 16 hours. The mixture was allowed to cool, diluted with water and extracted into ethyl acetate. The organics were washed with water, dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 15% ethyl acetate in hexane, to give the desired material as a pale yellow solid (1.2 g).

15

LCMS Spectrum no MH⁺ ion observed, retention time 2.53mins, method monitor base.

20

Example 38: 6-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxamide



-117-


Triethylamine (0.095 mL, 0.68 mmol) and HATU (205 mg, 0.54 mmol) were added to a stirred suspension of 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylic acid (195 mg, 0.43 mmol), in DCM (10 mL) at RT. After 10 minutes an aqueous solution of ammonia (2 mL) was added
5 and the reaction stirred for 45 minutes. The mixture was washed with a saturated aqueous solution of sodium hydrogen carbonate, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 0-10% methanol in ethyl acetate, to give the desired material as a yellow solid (10 mg).

NMR Spectrum: ¹H NMR (500.13 MHz, DMSO-d₆) δ 1.28 (3H, d), 3.27 (4H, m), 3.55 (1H, dd), 3.68 (1H, s), 3.78 (1H, d), 4.0 (1H, d), 4.19 (1H, s), 4.52 (3H, s), 6.80 (1H, s), 7.14 (1H, s), 7.35 (1H, s), 7.64 (1H, d), 7.95 (1H, s), 8.05 (1H, d), 8.48 (1H, s,), 11.65 (1H, s).

LCMS Spectrum: MH⁺ 430, retention time 1.72 mins, method monitor base.

The preparation of 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylic acid is described below.
15

6-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylic acid



A mixture of ethyl 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylate (480 mg, 1 mmol) in 2M aqueous sodium hydroxide solution (3 mL) and methanol (15 mL), was refluxed for 4 hours. The organics were removed *in vacuo* and the mixture adjusted to pH = 5 with 2M hydrochloric acid. The mixture was extracted with DCM and the organics dried (MgSO₄), filtered and evaporated. The residue was
25 triturated with a mixture of diethyl ether and hexane to give the desired material as a cream solid (200 mg).


-118-

NMR Spectrum: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.25 (3H, d), 3.26 (4H, s), 3.52 (1H, dd), 3.69 (1H, d), 3.79 (1H, d), 4.0 (1H, dd), 4.20 (1H, d), 4.52 (3H, s), 6.82 (1H, s), 6.85 (1H, s), 7.62 (1H, d), 8.09 (1H, d), 8.52 (1H, s), 11.40 (1H, s).

LCMS Spectrum: MH $^+$ 431, retention time 0.91mins, method monitor base.

5

Ethyl 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1*H*-indole-2-carboxylate




A soln of ethyl *tert*-butyl 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-

(methylsulfonylmethyl)pyrimidin-2-yl]indole-1,2-dicarboxylate (800 mg, 1.43 mmol) in TFA (4 mL) and DCM (10 mL) was stirred at RT for 2 hours. The mixture was concentrated in vacuo and the residue made basic with aqueous ammonia. The mixture was extracted with ethyl acetate and the organics dried (MgSO₄), filtered and evaporated. The residue was triturated with diethyl ether and filtered to give the desired material as a white solid (480 mg).

NMR Spectrum: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.28 (3H, d), 1.35 (3H, t), 3.25 (3H, s), 3.55 (1H, dd), 3.70 (1H, dd), 3.79 (1H, d), 4.02 (1H, dd), 4.20 (1H, d), 4.48 (1H, q), 4.55 (3H, s), 6.85 (1H, s), 7.18 (1H, s), 7.72 (1H, d), 8.13 (1H, d), 8.55 (1H, s), 12.00 (1H, s).

LCMS Spectrum: MH $^+$ 459, retention time 2.39mins, method monitor base.

Ethyl *tert*-butyl 6-[4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]indole-1,2-dicarboxylate



A mixture of ethyl *tert*-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1,2-dicarboxylate (918 mg, 2.2 mmol), 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-

(methylsulfonylmethyl)pyrimidine (450 mg, 1.45 mmol), potassium phosphate tribasic (1.1 g,

25


-119-

5.1 mmol) and bis(tri-*tert*-butylphosphine)palladium(0) (50 mg) in toluene (5 mL), ethanol (10 mL) and water (5 mL) was stirred at 80°C for 16 hours. After cooling the mixture was extracted with ethyl acetate, washed with water, the organics dried (MgSO₄), filtered and evaporated. The residue was chromatographed on silica, eluting with 50-70 % ethyl acetate in
 5 hexane, to give the desired material as a white solid (800 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.25 (3H, d), 1.32 (3H, t), 1.63 (9H, s), 3.28 (3H, s), 3.52 (1H, dd), 3.68 (1H, dd), 3.80 (1H, d), 3.88 (1H, s), 4.0 (1H, dd), 4.22 (1H, d), 4.35 (1H, q), 4.52 (3H, s), 6.88 (1H, s), 7.32 (1H, s), 7.80 (1H, d), 8.34 (1H, d), 8.98 (1H, s).

10 LCMS Spectrum: MH⁺ 559, retention time 2.97mins, method monitor base.

Ethyl *tert*-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1,2-dicarboxylate




A mixture of ethyl *tert*-butyl 6-bromoindole-1,2-dicarboxylate (3 g, 8.1 mmol),
 15 bispinacolatodiborane (2.48 g, 0.97 mmol), potassium acetate (3.2g, 0.032mol), and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct (200 mg), in dioxane (25 mL), was degassed several times, then heated at 90°C for 16 hours. The mixture was allowed to cool, diluted with water and extracted into ethyl acetate. The organics were washed with water, dried (MgSO₄), filtered and evaporated. The residue was
 20 chromatographed on silica, eluting with 15% ethyl acetate in hexane, to give the desired material as a colourless gum (2.17 g).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.33 (15H, s), 1.57 (9H, s), 4.33 (2H, q), 7.28 (1H, s), 7.58 (1H, d), 7.70 (1H, d), 8.89 (1H, s).

LCMS Spectrum; no MH⁺ ion observed, retention time 2.78mins, method monitor base

-120-

Example 39: 5-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1*H*-benzoimidazole




Nitrogen was bubbled through a mixture of *tert*-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoimidazole-1-carboxylate (464 mg, 1.34 mmol),
 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidine (250 mg, 0.75 mmol), sodium carbonate (397 mg, 3.75 mmol), palladium tetrakis triphenylphosphine (50 mg) in DME (4 mL) and water (0.5 mL) for 15 minutes then heated at 90°C for 16 hours. The mixture was concentrated *in vacuo* and dissolved in DCM. TFA (6 mL) was added and mixture heated at 40°C for 30 minutes before being concentrated *in vacuo* and partitioned between DCM and 2M hydrochloric acid. The aqueous layer was made basic with ammonia and extracted with DCM. The organic layer was dried (MgSO₄), filtered and evaporated to give the desired material as a cream solid (280 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-*d*₆) δ 1.25 (3H, d), 1.78 (6H, s), 3.05 (3H, s), 3.25 (1H, m), 3.52 (1H, dd), 3.68 (1H, d), 3.78 (1H, d), 4.0 (1H, d), 4.25 (1H, d), 4.65 (1H, s), 6.78 (1H, s), 7.65 (1H, s), 8.30 (2h, S), 8.62 (1H, s), 12.55 (1H, s).

LCMS Spectrum: MH⁺ 416, retention time 1.84mins, method monitor base.

The preparation of *tert*-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoimidazole-1-carboxylate is described below.

***tert*-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoimidazole-1-carboxylate**




A mixture of *tert*-butyl 5-bromobenzoimidazole-1-carboxylate (2.5 g, 8.5 mmol), bispinacolatodiboran (2.56 g, 10.07 mmol), potassium acetate (3.3 g, 33.67 mmol) and 1,1'-

-121-

bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane adduct (200 mg) in dioxane (25 mL) was degassed several times then heated at 80°C for 16 hours. The mixture was evaporated and dissolved in DCM, filtered and the filtrate chromatographed on silica, eluting with 20% ethyl acetate in hexane, to give the desired material as a pale yellow gum
 5 (2.65 g).

LCMS Spectrum M(-BOC)H+ 245, retention time 1.90mins, method monitor base.

tert-Butyl 5-bromobenzoimidazole-1-carboxylate




10 A solution of 5-bromo-1H-benzoimidazole (2 g, 10.1 mmol), (2-methylpropan-2-yl)oxycarbonyl *tert*-butyl carbonate (3.3 g, 15.1 mmol) and DMAP (200 mg) in THF (30 mL) was heated at reflux for 16 hours. The reaction was allowed to cool, diluted with ethyl acetate and washed with water. The organics were dried (MgSO₄), filtered and evaporated and the residue chromatographed on silica, eluting with 20% ethyl acetate in hexane, to give the
 15 desired material as a mixture of isomers (2.5 g). The material was used without further purification.

LCMS Spectrum no MH⁺ ion observed, retention time 2.67mins, method monitor base.

The preparation of 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidine is described below.
 20

2-Chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidine



2-Chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidine (2.1 g, 6.87
 25 mmol) was dissolved in DMF (20 mL) and the reaction cooled to -5°C. Sodium *tert*-butoxide (650 mg, 6.87 mmol) was added to the reaction, followed by iodomethane (0.4 mL, 6.87 mmol), maintaining the temperature at -5°C. A second equivalent of sodium *tert*-butoxide

-122-


(650 mg, 6.87 mmol) and iodomethane (0.4 mL, 6.87 mmol) were then added and the reaction stirred at -5°C for 1 hour, then at room temperature for 4 hours. DCM (20 mL) was added and the reaction washed with 2M aqueous hydrochloric acid (20 mL). The organic phase was dried over magnesium sulphate, filtered and concentrated *in vacuo*. The crude solid was chromatographed on silica, eluting with 0-50% ethyl acetate in DCM to give the desired material (2.2 g).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.21 (d, 3H), 1.68 (s, 6H), 2.74 (s, 3H), 3.21 (m, 1H), 3.45 (m, 1H), 3.59 (m, 1H), 3.73 (d, 1H), 3.94 (m, 1H), 4.07 (d, 1H), 4.45 (s, 1H), 6.86 (s, 1H)

LCMS Spectrum: MH⁺ 334, retention time 1.85 min, Method 5 Min Base

15

Example 40: 3-[4-[(3*S*)-3-Methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-5,7-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene






A mixture of 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidine (150 mg, 0.45 mmol), 5,7-diazabicyclo[4.3.0]nona-1,3,5,8-tetraen-3-ylboronic acid (130 mg, 0.81 mmol), sodium carbonate (238 mg, 2.2 mmol) and palladium tetrakis triphenylphosphine (50 mg) in DME (4 mL) and water (0.6 mL) was heated for 4 hours at 90°C. The reaction was allowed to cool, diluted with water and extracted with ethyl acetate. The organics were washed with water, dried (MgSO₄), filtered and evaporated. The residue was purified by basic prep HPLC to give the desired material (148 mg).

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ 1.25 (3H,d), 1.80 (6H, s), 3.03 (3H, s), 3.25 (1H, m), 3.52 (1H, m), 3.68 (1H, dd), 3.80 (1H, d), 4.0 (1H, d), 4.30 (1H, d), 4.55 (1H, s), 6.58 (1H, d), 6.80 (1H, s), 7.55-7.70 (2H, m), 8.87 (1H, s), 9.25 (1H, s), 11.85 (1H, s).

-123-

LCMS Spectrum: MH⁺ 416, retention time 1.94mins, method monitor base.

The following compounds were prepared in an analogous fashion.

Example	Structure	NAME	LCMS MH ⁺	Retention time (min)
41		5-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-indole	415	2.24
42		4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-indole	415	2.14
43		6-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-indole	415	2.32

5

Example 41: ¹H NMR (400.13MHz DMSO-d₆) δ 1.25 (3H, d), 1.75 (6H, s), 3.05 (3H, s), 3.22 (1H, dd), 3.52 (1H, dd), 3.65 (1H, dd), 3.78 (1H, d), 4.0 (1H, dd), 4.28 (1H, d), 4.65 (1H, s), 6.55 (1H, s), 6.72 (1h, S), 7.38 (1H, d), 7.42 (1H, d), 8.20 (1H, d), 8.62 (1H, s), 11.20 (1H, s).

10 **Example 42:** ¹H NMR (400.13MHz DMSO-d₆) δ 1.28 (3H, d), 1.80 (6H, s), 3.0 (3H, s), 3.25 (1H, dd), 3.52 (1H, dd), 3.68 (1H, d), 3.80 (1H, d), 4.01 (1H, d), 4.25 (1H, d), 4.65 (1H, s), 6.80 (1H, s), 7.18 (1H, dd), 7.82 (1H, d), 7.40 (1H, d), 7.52 (1H, d), 8.12 (1H, s), 11.20 (1H, s).


15 **Example 43:** ¹H NMR (400.13MHz DMSO-d₆) δ 1.25 (3H,d), 1.79 (6H,s), 3.08 (3H,s), 3.20-3.30 (4H,m), 3.52 (1H,dd), 3.69 (1H,dd), 3.79 (1H,d), 4.02 (1H,d), 4.25 (1H,d), 4.64 (1H,s), 6.48 (1H,s), 6.79 (1H,s), 7.45 (1H,d), 7.61 (1H,d), 8.10 (1H,d), 8.47(1H,s), 11.25(1H,s).

-124-

The preparation of 2-chloro-4-[(3*S*)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidine was described earlier.

5

Example 44: 4-[4-(Benzenesulfonylmethyl)-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1*H*-indole







To a solution of 4-(benzenesulfonylmethyl)-2-chloro-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidine (200 mg, 0.54 mmol) in ethanol was added toluene (1 mL), water (1 mL), 1*H*-indol-4-ylboronic acid (219 mg, 1.36 mmol), tri-potassium orthophosphate (404 mg, 1.90 mmol) and palladiumbis(tri-*t*-butylphosphine) (16.74 mg, 0.03 mmol). The reaction was degassed then purged with nitrogen and heated at 80°C for 2 hours.

The reaction mixture was cooled to RT diluted with ethyl acetate (10 mL) and washed with water (5 mL). The organic layer was dried (MgSO₄), filtered and evaporated. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% (3.5M ammonia in methanol) in DCM, to give the desired material as a beige solid (130 mg).

NMR Spectrum: ¹H NMR (400.132 MHz, DMSO-*d*₆) δ 1.22 (3H, d), 3.22 (1H, m), 3.50 (1H, t), 3.66 (1H, m), 3.79 (1H, d), 4.00 (1H, m), 4.06 (1H, m), 4.39 (1H, s), 4.75 (2H, s), 6.60 (1H, s), 7.08 (1H, t), 7.14 (1H, s), 7.36 (1H, t), 7.49 (1H, d), 7.61 (2H, t), 7.71 (2H, t), 7.85 (2H, d), 11.15 (1H, s)

LCMS Spectrum: MH⁺ 449, retention time 1.96 min

The following compounds were prepared in an analogous fashion from the appropriate boronic acid or boronic ester.

Example	Structure	NAME	LCMS MH+	Retention time (min)
45		5-[4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole	449	2.23
46		3-[4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-5,7-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene	450	1.97
47		6-[4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole	449	2.20
48		5-[4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-benzoimidazole	450	1.71

Example 45: ^1H NMR (400.132 MHz, DMSO- d_6) δ 1.21 (3H, d), 3.22 (1H, m), 3.49 (1H, m), 3.64 (1H, m), 3.78 (1H, d), 3.99 (1H, m), 4.13 (1H, d), 4.40 (1H, s), 4.72 (2H, s), 6.49 (1H, s), 6.60 (1H, s), 7.32 (1H, d), 7.38 (1H, t), 7.64 (2H, t), 7.79 (2H, m), 7.85 (2H, d), 8.15 (1H, s), 11.17 (1H, s)

Example 46: ^1H NMR (400.132 MHz, DMSO- d_6) δ 1.24 (3H, d), 3.26 (1H, m), 3.50 (1H, m), 3.65 (1H, m), 3.78 (1H, d), 3.99 (1H, m), 4.15 (1H, d), 4.42 (1H, s), 4.74 (2H, s), 6.52 (1H, m), 6.69 (1H, s), 7.50 (1H, t), 7.64 (2H, t), 7.77 (1H, m), 7.85 (2H, m), 8.36 (1H, d), 8.82 (1H, d), 11.76 (1H, s)

Example 47: ^1H NMR (400.132 MHz, DMSO- d_6) δ 1.22 (3H, d), 3.19 (1H, m), 3.50 (1H, m), 3.65 (1H, m), 3.78 (1H, d), 3.99 (1H, m), 4.11 (1H, d), 4.38 (1H, s), 4.72 (2H, s), 6.45 (1H,


-126-

m), 6.59 (1H, s), 7.44 (1H, t), 7.48 (2H, d), 7.64 (1H, t), 7.71 (1H, m), 7.76 (1H, m), 7.84 (2H, m), 8.14 (1H, s), 11.19 (1H, s)

Example 48: ^1H NMR (400.132 MHz, DMSO- d_6) δ 1.22 (3H, d), 3.20 (1H, m), 3.50 (1H, t), 3.65 (1H, d), 3.78 (1H, d), 3.99 (1H, d), 4.12 (1H, d), 4.40 (1H, s), 4.73 (2H, s), 6.64 (1H, s),
 5 7.63 (3H, m), 7.75 (1H, m), 7.87 (3H, m), 8.25 (2H, m), 12.51 (1H, s)

The preparation of 4-(benzenesulfonylmethyl)-2-chloro-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidine is described below.

10 4-(Benzenesulfonylmethyl)-2-chloro-6-[(3*S*)-3-methylmorpholin-4-yl]pyrimidine




4-(Benzenesulfonylmethyl)-2,6-dichloro-pyrimidine (2.8 g, 9.24 mmol) was dissolved in DCM (20 mL) and stirred (under nitrogen) at -5°C . Triethylamine (1.42 mL, 10.17 mmol) was added to give a clear brown solution. (3*S*)-3-methylmorpholine (935 mg, 9.24 mmol) was
 15 dissolved in DCM and added dropwise keeping the reaction below -5°C . The cooling bath was then removed and the reaction mixture stirred at room temperature for 1 hour. The reaction mixture was then washed with water (50 mL), dried over magnesium sulphate, filtered and concentrated *in vacuo*. The crude material was chromatographed on silica, eluting with 0-50% ethyl acetate in DCM to give the desired material as a white solid (2.6 g).

20 NMR Spectrum: ^1H NMR (400.13 MHz, DMSO- d_6) δ 1.15 (d, 3H), 3.15 (m, 1H), 3.42 (m, 1H), 3.56 (m, 1H), 3.72 (d, 1H), 3.92 (m, 2H), 4.15 (s, 1H), 4.62 (s, 2H), 6.66 (s, 1H), 7.74 (t, 1H), 7.76 (t, 1H), 7.78 (d, 1H), 7.80 (m, 2H)

LCMS Spectrum: MH $^+$ 368, retention time 1.95 min, Method 5 Min Base

25 4-(Benzenesulfonylmethyl)-2,6-dichloro-pyrimidine




-127-

6-(Benzenesulfonylmethyl)-1*H*-pyrimidine-2,4-dione (13.3 g, 49 mmol) was added to phosphorus oxychloride (100 mL) and the mixture heated to reflux for 16 hours. The reaction was then cooled to room temperature and the excess phosphorus oxychloride was removed *in vacuo*. The residue was azeotroped with toluene (2 x 100 mL) and dissolved in DCM. This mixture was then poured slowly onto ice (1 L) and stirred for 20 minutes, then extracted with DCM (3 x 500 mL). The extracts were combined, dried over magnesium sulphate, then concentrated *in vacuo* to give the desired material as a brown solid (12 g). The material was used without further purification.

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ4.97 (s, 2H), 7.65 (t, 2H), 7.72 (s, 1H), 7.79 (m, 3H)

LCMS Spectrum: M-H 301, retention time 2.08 min, Method 5 Min Basic

6-(Benzenesulfonylmethyl)-1*H*-pyrimidine-2,4-dione




6-(Chloromethyl)-1*H*-pyrimidine-2,4-dione (8 g, 50 mmol) was dissolved in DMF (200 mL) and benzenesulphinic acid sodium salt (9.8 g, 60 mmol) was added. The reaction was heated to 125°C for 2 hours then allowed to cool and the suspension filtered and concentrated *in vacuo* to give a yellow solid. The crude material was washed with water (100 mL), filtered, then triturated with acetonitrile to give the desired material as a cream solid (13.2 g). The material was used without further purification.

NMR Spectrum: ¹H NMR (400.13 MHz, DMSO-d₆) δ4.46 (s, 2H), 7.69 (t, 2H), 7.81 (m, 1H), 7.87 (m, 3H), 10.85 (s, 1H), 11.11 (s, 1H)

-128-

CLAIMS

1. A compound of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof; wherein

X is a linker group selected from $-\text{CR}^4=\text{CR}^5-$, $-\text{CR}^4=\text{CR}^5\text{CR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{CR}^5=\text{CR}^4-$, $-\text{C}\equiv\text{C}-$, $-\text{C}\equiv\text{CCR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7\text{C}\equiv\text{C}-$, $-\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{OCR}^6\text{R}^7-$, $-\text{SCR}^6\text{R}^7-$, $-\text{S}(\text{O})\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5\text{CR}^6\text{R}^7-$, $-\text{NR}^4\text{S}(\text{O})_2\text{CR}^6\text{R}^7-$, $-\text{S}(\text{O})_2\text{NR}^4\text{CR}^6\text{R}^7-$, $-\text{C}(\text{O})\text{NR}^4-$, $-\text{NR}^4\text{C}(\text{O})-$, $-\text{NR}^4\text{C}(\text{O})\text{NR}^5-$, $-\text{S}(\text{O})_2\text{NR}^4-$ and $-\text{NR}^4\text{S}(\text{O})_2-$;

^1Y and Y^2 are independently N or CR^8 provided that one of ^1Y and Y^2 is N and the other is CR^8 ;

R¹ is a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, carbocyclyl, carbocyclylC₁₋

6alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R⁹, -OR⁹, -SR⁹, -SOR⁹, -SO₂R⁹, -COR⁹, -CO₂R⁹, -CONR⁹R¹⁰, -NR⁹R¹⁰, -NR⁹COR¹⁰, -NR⁹CO₂R¹⁰, -NR⁹CONR¹⁰R¹⁵, -NR⁹COCONR¹⁰R¹⁵ and -NR⁹SO₂R¹⁰;

R² is a group selected from C₁₋₆alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, R¹¹, -OR¹¹, -SR¹¹, -SOR¹¹, -SO₂R¹¹, -COR¹¹, -CO₂R¹¹, -CONR¹¹R¹², -NR¹¹R¹², and -NR¹¹COCONR¹²R¹⁶;

R³ is selected from halo, cyano, nitro, -R¹³, -OR¹³, -SR¹³, -SOR¹³, -SO₂R¹³, -COR¹³, -CO₂R¹³, -CONR¹³R¹⁴, -NR¹³R¹⁴, -NR¹³COR¹⁴, -NR¹³CO₂R¹⁴ and -NR¹³SO₂R¹⁴;

R⁴ and **R**⁵ are independently hydrogen or C₁₋₆alkyl;

or **R**¹ and **R**⁴ together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally

replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R⁶ and **R⁷** are independently selected from hydrogen, halo, cyano, nitro and C₁₋₆alkyl;

10 **R⁸** is selected from hydrogen, halo, cyano and C₁₋₆alkyl;

R⁹ and **R¹⁰** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

20 **R¹¹** and **R¹²** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl;

R¹³, **R¹⁴**, **R¹⁵** and **R¹⁶** are independently hydrogen or a group selected from C₁₋₆alkyl, carbocyclyl, carbocyclylC₁₋₆alkyl, heterocyclyl and heterocyclylC₁₋₆alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkoxy, amino, C₁₋₆alkylamino, bis(C₁₋

-130-

₆alkyl)amino, aminoC₁₋₆alkyl, (C₁₋₆alkyl)aminoC₁₋₆alkyl, bis(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfonylamino, C₁₋₆alkylsulfonyl(C₁₋₆alkyl)amino, sulfamoyl, C₁₋₆alkylsulfamoyl, bis(C₁₋₆alkyl)sulfamoyl, C₁₋₆alkanoylamino, C₁₋₆alkanoyl(C₁₋₆alkyl)amino, carbamoyl, C₁₋₆alkylcarbamoyl and bis(C₁₋₆alkyl)carbamoyl.

5

2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein ¹Y is CH and Y² is N.

3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to
10 claim 1 or 2 wherein X is -S(O)₂CR⁶R⁷- or -C(O)NHR⁴-.

4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 3 wherein X is -S(O)₂CH₂-, -S(O)₂CH(CH₃)-, -S(O)₂C(CH₃)₂- or -C(O)NH-.

15 5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4 wherein R¹ is a group selected from methyl, ethyl, isopropyl, sec-butyl, isobutyl, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-
20 [(anilinocarbonyl)amino]phenyl.

6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 5 wherein -XR¹ is a group selected from -CH₂SO₂-R¹ and -C(CH₃)₂SO₂-R¹ wherein R¹ is methyl, ethyl, isopropyl, sec-butyl, isobutyl or phenyl; or

25 -XR¹ is -NHCO-R¹ wherein R¹ is 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl or 4-[(anilinocarbonyl)amino]phenyl..

30 7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6 wherein R² is selected from morpholinyl, piperidinyl, phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl,

-131-

azaindolyl, indolyl, quinoliny, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, -CONH₂, -CONHCH₃ and -CON(CH₃)₂.

5

8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6 wherein R² is (pyrazol-3yl)amino, hydroxypiperidinyl, indol-4-yl, indol-5-yl, indol-6-yl, azaindolyl, benzimidazol-5-yl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-aminocarbonylindol-5-yl, 2-aminocarbonylindol-6-yl, 3-aminocarbonylindol-6-yl, morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl or methylmorpholinyl.

9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 selected from any one of

15 N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-methoxy-benzamide,
N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-methoxy-3-(trifluoromethyl)benzamide,

N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-3-methoxy-benzamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-methoxy-3-(trifluoromethyl)benzamide,

N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-3-methoxy-benzamide,
N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-6-methoxy-pyridine-3-carboxamide,

N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-2-methoxy-pyridine-4-carboxamide,

6-Acetamido-N-[2,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]pyridine-3-carboxamide,

N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-2-methoxy-benzamide,
2-Acetamido-N-[2,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]pyridine-4-carboxamide,

N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-3-fluoro-4-methoxy-benzamide,

-132-

- N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-2-methoxy-pyridine-4-carboxamide,
 6-Acetamido-N-[4,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridine-3-carboxamide,
 5 N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-2-methoxy-benzamide,
 2-Acetamido-N-[4,6-bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridine-4-carboxamide,
 N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-3-fluoro-4-methoxy-benzamide,
 N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-
 10 (phenylcarbamoylamino)benzamide,
 N-[4,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-4-(phenylcarbamoylamino)benzamide,
 N-[2,6-Bis[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]-4-methoxy-benzamide,
 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-4-[(3S)-3-methylmorpholin-4-yl]-6-
 15 (methylsulfonylmethyl)pyrimidine,
 1-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]piperidin-3-ol,
 4-[(3S)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-morpholin-4-yl-pyrimidine,
 3-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-5,7-diazabicyclo[4.3.0]nona-1,3,5,8-tetraene,
 20 5-[4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
 5-[4-[(3R)-3-methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
 5-[4-(Butan-2-ylsulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
 5-[4-(butan-2-ylsulfinylmethyl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
 5-[4-[(3R)-3-methylmorpholin-4-yl]-6-(propan-2-ylsulfonylmethyl)pyrimidin-2-yl]-1H-
 25 indole,
 5-[4-(ethylsulfonylmethyl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-N-(1H-pyrazol-3-yl)pyrimidin-2-amine,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[4-(1H-pyrazol-4-
 30 yl)phenyl]pyrimidine,
 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[3-(1H-pyrazol-4-yl)phenyl]pyrimidine,

-133-

- 5-4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-3-carboxamide,
- 4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)-2-[2-(1H-pyrazol-4-yl)-1,3-thiazol-5-yl]pyrimidine,
- 5 6-4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole,
- 6-4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-3-carboxamide,
- 5-4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-2-carboxamide,
- 10 6-4-[(3S)-3-Methylmorpholin-4-yl]-6-(methylsulfonylmethyl)pyrimidin-2-yl]-1H-indole-2-carboxamide,
- 5-4-[(3S)-3-Methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-benzoimidazole,
- 3-4-[(3S)-3-Methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-5,7-
- 15 diazabicyclo[4.3.0]nona-1,3,5,8-tetraene,
- 5-4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-indole,
- 4-4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-indole,
- 20 6-4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]-1H-indole,
- 4-4-(Benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
- 5-4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
- 3-4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-5,7-
- 25 diazabicyclo[4.3.0]nona-1,3,5,8-tetraene,
- 6-4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-indole,
- and
- 5-4-(benzenesulfonylmethyl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]-1H-benzoimidazole, or a pharmaceutically acceptable salt thereof.

30

10. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of Claims 1 to 9 for use as a medicament in the treatment of proliferative disease.

-134-

11. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of proliferative disease.

5

12. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9 for the production of an anti-proliferative effect in a warm-blooded animal such as man.

10 13. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9 in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

14. A method for producing an anti-proliferative effect in a warm-blooded animal, such as
15 man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9.

15. A method for treating cancer, inflammatory diseases, obstructive airways diseases,
20 immune diseases or cardiovascular diseases in a warm blooded animal such as man that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9.

25 16. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.

17. A compound of formula (I) as defined in any one of claims 1 to 9, or a
30 pharmaceutically acceptable salt thereof, for use as a medicament.